(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2013 (14.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/170118 A1

(51) International Patent Classification:
C07D 417/12 (2006.01) *A61K 31/427* (2006.01)
C07D 417/14 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2013/040485

(22) International Filing Date:
10 May 2013 (10.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2012/075327 11 May 2012 (11.05.2012) CN

(71) Applicant: **ABBVIE INC.** [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US).

(72) Inventors: **SWEIS, Ramzi F.**; 1012 Plaister Ave., Lake Bluff, Illinois 60044 (US). **CURTIN, Michael L.**; 8625 113TH Ave., Pleasant Prairie, Wisconsin 53158 (US). **PLIUSHCHEV, Marina A.**; 337 Albert Dr., Vernon Hills, Illinois 60061 (US). **HANSEN, Todd M.**; 191 Seymour Ave., Grayslake, Illinois 60030 (US). **LONGENECKER, Kenton**; 1371 Osage Orange Road, Grayslake, Illinois 60030 (US).

(74) Agents: **GESICKI, Glen J** et al.; 100 Abbott Park Road, Bld AP06A-1/V377, Abbott Park, Illinois 60064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS

(I)



(57) Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

WO 2013/170118 A1

THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS

This application claims priority to Patent Cooperation Treaty Patent Application Serial No. PCT/CN2012/075327, filed May 11, 2012, which is incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention pertains to compounds which inhibit the activity of NAMPT, compositions containing the compounds, and methods of treating diseases during which NAMPT is expressed.

BACKGROUND OF THE INVENTION

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that plays a critical role in many physiologically essential processes (Ziegkel, M. *Eur. J. Biochem.* **267**,1550-1564, 2000). NAD is necessary for several signaling pathways including among others poly ADP-ribosylation in DNA repair, mono-ADP-ribosylation in both the immune system and G-protein-coupled signaling, and NAD is also required by sirtuins for their deacetylase activity (Garten, A. et al *Trends in Endocrinology and Metabolism*, **20**, 130-138, 2008).

NAMPT (also known as pre-B-cell-colony-enhancing factor (PBEF) and visfatin) is an enzyme that catalyzes the phosphoribosylation of nicotinamide and is the rate-limiting enzyme in one of two pathways that salvage NAD.



Increasing evidence suggests that NAMPT inhibitors have potential as anticancer agents. Cancer cells have a higher basal turnover of NAD and also display higher energy requirements compared with normal cells. Additionally, increased NAMPT expression has been reported in colorectal cancer (Van Beijnum, J.R. et al *Int. J. Cancer* **101**, 118-127, 2002) and NAMPT is involved in angiogenesis (Kim, S.R. et al. *Biochem. Biophys. Res. Commun.*

357, 150-156, 2007). Small-molecule inhibitors of NAMPT have been shown to cause depletion of intracellular NAD+ levels and ultimately induce tumor cell death (Hansen, CM et al. *Anticancer Res.* **20**, 42111-4220, 2000) as well as inhibit tumor growth in xenograft models (Olese, U.H. et al. *Mol Cancer Ther.* **9**, 1609-1617, 2010).

NAMPT inhibitors also have potential as therapeutic agents in inflammatory and metabolic disorders (Galli, M. et al *Cancer Res.* **70**, 8-11, 2010). For example, NAMPT is the predominant enzyme in T and B lymphocytes. Selective inhibition of NAMPT leads to NAD+ depletion in lymphocytes blocking the expansion that accompanies autoimmune disease progression whereas cell types expressing the other NAD+ generating pathways might be spared. A small molecule NAMPT inhibitor (FK866) has been shown to selectively block proliferation and induce apoptosis of activated T cells and was efficacious in animal models of arthritis (collagen –induced arthritis) (Busso, N.et al. *Plos One* **3**, e2267, 2008). FK866 ameliorated the manifestations of experimental autoimmune encephalomyelitis (EAE), a model of T-cell mediated autoimmune disorders. (Bruzzone, Set al. *Plos One* **4**, e7897, 2009). NaMPT activity increases NF-kB transcriptional activity in human vascular endothelial cell, resulting in MMP-2 and MMP-9 activation, suggesting a role for NAMPT inhibitors in the prevention of inflammatory mediated complications of obesity and type 2 diabetes (Adya, R. et. Al. *Diabetes Care*, **31**, 758-760, 2008).

SUMMARY OF THE INVENTION

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)



Formula (I),

wherein

R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6; or

R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring; wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of R^7, OR^7, SR^7, $S(O)R^7$, SO_2R^7, $C(O)R^7$, $CO(O)R^7$, $OC(O)R^7$, $OC(O)OR^7$, NH_2, NHR^7, $N(R^7)_2$, $NHC(O)R^7$,

$NR^7C(O)R^7$, $NHS(O)_2R^7$, $NR^7S(O)_2R^7$, $NHC(O)OR^7$, $NR^7C(O)OR^7$, $NHC(O)NH_2$, $NHC(O)NHR^7$, $NHC(O)N(R^7)_2$, $NR^7C(O)NHR^7$, $NR^7C(O)N(R^7)_2$, $C(O)NH_2$, $C(O)NHR^7$, $C(O)N(R^7)_2$, C(O)NHOH, $C(O)NHOR^7$, $C(O)NHSO_2R^7$, $C(O)NR^7SO_2R^7$, SO_2NH_2, SO_2NHR^7, $SO_2N(R^7)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^7$, $C(N)N(R^7)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^3, R^4, and R^5 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, F, Cl, Br and I;

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$,

$C(O)NHOH$, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, $C(O)H$, $C(O)OH$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, $C(O)H$, $C(O)OH$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, $C(O)H$, $C(O)OH$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, $C(O)H$, $C(O)OH$, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, $C(O)H$, $C(O)OH$, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (I), R^1 is $C(O)R^6$; and R^2 is R^6. In another embodiment of Formula (I), R^1 and R^2 are each R^6. In another embodiment of Formula (I), R^1 is $C(O)NHR^6$; and R^2 is R^6. In another embodiment of Formula (I), R^1 is $C(O)N(R^6)_2$; and R^2 is R^6. In another embodiment of Formula (I), R^3, R^4 and R^5 are hydrogen. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally

substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

Still another embodiment pertains to compounds, which are

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium;

2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(4-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide;

2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide;

2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)(methyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide;

2-{[ethyl(2-methoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide;

2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide;

2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-[3-(2-hydroxyethyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Another embodiment pertains to a composition for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic upus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (I), or pharmaceutically acceptable salts thereof.

Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or pharmaceutically acceptable salts thereof.

Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a

patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I), or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

DETAILED DESCRIPTION OF THE INVENTION

This detailed description is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.

Abbreviations and Definitions

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. With reference to the use of the words "comprise" or "comprises" or "comprising" in this patent application (including the claims), Applicants note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicants intend each of those words to be so interpreted in construing this patent application, including the claims below. For a variable that occurs more than one time in any substituent or in the compound of the invention or any other formulae herein, its definition on each occurrence is independent of its definition at every other occurrence. Combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds which can be isolated in a useful degree of purity from a reaction mixture.

It is meant to be understood that proper valences are maintained for all combinations herein, that monovalent moieties having more than one atom are attached through their left ends, and that divalent moieties are drawn from left to right.

As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:

The term "alkyl" (alone or in combination with another term(s)) means a straight-or branched-chain saturated hydrocarbyl substituent typically containing from 1 to about 10 carbon atoms; or in another embodiment, from 1 to about 8 carbon atoms; in another

embodiment, from 1 to about 6 carbon atoms; and in another embodiment, from 1 to about 4 carbon atoms. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl and the like.

The term "alkenyl" (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl and the like.

The term "alkynyl" (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethynyl, 2-propynyl, 3-propynyl, 2-butynyl, and 3-butynyl and the like.

The term "carbocyclyl" (alone or in combination with another term(s)) means a saturated cyclic (*i.e.*, "cycloalkyl"), partially saturated cyclic (*i.e.*, "cycloalkenyl"), or completely unsaturated (*i.e.*, "aryl") hydrocarbyl substituent containing from 3 to 14 carbon ring atoms ("ring atoms" are the atoms bound together to form the ring or rings of a cyclic substituent). A carbocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.

A carbocyclyl may be a single ring structure, which typically contains from 3 to 8 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of such single-ring carbocyclyls include cyclopropyl (cyclopropanyl), cyclobutyl (cyclobutanyl), cyclopentyl (cyclopentanyl), cyclopentenyl, cyclopentadienyl, cyclohexyl (cyclohexanyl), cyclohexenyl, cyclohexadienyl, and phenyl. A carbocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic carbocyclyls include bridged, fused, and spirocyclic carbocyclyls. In a spirocyclic carbocyclyl, one atom is common to two different rings. An example of a spirocyclic carbocyclyl is spiropentanyl. In a bridged carbocyclyl, the rings share at least two common non-adjacent atoms. Examples of bridged carbocyclyls include bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, and adamantanyl. In a fused-ring carbocyclyl system, two or more rings may be fused together, such that two rings share one common bond. Examples of two- or three-fused ring carbocyclyls include naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenanthrenyl, and decalinyl.

The term "cycloalkyl" (alone or in combination with another term(s)) means a saturated cyclic hydrocarbyl substituent containing from 3 to 14 carbon ring atoms. A cycloalkyl may be a single carbon ring, which typically contains from 3 to 8 carbon ring

atoms and more typically from 3 to 6 ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls.

The term "aryl" (alone or in combination with another term(s)) means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. An aryl may be monocyclic or polycyclic (i.e., may contain more than one ring). In the case of polycyclic aromatic rings, only one ring the polycyclic system is required to be unsaturated while the remaining ring(s) may be saturated, partially saturated or unsaturated. Examples of aryls include phenyl, naphthalenyl, indenyl, indanyl, and tetrahydronapthyl.

In some instances, the number of carbon atoms in a hydrocarbyl substituent (e.g., alkyl, alkenyl, alkynyl, or cycloalkyl) is indicated by the prefix "C_x-C_y-", wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, "C_1-C_6-alkyl" refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C_3-C_8-cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 8 carbon ring atoms.

The term "hydrogen" (alone or in combination with another term(s)) means a hydrogen radical, and may be depicted as -H.

The term "hydroxy" (alone or in combination with another term(s)) means -OH.

The term "carboxy" (alone or in combination with another term(s)) means -C(O)-OH.

The term "amino" (alone or in combination with another term(s)) means $-NH_2$.

The term "halogen" or "halo" (alone or in combination with another term(s)) means a fluorine radical (which may be depicted as -F), chlorine radical (which may be depicted as -Cl), bromine radical (which may be depicted as -Br), or iodine radical (which may be depicted as -I).

If a substituent is described as being "substituted", a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro radical, and difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there are more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).

If a substituent is described as being "optionally substituted", the substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent,

whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.

This patent application uses the terms "substituent" and "radical" interchangeably.

The prefix "halo" indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical. Examples of haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).

The prefix "perhalo" indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, *i.e.*, each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term "perfluoro" means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term "perfluoroalkyl" means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.

The term "carbonyl" (alone or in combination with another term(s)) means -C(O)-.

The term "aminocarbonyl" (alone or in combination with another term(s)) means -C(O)-NH_2.

The term "oxo" (alone or in combination with another term(s)) means (=O).

The term "oxy" (alone or in combination with another term(s)) means an ether substituent, and may be depicted as -O-.

The term "alkylhydroxy" (alone or in combination with another term(s)) means –alkyl-OH.

The term "alkylamino" (alone or in combination with another term(s)) means –alkyl-NH_2.

The term "alkyloxy" (alone or in combination with another term(s)) means an alkylether substituent, i.e., -O-alkyl. Examples of such a substituent include methoxy (-O-CH_3), ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.

The term "alkylcarbonyl" (alone or in combination with another term(s)) means -C(O)-alkyl.

The term "aminoalkylcarbonyl" (alone or in combination with another term(s)) means -C(O)-alkyl-NH_2.

The term "alkyloxycarbonyl" (alone or in combination with another term(s)) means -C(O)-O-alkyl.

The term "carbocyclylcarbonyl" (alone or in combination with another term(s)) means -C(O)-carbocyclyl.

Similarly, the term "heterocyclylcarbonyl" (alone or in combination with another term(s)) means -C(O)-heterocyclyl.

The term "carbocyclylalkylcarbonyl" (alone or in combination with another term(s)) means -C(O)-alkyl-carbocyclyl.

Similarly, the term "heterocyclylalkylcarbonyl" (alone or in combination with another term(s)) means -C(O)-alkyl-heterocyclyl.

The term "carbocyclyloxycarbonyl" (alone or in combination with another term(s)) means -C(O)-O-carbocyclyl.

The term "carbocyclylalkyloxycarbonyl" (alone or in combination with another term(s)) means -C(O)-O-alkyl-carbocyclyl.

The term "thio" or "thia" (alone or in combination with another term(s)) means a thiaether substituent, *i.e.*, an ether substituent wherein a divalent sulfur atom is in the place of the ether oxygen atom. Such a substituent may be depicted as -S-. This, for example, "alkyl-thio-alkyl" means alkyl-S-alkyl (alkyl-sulfanyl-alkyl).

The term "thiol" or "sulfhydryl" (alone or in combination with another term(s)) means a sulfhydryl substituent, and may be depicted as -SH.

The term "(thiocarbonyl)" (alone or in combination with another term(s)) means a carbonyl wherein the oxygen atom has been replaced with a sulfur. Such a substituent may be depicted as -C(S)-.

The term "sulfonyl" (alone or in combination with another term(s)) means -$S(O)_2$-.

The term "aminosulfonyl" (alone or in combination with another term(s)) means -$S(O)_2$-NH_2.

The term "sulfinyl" or "sulfoxido" (alone or in combination with another term(s)) means -S(O)-.

The term "heterocyclyl" (alone or in combination with another term(s)) means a saturated (*i.e.*, "heterocycloalkyl"), partially saturated (*i.e.*, "heterocycloalkenyl"), or completely unsaturated (*i.e.*, "heteroaryl") ring structure containing a total of 3 to 14 ring atoms. At least one of the ring atoms is a heteroatom (*i.e.*, oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon,

oxygen, nitrogen, and sulfur. A heterocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.

A heterocyclyl may be a single ring, which typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of single-ring heterocyclyls include 1,2,3,6-tetrahydropyridine, thiomorpholinyl, tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl (furazanyl), or 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4-oxatriazolyl or 1,2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, or 1,3,4-dioxazolyl), oxathiazolyl, oxathiolyl, oxathiolanyl, pyranyl, dihydropyranyl, thiopyranyl, tetrahydrothiopyranyl, pyridinyl (azinyl), piperidinyl, diazinyl (including pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), or pyrazinyl (1,4-diazinyl)), piperazinyl, pyrrolidin-2-only, triazinyl (including 1,3,5-triazinyl, 1,2,4-triazinyl, and 1,2,3-triazinyl)), oxazinyl (including 1,2-oxazinyl, 1,3-oxazinyl, or 1,4-oxazinyl)), oxathiazinyl (including 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl, or 1,2,6-oxathiazinyl)), oxadiazinyl (including 1,2,3-oxadiazinyl, 1,2,4-oxadiazinyl, 1,4,2-oxadiazinyl, or 1,3,5-oxadiazinyl)), morpholinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.

A heterocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic heterocyclyls include bridged, fused, and spirocyclic heterocyclyls. In a spirocyclic heterocyclyl, one atom is common to two different rings. In a bridged heterocyclyl, the rings share at least two common non-adjacent atoms. In a fused-ring heterocyclyl, two or more rings may be fused together, such that two rings share one common bond. Examples of fused-ring heterocyclyls include hexahydro-furo[3,4-c]pyrrole, hexahydro-furo[3,4-b]pyrrole, octahydro-pyrrolo[3,4-b]pyridine, octahydro-pyrrolo[3,4-c]pyridine, (3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrole, (3aR,6aR)-octahydro-pyrrolo[3,4-b]pyrrole, 6-methyl-2,6-diaza-bicyclo[3.2.0]heptane, (3aS,6aR)-2-methyl-octahydro-pyrrolo[3,4-c]pyrrole, decahydro-[1,5]naphthyridine, 2,3-dihydrobenzofuranyl, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, (trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-onyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,5-

a]pyrazinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, or pyrido[4,3-b]-pyridinyl), and pteridinyl. Other examples of fused-ring heterocyclyls include benzo-fused heterocyclyls, such as benzimidazolyl, benzo[d][1,3]dioxolyl, indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1-benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl, 1,4,2-benzoxazinyl, 2,3,1-benzoxazinyl, or 3,1,4-benzoxazinyl), and benzisoxazinyl (including 1,2-benzisoxazinyl or 1,4-benzisoxazinyl). Examples of spirocyclic heterocyclyls include 1,4-dioxa-8-azaspiro[4.5]decanyl.

The term "heterocycloalkyl" (alone or in combination with another term(s)) means a saturated heterocyclyl.

The term "heteroaryl" (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms. A heteroaryl may be a single ring or 2 or 3 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5-membered ring substituents such as imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, benzisoxazolyl, benzoxazolyl, and purinyl; and 6/6-membered fused rings such as benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and benzoxazinyl.

A prefix attached to a multi-component substituent only applies to the first component. To illustrate, the term "alkylcycloalkyl" contains two components: alkyl and cycloalkyl. Thus, the C_1-C_6- prefix on C_1-C_6-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the C_1-C_6-prefix does not describe the cycloalkyl component. To illustrate further, the prefix "halo" on haloalkyloxyalkyl indicates that only the alkyloxy component of the alkyloxyalkyl substituent is substituted with one or more halogen radicals. If halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as "halogen-substituted alkyloxyalkyl" rather than "haloalkyloxyalkyl." And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as "alkyloxyhaloalkyl."

The terms "treat", "treating" and "treatment" refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.

The terms "prevent", "preventing" and "prevention" refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, "prevent", "preventing" and "prevention" also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.

The term "therapeutically effective amount" refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.

The term "modulate" refers to the ability of a compound to increase or decrease the function, or activity, of a kinase. "Modulation", as used herein in its various forms, is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with kinase. Kinase inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate signal transduction. Kinase activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize or up regulate signal transduction.

The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The "subject" is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.

Isotope Enriched or Labeled Compounds

Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, ^{2}H, ^{3}H, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{32}P, ^{35}S, ^{18}F, ^{36}Cl, and ^{125}I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.

In another embodiment, the isotope-labeled compounds contain deuterium (^{2}H), tritium (^{3}H) or ^{14}C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in

the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D_2SO_4/D_2O. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al., *Drugs Fut*, 21(11), 1116 (1996); Brickner, S J *et al., J Med Chem*, 39(3), 673 (1996); Mallesham, B et al., *Org Lett*, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; US Patent Nos. 7538189; 7534814; 7531685; 7528131; 7521421; 7514068; 7511013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, the methods are hereby incorporated by reference.

The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. *J. Pharm. Sci.* 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the *in vivo* active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. *Labelled Comp. Radiopharmaceut.*, 36(10):927-932 (1995); Kushner et al., *Can. J. Physiol. Pharmacol.*, 77, 79-88 (1999).

In addition, non-radio active isotope containing drugs, such as deuterated drugs called "heavy drugs," can be used for the treatment of diseases and conditions related to NAMPT activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in "Dosimetry & Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134; Diabetes Metab. 23: 251 (1997)).

Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.

Compounds

Suitable groups for R^1, R^2, R^3, R^4, and R^5 in compounds of Formula (I) are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of R^1, R^2, R^3, R^4, and R^5 can be combined with embodiments defined for any other of R^1, R^2, R^3, R^4, and R^5.

Embodiments of Formula (I)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)



Formula (I),

wherein

R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6; or

R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring; wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of R^7, OR^7, SR^7, $S(O)R^7$, SO_2R^7, $C(O)R^7$, $CO(O)R^7$, $OC(O)R^7$, $OC(O)OR^7$, NH_2, NHR^7, $N(R^7)_2$, $NHC(O)R^7$, $NR^7C(O)R^7$, $NHS(O)_2R^7$, $NR^7S(O)_2R^7$, $NHC(O)OR^7$, $NR^7C(O)OR^7$, $NHC(O)NH_2$, $NHC(O)NHR^7$, $NHC(O)N(R^7)_2$, $NR^7C(O)NHR^7$, $NR^7C(O)N(R^7)_2$, $C(O)NH_2$, $C(O)NHR^7$, $C(O)N(R^7)_2$, C(O)NHOH, $C(O)NHOR^7$, $C(O)NHSO_2R^7$, $C(O)NR^7SO_2R^7$, SO_2NH_2,

SO_2NHR^7, $SO_2N(R^7)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^7$, $C(N)N(R^7)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^3, R^4, and R^5 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, F, Cl, Br and I;

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented

by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (I), R^3, R^4, and R^5 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, F, Cl, Br and I. In another embodiment of Formula (I), R^3, R^4, and R^5 are are each independently selected from the group consisting of hydrogen and C_{1-6} alkyl. In another embodiment of Formula (I), one of R^3, R^4, and R^5 is C_{1-6} alkyl, and the remainder are hydrogen. In another embodiment of Formula (I), R^3 is C_{1-6} alkyl, and R^4 and R^5 are hydrogen. In another embodiment of Formula (I), R^4 is C_{1-6} alkyl, and R^3 and R^5 are hydrogen. In another embodiment of Formula (I), R^5 is C_{1-6} alkyl, and R^3 and R^4 are hydrogen. In another embodiment of Formula (I), R^3, R^4 and R^5 are hydrogen.

In another embodiment of Formula (I), R^3, R^4, and R^5 are are each independently selected from the group consisting of hydrogen and methyl. In another embodiment of Formula (I), one of R^3, R^4, and R^5 is methyl, and the remainder are hydrogen. In another embodiment of Formula (I), R^3 is methyl, and R^4 and R^5 are hydrogen. In another embodiment of Formula (I), R^4 is methyl, and R^3 and R^5 are hydrogen. In another embodiment of Formula (I), R^5 is methyl, and R^3 and R^4 are hydrogen.

In one embodiment of Formula (I), R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)NHOH$, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, $C(O)NHOH$, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)OH$, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, $C(O)OH$, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (I), R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$,

$C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^9, at each occurrence, is $C_{1\text{-}6}$ alkyl.

In one embodiment of Formula (I), R^{10}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, $C_{1\text{-}6}$ haloalkyl, and $C_{1\text{-}6}$ hydroxyalkyl.

In one embodiment of Formula (I), R^{11}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^{11}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, aryl, and heteroaryl; wherein the $C_{1\text{-}6}$ alkyl and $C_{2\text{-}6}$ alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (I), R^{12}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each

independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (I), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (I), R^1 is $C(O)R^6$; and R^2 is R^6. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NHR^8$, and OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, OH, CN, F, Cl, Br and I. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I. In another embodiment of Formula (I), R^9, at each occurrence, is C_{1-6} alkyl. In another embodiment of Formula (I), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and aryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In another embodiment of Formula (I), R^1 and R^2 are each R^6. In another embodiment of Formula (I), R^6, at each occurrence, is C_{1-6} alkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, $C(O)R^8$, $C(O)NHR^8$, and $C(O)N(R^8)_2$. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, and heterocycloalkyl; wherein the aryl, and heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, CN, F, Cl, Br and I. In another embodiment of Formula (I), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl and heteroaryl.

In another embodiment of Formula (I), R^1 is $C(O)NHR^6$; and R^2 is R^6. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C(O)NH_2$, C(O)OH, F, Cl, Br and I. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, and heteroaryl; wherein the C_{1-6} alkyl represented by R^8 is independently optionally substituted with one or more OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, CN, F, Cl, Br and I.

In another embodiment of Formula (I), R^1 is $C(O)N(R^6)_2$; and R^2 is R^6. In another embodiment of Formula (I), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, and heterocycloalkyl; wherein the C_{1-6} alkyl represented by R^8 is independently optionally substituted with one or more OH; wherein the aryl and heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, CN, F, Cl, Br and I.

In another embodiment of Formula (I), R^6, at each occurrence, is C_{1-6} alkyl; wherein the C_{1-6} alkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, and OR^8. In another embodiment of Formula (I), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, and aryl; wherein the aryl represented by R^8 is independently optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, Br and I.

In another embodiment of Formula (I), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring. In another embodiment

of Formula (I), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl ring. In another embodiment of Formula (I), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl ring wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more R^7. In another embodiment of Formula (I), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (I), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, and aryl; wherein the C_{1-6} alkyl represented by R^7 is independently optionally substituted with one or more substituents independently selected from the group consisting of aryl and OH; wherein the aryl represented by R^7 is independently optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, Br and I.

Still another embodiment pertains to compounds having Formula (I), which include

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium;

2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(4-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide;

2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide;

2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)(methyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide;

2-{[ethyl(2-methoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide;

2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide;

2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-[3-(2-hydroxyethyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Embodiments of Formula (II)

In another aspect, the present invention provides compounds of Formula (II)



(II);

and pharmaceutically acceptable salts thereof; wherein R^1 and R^2 are as described herein for Formula (I).

One embodiment of this invention pertains to compounds of Formula (II) or pharmaceutically acceptable salts thereof;

wherein

R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6; or

R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring; wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of R^7, OR^7, SR^7, $S(O)R^7$, SO_2R^7, $C(O)R^7$, $CO(O)R^7$, $OC(O)R^7$, $OC(O)OR^7$, NH_2, NHR^7, $N(R^7)_2$, $NHC(O)R^7$, $NR^7C(O)R^7$, $NHS(O)_2R^7$, $NR^7S(O)_2R^7$, $NHC(O)OR^7$, $NR^7C(O)OR^7$, $NHC(O)NH_2$, $NHC(O)NHR^7$, $NHC(O)N(R^7)_2$, $NR^7C(O)NHR^7$, $NR^7C(O)N(R^7)_2$, $C(O)NH_2$, $C(O)NHR^7$, $C(O)N(R^7)_2$, C(O)NHOH, $C(O)NHOR^7$, $C(O)NHSO_2R^7$, $C(O)NR^7SO_2R^7$, SO_2NH_2, SO_2NHR^7, $SO_2N(R^7)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^7$, $C(N)N(R^7)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3,

NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected

from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (II), R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6. In another embodiment of Formula (II), R^6, at each occurrence, is independently

selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)NHOH$, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, $C(O)NHOH$, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)OH$, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, $C(O)OH$, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, $C(O)NHOH$, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$,

$C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the $C_{1\text{-}6}$ alkyl and $C_{2\text{-}6}$ alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (II), R^9, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$,

CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^9, at each occurrence, is C_{1-6} alkyl.

In one embodiment of Formula (II), R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl.

In one embodiment of Formula (II), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, and heteroaryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (II), R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (II), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (II), R^1 is $C(O)R^6$; and R^2 is R^6. In another embodiment of Formula (II), R^6, at each occurrence, is independently selected from the group

consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NHR^8$, and OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, OH, CN, F, Cl, Br and I. In another embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I. In another embodiment of Formula (II), R^9, at each occurrence, is C_{1-6} alkyl. In another embodiment of Formula (II), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and aryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In another embodiment of Formula (II), R^1 and R^2 are each R^6. In another embodiment of Formula (II), R^6, at each occurrence, is C_{1-6} alkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, $C(O)R^8$, $C(O)NHR^8$, and $C(O)N(R^8)_2$. In another embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, and heterocycloalkyl; wherein the aryl, and heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, CN, F, Cl, Br and I. In another embodiment of Formula (II), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl and heteroaryl.

In another embodiment of Formula (II), R^1 is $C(O)NHR^6$; and R^2 is R^6. In another embodiment of Formula (II), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C(O)NH_2$, C(O)OH, F, Cl, Br and I. In another embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, and heteroaryl;

wherein the C_{1-6} alkyl is independently optionally substituted with one or more OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, CN, F, Cl, Br and I.

In another embodiment of Formula (II), R^1 is $C(O)N(R^6)_2$; and R^2 is R^6. In another embodiment of Formula (II), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I. In another embodiment of Formula (II), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, and heterocycloalkyl; wherein the C_{1-6} alkyl is independently optionally substituted with one or more OH; wherein the aryl and heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, CN, F, Cl, Br and I.

In another embodiment of Formula (II), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring. In another embodiment of Formula (II), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl ring. In another embodiment of Formula (II), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl ring wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more R^7. In another embodiment of Formula (II), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6}

alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (II), R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, and aryl; wherein the C_{1-6} alkyl is independently optionally substituted with one or more substituents independently selected from the group consisting of aryl and OH; wherein the aryl represented by R^7 is independently optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, Br and I.

Still another embodiment pertains to compounds having Formula (II), which include

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium;

2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide;

2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide;

2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)(methyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide;

2-{[ethyl(2-methoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide;

2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide;

2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-[3-(2-hydroxyethyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Embodiments of Formula (III)

In another aspect, the present invention provides compounds of Formula (III)



(III);

and pharmaceutically acceptable salts thereof; wherein each R^6 is as described herein for Formula (I).

One embodiment of this invention pertains to compounds of Formula (III) or pharmaceutically acceptable salts thereof;

wherein

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents

independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (III), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$,

CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (III), R^6, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the $C_{1\text{-}6}$ alkyl, and $C_{2\text{-}6}$ alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (III), R^8, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$,

CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (III), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (III), R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (III), R^9, at each occurrence, is C_{1-6} alkyl.

In one embodiment of Formula (III), R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl.

In one embodiment of Formula (III), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of

C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (III), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, and heteroaryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (III), R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (III), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (III), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NHR^8$, and OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, OH, CN, F, Cl, Br and I. In another embodiment of Formula (III), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of

R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I. In another embodiment of Formula (III), R^9, at each occurrence, is C_{1-6} alkyl. In another embodiment of Formula (III), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and aryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

Still another embodiment pertains to compounds having Formula (III), which include

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium;

2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide;

2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide;

2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide;

2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide;

2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Embodiments of Formula (IV)

In another aspect, the present invention provides compounds of Formula (IV)



(IV);

and pharmaceutically acceptable salts thereof; wherein each R^6 is as described herein for Formula (I).

One embodiment of this invention pertains to compounds of Formula (IV) or pharmaceutically acceptable salts thereof;

wherein

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)NHOH$, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$,

SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl,

heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, $C(O)NHOH$, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (IV), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$,

$C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the $C_{1\text{-}6}$ alkyl and $C_{2\text{-}6}$ alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (IV), R^9, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$,

CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^9, at each occurrence, is C_{1-6} alkyl.

In one embodiment of Formula (IV), R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl.

In one embodiment of Formula (IV), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, and heteroaryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (IV), R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (IV), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (IV), R^6, at each occurrence, is C_{1-6} alkyl; wherein the C_{1-6} alkyl represented by R^6 is independently optionally substituted with one or more

substituents independently selected from the group consisting of R^8, $C(O)R^8$, $C(O)NHR^8$, and $C(O)N(R^8)_2$. In another embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, and heterocycloalkyl; wherein the aryl, and heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, CN, F, Cl, Br and I. In another embodiment of Formula (IV), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl and heteroaryl.

Still another embodiment pertains to compounds having Formula (IV), which include

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Embodiments of Formula (V)

In another aspect, the present invention provides compounds of Formula (V)



(V);

and pharmaceutically acceptable salts thereof; wherein each R^6 is as described herein for Formula (I).

One embodiment of this invention pertains to compounds of Formula (V) or pharmaceutically acceptable salts thereof;

wherein

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$,

$CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented

by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted

with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (V), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (V), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (V), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl,

heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (V), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (V), R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl

represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (V), R^9, at each occurrence, is C_{1-6} alkyl.

In one embodiment of Formula (V), R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl.

In one embodiment of Formula (V), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (V), R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, and heteroaryl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (V), R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (V), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In another embodiment of Formula (V), R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C(O)NH_2$, C(O)OH, F, Cl, Br and I. In another embodiment of Formula (V), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, aryl, heterocycloalkyl, and heteroaryl; wherein the C_{1-6} alkyl is independently optionally substituted with one or more OH; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, CN, F, Cl, Br and I.

Still another embodiment pertains to compounds having Formula (V), which include

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

Embodiments of Formula (VI)

In another aspect, the present invention provides compounds of Formula (VI)



(VI);

and pharmaceutically acceptable salts thereof; wherein each R^6 is as described herein for Formula (I), and R^x is as described herein for substituents on R^8 when R^8 is aryl.

One embodiment of this invention pertains to compounds of Formula (VI) or pharmaceutically acceptable salts thereof;

wherein

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$,

$NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^x is independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$,

SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented

by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (IV), R^6 is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)NHOH, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^6 is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently

optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, and heteroaryl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, NH_2, $N(R^{11})_2$, C(O)H, OH, CN, F, Cl, Br and I.

In one embodiment of Formula (IV), R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$,

$C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^9, at each occurrence, is $C_{1\text{-}6}$ alkyl.

In one embodiment of Formula (IV), R^{10}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, $C_{1\text{-}6}$ haloalkyl, and $C_{1\text{-}6}$ hydroxyalkyl.

In one embodiment of Formula (IV), R^{11}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I. In another embodiment of Formula (IV), R^{11}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, aryl, and heteroaryl; wherein the $C_{1\text{-}6}$ alkyl and $C_{2\text{-}6}$ alkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, cycloalkyl, OH, F, Cl, Br and I.

In one embodiment of Formula (IV), R^{12}, at each occurrence, is independently selected from the group consisting of $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, $C_{2\text{-}6}$ alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl, and $C_{2\text{-}6}$ alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of $C_{1\text{-}6}$ alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl,

NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (IV), R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

In one embodiment of Formula (IV), R^6 is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, heterocycloalkyl, and cycloalkyl; wherein the C_{1-6} alkyl and C_{2-6} alkenyl represented by R^6 are independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)OR^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the heterocycloalkyl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of C(O)OH, F, Cl, Br and I. In another embodiment of Formula (IV), R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl and heterocycloalkyl; wherein the C_{1-6} alkyl is independently optionally substituted with one or more OH; wherein the heterocycloalkyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of OH, F, Cl, Br and I.

In one embodiment of Formula (IV), R^x is selected from the group consisting of CN, F, Cl, Br and I. In another embodiment of Formula (IV), R^x is selected from the group consisting of F, Cl, Br and I. In another embodiment of Formula (IV), R^x is CN. In another embodiment of Formula (IV), R^x is F.

Still another embodiment pertains to compounds having Formula (VI), which include

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid; and pharmaceutically acceptable salts thereof.

Pharmaceutical Compositions, Combination Therapies, Methods of Treatment, and Administration

Another embodiment comprises pharmaceutical compositions comprising a compound having Formula (I) and an excipient.

Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I).

Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).

Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).

Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin

damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).

Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).

Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease,

stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with NAMPT.

Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with NAMPT.

Compounds having Formula (I) may exist as acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during isolation or following purification of the compounds. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate salts of

the compounds are contemplated as being embraced by this invention. Basic addition salts of the compounds are those derived from the reaction of the compounds with the hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium.

The compounds having Formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally or vaginally.

Therapeutically effective amounts of compounds having Formula (I) depend on the recipient of the treatment, the disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered. The amount of a compound of this invention having Formula (I) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.

Compounds having Formula (I) may be administered with or without an excipient. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.

Excipients for preparation of compositions comprising a compound having Formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene

glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.

Compounds having Formula (I) are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters (for example, Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNA's, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteosome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, and the like, and in combination with one or more of these agents .

BiTE antibodies are bi-specific antibodies that direct T-cells to attack cancer cells by simultaneously binding the two cells. The T-cell then attacks the target cancer cell. Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like. Without being limited by theory, one of the mechanisms by which T-cells elicit apoptosis of the target cancer cell is by exocytosis of cytolytic granule components, which include perforin and granzyme B.

SiRNAs are molecules having endogenous RNA bases or chemically modified nucleotides. The modifications do not abolish cellular activity, but rather impart increased stability and/or increased cellular potency. Examples of chemical modifications include

phosphorothioate groups, 2'-deoxynucleotide, 2'-OCH_3-containing ribonucleotides, 2'-F-ribonucleotides, 2'-methoxyethyl ribonucleotides, combinations thereof and the like. The siRNA can have varying lengths (e.g., 10-200 bps) and structures (e.g., hairpins, single/double strands, bulges, nicks/gaps, mismatches) and are processed in cells to provide active gene silencing. A double-stranded siRNA (dsRNA) can have the same number of nucleotides on each strand (blunt ends) or asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be present on the sense and/or the antisense strand, as well as present on the 5'- and/ or the 3'-ends of a given strand.

Multivalent binding proteins are binding proteins comprising two or more antigen binding sites. Multivalent binding proteins are engineered to have the three or more antigen binding sites and are generally not naturally occurring antibodies. The term "multispecific binding protein" means a binding protein capable of binding two or more related or unrelated targets. Dual variable domain (DVD) binding proteins are tetravalent or multivalent binding proteins binding proteins comprising two or more antigen binding sites. Such DVDs may be monospecific (i.e., capable of binding one antigen) or multispecific (i.e., capable of binding two or more antigens). DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as DVD Ig's. Each half of a DVD Ig comprises a heavy chain DVD polypeptide, a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.

Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, trofosfamide and the like.

Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.

Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine,

doxifluridine, eflornithine, EICAR (5-ethynyl-1-β -D-ribofuranosylimidazole-4-carboxamide), enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.

Antivirals include ritonavir, hydroxychloroquine and the like.

Aurora kinase inhibitors include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific kinase inhibitors and pan-Aurora kinase inhibitors and the like.

Bcl-2 protein inhibitors include AT-101 ((-)gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2-targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.

Bcr-Abl kinase inhibitors include DASATINIB® (BMS-354825), GLEEVEC® (imatinib) and the like.

CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.

COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX® (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.

EGFR inhibitors include ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.

ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.

Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.

HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (human recombinant antibody to HSP-90), NCS-683664, PU24FCl, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.

Inhibitors of inhibitors of apoptosis proteins include HGS1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.

Antibody drug conjugates include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like

Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.

Kinesin inhibitors include Eg5 inhibitors such as AZD4877, ARRY-520; CENPE inhibitors such as GSK923295A and the like.

JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and INCB018424 and the like.

MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.

mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI-103, PP242, PP30, Torin 1 and the like.

Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like.

PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.

Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin and the like.

Polo-like kinase inhibitors include BI-2536 and the like.

Phosphoinositide-3 kinase (PI3K) inhibitors include wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.

Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.

VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals (Boulder, CO.) and Chiron, (Emeryville, CA)) , axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, ZACTIMA™ (vandetanib, ZD-6474) and the like.

Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (liposomal doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (valrubicin), zinostatin and the like.

Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.

Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab, CD20 antibodies types I and II and the like.

Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMA™ (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA® (finasteride), rilostane, SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), VANTAS® (Histrelin implant), VETORYL® (trilostane or modrastane), ZOLADEX® (fosrelin, goserelin) and the like.

Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like.

PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.

Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.

Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.

Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, ACTIMMUNE® (interferon gamma-1b) or interferon gamma-n1, combinations thereof and the like. Other agents include ALFAFERONE®,(IFN-α), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE® (sipuleucel-T), sargaramostim, sizofilan, teceleukin, THERACYS® (Bacillus Calmette-Guerin), ubenimex, VIRULIZIN® (immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF-10 (Tetrachlorodecaoxide (TCDO)), PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like.

Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.

Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.

Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL® (mercaptopurine).

Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.

Ubiquitin ligase inhibitors include MDM2 inhibitors, such as nutlins, NEDD8 inhibitors such as MLN4924 and the like.

Compounds of this invention can also be used as radiosensitizers that enhance the efficacy of radiotherapy. Examples of radiotherapy include external beam radiotherapy, teletherapy, brachytherapy and sealed, unsealed source radiotherapy and the like.

Additionally, compounds having Formula (I) may be combined with other chemotherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN® (Ad5CMV-p53 vaccine), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN® (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotene), AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX® (human papillomavirus vaccine), CHOP® (C: CYTOXAN® (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); O: Vincristine (ONCOVIN®); P: prednisone), CYPAT™ (cyproterone acetate), combrestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor) or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE® (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EPO906 (epithilone B), GARDASIL® (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), GASTRIMMUNE®, GENASENSE®, GMK (ganglioside conjugate vaccine), GVAX® (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT®(AE-941), NEUTREXIN® (trimetrexate glucuronate), NIPENT® (pentostatin), ONCONASE® (a ribonuclease enzyme), ONCOPHAGE® (melanoma vaccine treatment), ONCOVAX® (IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM® (antibody-based cell drug), OVAREX® MAb (murine monoclonal antibody), paclitaxel, PANDIMEX™ (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB® (catumaxomab), REVLIMID® (lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), TAXOPREXIN® (DHA-paclitaxel), TELCYTA® (canfosfamide, TLK286), temilifene, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline

dihydrochloride), TNFERADE™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER® or ZAVESCA® (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN® (motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS® (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), ZOMETA® (zolendronic acid), zorubicin and the like.

Data

Determination of the utility of compounds having Formula (I) as binders to and inhibitors of NAMPT was performed using Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) binding assays.

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Binding Assay of NAMPT

Test compounds were serially diluted (typically 11 half log dilutions) in neat DMSO to 50X final concentrations prior to dilution with assay buffer (50 mM HEPES (NaOH), pH 7.5, 100 mM NaCl, 10 mM $MgCl_2$, 1 mM DTT, 1% Glycerol) to 3X and 6% DMSO. Six μL were transferred to 384-well low-volume plates (Owens Corning #3673). To this, 12 μL of a 1.5X solution containing enzyme, probe and antibody were added. Final concentrations in the 18 μL reactions were 1X assay buffer, 2% DMSO, 6.8 nM NAMPT (human, recombinant, C-terminally His-tagged), 200 nM probe (a potent nicotinamide-competitive inhibitor conjugated to Oregon Green 488) and 1 nM Tb-anti-His antibody (Invitrogen # PV5895). Reactions were equilibrated at room temperature for 3 hours prior to reading on an Envision multi-label plate reader (Perkin Elmer; Ex = 337 nm, Em = 520 and 495 nm). Time-resolved FRET ratios (Em_{520}/Em_{495}) were normalized to controls, plotted as a function of compound concentration and fit with the four-parameter logistic equation to determine IC50s.

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Binding Assay of NAMPT with PRPP

Compound handling and data processing were identical to the assay in the absence of substrates (above). Final concentrations were 1X assay buffer, 2% DMSO, 2 nM NAMPT, 2 nM probe, 1 nM Tb-anti-His antibody (Invitrogen # PV5895), 200 μM PRPP and 2.5 mM ATP. Reactions were equilibrated for 16 hours prior to measurement to allow for potential enzymatic modification of test compounds.

Table 1 shows the utility of compounds having Formula I to functionally inhibit NAMPT.

5 TABLE 1

Example	TR-FRET Binding - IC50 (μM)	TR-FRET Binding - IC50 (with PRPP) (μM)	Example	TR-FRET Binding - IC50 (μM)	TR-FRET Binding - IC50 (with PRPP) (μM)
1	0.0638	nd	108	1.45	0.00161
2	7.56	0.00429	109	>10	0.00374
3	12.5	0.0715	110	>10	0.0232
4	1.22	0.000548	111	>10	0.00587
5	0.72	0.000461	112	3.68	0.00208
6	nd	nd	113	4.99	0.00676
7	1.61	0.486	114	1.99	0.00231
8	3.16	0.29	115	1.42	0.0036
9	12.5	0.641	116	nd	nd
10	0.281	0.0196	117	1.25	0.00302
11	0.476	0.00047	118	nd	nd
12	0.303	0.000241	119	4.57	0.00189
13	1.75	0.000403	120	3.78	0.00229
14	12.5	0.338	121	>10	0.00925
15	3.82	0.0921	122	>10	0.00431
16	4.72	0.217	123	3.82	0.000631
17	12.5	1.22	124	3.52	0.000624
18	4.82	0.814	125	>10	0.000712
19	12.5	12.5	126	4.18	0.0013
20	12.5	12.5	127	3.18	0.000533
21	0.996	0.505	128	>10	0.000727
22	0.384	0.0602	129	>10	0.00116
23	nd	nd	130	>10	0.00111
24	4.14	0.000682	131	4.78	0.000743
25	1.63	0.0014	132	4.85	0.00102
26	12.5	0.00121	133	0.0589	0.000527
27	>10	0.000632	134	0.2	0.000617
28	7.02	0.000833	135	0.0937	0.000169
29	>10	0.00216	136	0.0244	0.000174
30	>10	0.00229	137	0.0402	0.000236
31	3.6	0.000893	138	0.0555	0.000541
32	>10	0.00133	139	0.0561	0.000251
33	8.95	0.00122	140	>10	0.0223
34	7.57	0.000502	141	>10	0.0231
35	>10	0.00318	142	6.04	0.0169
36	2.42	0.000725	143	>10	0.0137
37	4.81	0.000531	144	>10	0.0332
38	2.69	0.00135	145	>10	0.107
39	2.39	0.000938	146	>10	0.098
40	2.2	0.00199	147	>10	0.0719
41	8.5	0.0297	148	>10	0.0606
42	>10	0.0246	149	>10	0.0942

43	8.11	0.000709	150	0.252	0.00021
44	>10	0.00777	151	0.219	0.000412
45	0.611	0.000206	152	0.768	0.000232
46	9.52	0.0022	153	1.43	0.000286
47	nd	nd	154	0.23	0.000518
48	0.807	0.000701	155	0.669	0.000254
49	1.69	0.00107	156	nd	nd
50	1.18	0.00252	157	nd	nd
51	>10	0.00494	158	nd	nd
52	1.01	0.000881	159	8.23	0.291
53	2.53	0.32	160	>10	0.195
54	2.11	0.0056	161	>10	0.215
55	>10	3.18	162	3.33	0.187
56	6.07	0.000719	163	6.8	0.171
57	>10	1.16	164	>10	0.583
58	1.72	0.807	165	0.34	0.0991
59	>10	0.266	166	>10	0.63
60	>10	0.00497	167	nd	nd
61	1.9	0.00178	168	>10	1.39
62	0.81	0.00108	169	8.45	0.266
63	2.25	0.000693	170	nd	nd
64	1.85	0.00297	171	8.79	0.0321
65	>10	0.00537	172	>10	0.153
66	>10	0.00242	173	0.707	0.00233
67	>10	0.00353	174	0.334	0.000714
68	>10	0.00468	175	1.15	0.0006
69	>10	0.00398	176	7.36	0.000365
70	>10	0.00508	177	4.62	0.000653
71	0.533	0.0007	178	6.97	0.000813
72	>10	0.00399	179	9.8	0.000492
73	>10	0.00704	180	7.71	0.000333
74	nd	nd	181	>10	0.000556
75	nd	nd	182	2.59	0.000264
76	nd	nd	183	2.94	0.000281
77	0.0956	0.000774	184	0.763	0.000285
78	2.9	0.000969	185	0.633	0.000476
79	6.58	0.00277	186	1.1	0.00123
80	8.02	0.00137	187	3.21	0.000216
81	5.28	0.00178	188	0.356	0.000195
82	7.54	0.00172	189	4.7	0.000586
83	2.89	0.000998	190	2.61	0.000606
84	3.2	0.00172	191	>10	0.000265
85	nd	nd	192	>10	0.000262
86	>10	0.00266	193	6.06	0.000755
87	2.26	0.00126	194	7.25	0.00112
88	>10	0.000602	195	>10	0.000338
89	5.83	0.00198	196	7.01	0.000538
90	>10	0.00225	197	9.21	0.000251

91	8.69	0.000543	198	2.61	0.000633
92	>10	0.000868	199	>10	0.000493
93	>10	0.0166	200	>10	0.000747
94	2.87	0.00122	201	>10	0.000457
95	3.89	0.0151	202	4.99	0.000405
96	4.19	0.00335	203	>10	0.0136
97	>10	0.00589	204	3.73	0.00146
98	1.5	0.00147	205	0.739	0.000177
99	3.56	0.0015	206	5.63	0.000633
100	nd	nd	207	3.86	0.000331
101	5.62	0.00284	208	2.89	0.00025
102	0.306	0.00216	209	6.7	0.000245
103	0.709	0.00306	210	2.74	0.000192
104	0.445	0.00131	211	nd	nd
105	nd	nd	212	5.71	0.00103
106	1.93	0.0018	213	9.86	0.000411
107	0.814	0.00224			

nd = no data

Compounds which inhibit NAMPT are useful for treating diseases in which activation of NF-KB is implicated. Such methods are useful in the treatment of a variety of diseases including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia.

Involvement of NAMPT in the treatment of cancer is described in WO 97/48696. Involvement of NAMPT in immuno-supression is described in WO 97/48397. Involvement of NAMPT for the treatment of diseases involving angiogenesis is described in WO 2003/80054. Involvement of NAMPT for the treatment of rheumatoid arthritis and septic shock is described in WO 2008/025857. Involvement of NAMPT for the prophlaxis and treatment of ischaemia is described in WO 2009/109610.

Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct

carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like.

Schemes and Experimentals

The following abbreviations have the meanings indicated. ADDP means 1,1'-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of $(DHQD)_2PHAL$, $K_3Fe(CN)_6$, K_2CO_3, and K_2SO_4; 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means tert-butoxycarbonyl; $(DHQD)_2PHAL$ means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; dppm

means 1,1-bis(diphenylphosphino)methane; EDAC·HCl means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N'N'N'-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH_3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh_3 means triphenylphosphine.

The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.

Schemes

Scheme 1



As shown in Scheme 1, 2-bromothiazole-5-carboxylic acid can be coupled with a suitable amine of formula (1), wherein R^3, R^4, and R^5 are as described herein, under reaction conditions known to those skilled in the art and readily available in the literature, to provide compounds of formula (2). Compounds of formula (2) can be reacted with suitable amines of formula (3), wherein R^6 is as described herein, to provide compounds of formula (4). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to acetonitrile. Compounds of formula (6), which are representative of compounds of Formula (I), can be prepared by reacting compounds of formula (4) with a suitable compound of formula (5), wherein R^6 as described herein. The reaction is typically performed in a suitable solvent such as but not limited to dichloromethane at ambient temperature in the presence of a base such as but not limited to pyridine.

Scheme 2



Compounds of formula (4), which can be prepared as described in Scheme 1, can be reacted with bis(2,5-dioxopyrrolidin-1-yl)carbonate at an elevated temperature in the presence of a base such as but not limited to pyridine, followed by the addition of a base such as but not limited to N, N –diisopropylethylamine, and an amine of formula (3) to provide compounds of formula (6) which are representative of the compounds of Formula (I).

Scheme 3



As shown in Scheme 3, compounds of formula (4), which can be prepared as described in Scheme 1, can be reacted with a suitable alkyl halide of formula (7), wherein X is an appropriate halide and R^6 is as described herein, to provide compounds of formula (8), which are representative of the compounds of Formula (I). The reaction is typically performed at an elevated temperature in a suitable solvent such as but not limited to acetonitrile, and may involve the use of microwave heating.

Scheme 4



Compounds of formula (4), which can be prepared as described in Scheme 1, can be reacted with compounds of formula (9), wherein R^6 is as described herein, in the presence of a base such as but not limited to N, N-diisopropylethylamine, to provide compounds of formula (10), which are representative of the compounds of Formula (I). The reaction is typically performed at an elevated temperature in a suitable solvent such as but not limited to dimethylsulfoxide, methanol, or mixtures thereof.

Scheme 5



As shown in Scheme 5, chloroacetyl bromide can be reacted with compounds of formula (4), which can be prepared as described in Scheme 5, in the presence of a base such as but not limited to pyridine, at a reduced temperature followed by reaction with a suitable amine of formula (11), wherein each R^8 is as described herein, at an elevated temperature, to provide compounds of formula (12). The reaction is typically performed in a solvent such as but not limited to dichloromethane.

Scheme 6



As shown in Scheme 6, compounds of formula (2), which can be prepared as described in Scheme 1, can be coupled with a suitable amine of formula (13), wherein R^1 and R^2 taken together with the N to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring, to provide compounds of formula (14). The reaction is typically performed at an elevated temperature in the presence of potassium phosphate, a catalyst such as but not limited to tris(dibenzylideneacetone)dipalladium(0), and a ligand such as but not limited to 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos). The reaction is typically performed in a suitable solvent such as but not limited to dioxane.

Examples

The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Each exemplified compound and intermediate was named using ACD/ChemSketch Version 12.5 (13 May 2009), Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA).

Experimentals

Example 1

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

The title compound was prepared as described in Example 9, substituting 3-(4-(chloromethyl)phenyl)pyridine for 1-(2-chloroethyl)pyrrolidine.

Example 2

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide

Example 2A

methyl 2-(4-(pyridin-3-yl)benzylamino)thiazole-5-carboxylate

To a 250 mL round-bottomed flask was added 4-(pyridin-3-yl)benzaldehyde (4 g, 21.8 mmol), methyl 2-aminothiazole-5-carboxylate (3.45 g, 21.83 mmol) and acetic acid (0.375 ml, 6.55 mmol) in toluene (109 ml). The reaction mixture was heated at reflux under Dean-Stark conditions for 3 hours, cooled to room temperature, and the volatiles were removed by rotary evaporation. Methanol was added, the solution was cooled to 0 °C, and sodium borohydride (1.322 g, 34.9 mmol) was carefully added. The reaction was stirred at 0 °C for 15 minutes and allowed to warm to room temperature while stirring for an additional 2 hour. The solids were filtered off, washed with water and dried under high vaccuum to give the title compound which was used in the next step without further purification.

Example 2B

2-(methyl(4-(pyridin-3-yl)benzyl)amino)thiazole-5-carboxylic acid

Example 2A (500 mg, 1.537 mmol) was dissolved in tetrahydrofuran (7683 µl) and sodium hydride (92 mg, 2.305 mmol) was added carefully. The suspension was allowed to stir for about 20 minutes at room temperature. Iodomethane (106 µl, 1.690 mmol) was then added and the reaction was stirred for an additional 30 minutes. To the mixture was added excess 1N aqueous NaOH followed by additional methanol and stirred at 55 °C for 1.5 hours. The reaction mixture was concentrated by rotary evaporation and the residue was taken up in water. The pH was adjusted to around 5-6 by addition of 2 N aqueous HCl, upon which time white solids precipitated out and were collected by vacuum filtration. The solids were washed with water, diethyl ether, and dried under high vaccuum overnight to provide the title compound.

Example 2C

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide

To a 20 mL vial was added Example 2B (100 mg, 0.307 mmol) and 3-(1H-imidazol-1-yl)propan-1-amine (40.3 µl, 0.338 mmol) in DMF (1229 µl). 1-Ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (103 mg, 0.538 mmol) and 1-hydroxybenzotriazole hydrate (82 mg, 0.538 mmol) were added and the reaction mixture was stirred over the weekend at room temperature. The reaction mixture was purified directly by HPLC (0-70% water acetonitrile) to give the title compound. ^{1}H NMR (300 MHz, DMSO-d_6)

δ 8.88 (d, J = 1.8 Hz, 1H), 8.56 (dd, J = 4.8, 1.5 Hz, 1H), 8.22 (t, J = 5.6 Hz, 1H), 8.10 – 8.00 (m, 1H), 7.80 (s, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.64 (s, 1H), 7.52 – 7.44 (m, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.19 (s, 1H), 6.88 (s, 1H), 4.79 (s, 2H), 3.99 (t, J = 6.9 Hz, 2H), 3.20 – 3.11 (m, 2H), 3.11 (s, 3H), 1.90 (p, J = 6.9 Hz, 2H); MS (ESI(+)) m/e 433.13 $(M+H)^+$.

Example 3

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 3A

methyl 2-(4-fluorobenzylamino)thiazole-5-carboxylate

The title compound was prepared as described in Example 2A, substituting 4-fluorobenzaldehyde for 4-(pyridin-3-yl)benzaldehyde.

Example 3B

2-((4-fluorobenzyl)(methyl)amino)thiazole-5-carboxylic acid

The title compound was prepared as described in Example 2B, substituting Example 3A for Example 2A.

Example 3C

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

The title compound was prepared as described in Example 2C, substituting Example 3B for Example 2B. ^{1}H NMR (300 MHz, DMSO-d_6) δ 8.20 (t, J = 5.6 Hz, 1H), 7.78 (s, 1H), 7.63 (s, 1H), 7.37 – 7.28 (m, 2H), 7.22 – 7.13 (m, 3H), 6.88 (t, J = 1.1 Hz, 1H), 4.71 (bs, 2H), 3.99 (t, J = 6.9 Hz, 2H), 3.20 – 3.09 (m, 2H), 3.05 (s, 3H), 1.90 (p, J = 6.9 Hz, 2H); MS (ESI(+)) m/e 374.1 $(M+H)^+$.

Example 6

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6A

N-(3-(1H-imidazol-1-yl)propyl)-2-bromothiazole-5-carboxamide

2-Bromothiazole-5-carboxylic acid (0.4 g, 1.923 mmol), 3-(1H-imidazole-1-yl)propan-1-amine (0.265 g, 2.115 mmol), and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) (0.935 g, 2.115 mmol) were mixed in dichloromethane (7 ml), treated with Hunig's base (0.705 ml, 4.04 mmol) and stirred at 25 °C for 2 hours. The reaction mixture was diluted with dichloromethane and washed with water and brine. The organic layer was dried ($MgSO_4$), filtered and concentrated. Purification by flash chromatography (silica gel, 2-20% methanol/dichloromethane) afforded the title compound.

Example 6B

N-(3-(1H-imidazol-1-yl)propyl)-2-((4-fluorobenzyl)amino)thiazole-5-carboxamide

Example 6A (2 g, 6.35 mmol) and (4-fluorophenyl)methanamine (0.794 g, 6.35 mmol) in acetonitrile (10 ml) were stirred at 120 °C overnight. The reaction mixture was cooled, concentrated, taken into ethyl acetate and washed with saturated aqueous $NaHCO_3$ and brine. The combined aqueous layers were extracted twice with ethyl acetate. The combined organic extracts were dried ($MgSO_4$) and filtered. The filtrate was concentrated until solid material precipitated. The mixture was filtered to provide the title compound.

Example 6C

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6B (0.2 g, 0.556 mmol) was dissolved in dichloromethane (2.7 ml) and pyridine (0.3 ml) and was treated dropwise with a solution of 3-methylbutanoyl chloride (0.102 ml, 0.835 mmol) in dichloromethane (0.5 ml). The reaction mixture was stirred at 25 °C for 2 hours, concentrated, and purified using reverse phase HPLC (Phenomenex Luna C8(2) 5 um 100Å AXIA column (30mm × 75mm) run with a gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B), at a flow rate of 50mL/min (0-0.5 min 10% A, 0.5-7.0 min linear gradient 10-95% A, 7.0-10.0 min 95% A, 10.0-12.0 min linear gradient 95-10% A) to afford the title compound. ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.87 (s, 1H), 7.60 (s, 1H), 7.19 – 7.07 (m, 3H), 7.07 – 6.97 (m, 3H), 5.89 (s, 1H), 5.47 (s, 2H), 4.07 (t, J = 6.9 Hz, 2H), 3.46 (q, J = 6.6 Hz, 2H), 2.43 (d, J = 6.8 Hz, 2H), 2.36 – 2.19 (m, 1H), 2.19 – 2.04 (m, 2H), 0.93 (d, J = 6.6 Hz, 6H); MS (ESI(+)) m/e 443.5 $(M+H)^+$.

The following examples were prepared as described in Example 6, substituting the appropriate amine in Example 6B and the appropriate acyl chloride in Example 6C. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as described in Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA
4	2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.08 (s, 1H), 7.93 (s, 1H), 7.36 (d, J = 14.1 Hz, 2H), 7.17 – 7.08 (m, 2H), 7.03 (t, J = 8.5 Hz, 2H), 6.76 (ddd, J = 47.8, 25.3, 16.1 Hz, 1H), 5.47	(ESI(+)) m/e 486 $(M+H)^+$

	thiazole-5-carboxamide	(s, 2H), 4.31 (d, *J* = 2.8 Hz, 2H), 3.93 (d, *J* = 11.0 Hz, 2H), 3.50 (dd, *J* = 11.4, 5.8 Hz, 2H), 3.42 (t, *J* = 11.8 Hz, 2H), 2.48 (d, *J* = 6.7 Hz, 2H), 2.27 – 2.20 (m, 2H), 1.65 (d, *J* = 11.2 Hz, 2H), 1.30 – 1.14 (m, 2H).	
5	2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.00 (s, 1H), 7.95 (s, 1H), 7.32 (d, *J* = 17.1 Hz, 2H), 7.19 – 7.08 (m, 2H), 7.02 (t, *J* = 8.6 Hz, 2H), 6.77 (s, 1H), 5.46 (s, 2H), 4.29 (t, *J* = 6.5 Hz, 2H), 3.55 – 3.40 (m, 2H), 2.42 (d, *J* = 6.7 Hz, 2H), 2.23 (d, *J* = 6.8 Hz, 2H), 2.19 (d, *J* = 6.4 Hz, 1H), 1.71 (dd, *J* = 35.7, 15.8 Hz, 2H), 1.35 – 1.19 (m, 2H), 1.15 (d, *J* = 12.4 Hz, 2H), 1.00 (t, *J* = 12.6 Hz, 2H), 0.87 (dd, *J* = 22.6, 10.6 Hz, 2H).	(ESI(+)) m/e 484 $(M+H)^+$
11	2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.33 (s, 1H), 8.05 (d, *J* = 6.3 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 2H), 7.47 (d, *J* = 8.3 Hz, 2H), 7.31 (s, 2H), 6.97 – 6.89 (m, 4H), 6.82 – 6.71 (m, 1H), 5.31 (s, 2H), 4.35 (d, *J* = 4.9 Hz, 2H), 3.49 (d, *J* = 5.9 Hz, 2H), 2.23 (dd, *J* = 7.9, 2.8 Hz, 2H).	(ESI(+)) m/e 489 (M+H)+
12	2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.16 (s, 1H), 8.00 (s, 1H), 7.51 – 7.44 (m, 1H), 7.38 – 7.32 (m, 4H), 7.01 – 6.88 (m, 5H), 5.37 (s, 2H), 4.34 (t, *J* = 6.4 Hz, 2H), 3.53 – 3.47 (m, 2H), 2.30 – 2.19 (m, 2H).	(ESI(+)) m/e 498 (M+H)+

13	2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.20 (s, 1H), 7.99 (s, 1H), 7.48 – 7.39 (m, 2H), 7.35 (d, *J* = 15.2 Hz, 2H), 7.12 (dt, *J* = 19.0, 8.6 Hz, 2H), 6.96 (qd, *J* = 8.7, 6.0 Hz, 4H), 5.39 (s, 2H), 4.34 (t, *J* = 6.5 Hz, 2H), 3.51 (dd, *J* = 11.6, 6.0 Hz, 2H), 2.31 – 2.19 (m, 2H).	(ESI(+)) m/e 482 (M+H)+
24	2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.88 (s, 1H), 7.61 (s, 1H), 7.15 (dd, *J* = 8.6, 5.2 Hz, 2H), 7.10 (s, 1H), 7.03 (d, *J* = 8.6 Hz, 2H), 6.99 (d, *J* = 8.1 Hz, 2H), 5.45 (s, 2H), 4.30 – 4.24 (m, 2H), 4.07 (t, *J* = 6.9 Hz, 2H), 3.48 – 3.43 (m, 5H), 2.18 – 2.10 (m, 2H).	(ESI(+)) m/e 432 (M+H)+
25	2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.88 (s, 1H), 7.60 (s, 1H), 7.16 (dd, *J* = 8.6, 5.2 Hz, 2H), 7.10 (s, 1H), 7.04 – 6.99 (m, 2H), 6.98 (s, 1H), 5.92 (s, 1H), 5.51 (s, 2H), 4.06 (t, *J* = 6.9 Hz, 2H), 3.75 (t, *J* = 6.2 Hz, 2H), 3.48 – 3.41 (m, 2H), 3.33 (s, 3H), 2.81 (t, *J* = 6.2 Hz, 2H), 2.12 (dd, *J* = 6.9, 3.9 Hz, 2H).	(ESI(+)) m/e 446 (M+H)+
44	1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium		(ESI(+)) m/e 480 (M+H)+
45	2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.98 (s, 1H), 7.58 (s, 1H), 7.20 – 7.07 (m, 3H), 7.07 – 6.95 (m, 3H), 5.87 (dd, *J* = 8.9, 3.5 Hz, 1H), 4.35 (t, *J* = 7.3 Hz, 2H), 4.07 (t, *J* = 6.9 Hz, 2H), 3.46 (dd, *J* = 8.0, 4.8 Hz, 2H),	(ESI(+)) m/e 458 (M+H)+

		3.04 (t, *J* = 7.3 Hz, 2H), 2.21 (d, *J* = 6.7 Hz, 2H), 2.19 – 2.16 (m, 1H), 2.16 – 2.08 (m, 2H), 0.92 (d, *J* = 6.2 Hz, 6H).	
48	2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.09 (s, 1H), 8.01 (s, 1H), 7.63 (d, *J* = 8.1 Hz, 2H), 7.37 (s, 1H), 7.33 (d, *J* = 7.9 Hz, 3H), 6.74 (s, 1H), 4.39 (t, *J* = 7.4 Hz, 2H), 4.33 (t, *J* = 6.3 Hz, 2H), 3.51 (d, *J* = 5.4 Hz, 2H), 3.20 – 3.07 (m, 2H), 2.31 – 2.21 (m, 5H), 0.95 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 465 (M+H)+
49	2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.12 (s, 1H), 8.00 (s, 1H), 7.63 (d, *J* = 8.0 Hz, 2H), 7.39 (s, 1H), 7.33 (d, *J* = 8.2 Hz, 3H), 6.72 (s, 1H), 4.45 – 4.25 (m, 4H), 3.97 (d, *J* = 8.2 Hz, 2H), 3.60 – 3.33 (m, 4H), 3.14 (t, *J* = 7.3 Hz, 2H), 2.33 (d, *J* = 6.5 Hz, 4H), 1.65 (d, *J* = 12.9 Hz, 2H), 1.36 – 1.19 (m, 2H).	(ESI(+)) m/e 507 (M+H)+
50	2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.21 (dd, *J* = 17.5, 1.7 Hz, 1H), 7.91 (d, *J* = 4.2 Hz, 1H), 7.64 (d, *J* = 8.3 Hz, 2H), 7.35 (d, *J* = 18.5 Hz, 2H), 7.24 (s, 1H), 7.04 – 6.89 (m, 1H), 5.53 (s, 2H), 4.34 (dd, *J* = 9.6, 3.6 Hz, 2H), 3.57 – 3.43 (m, 2H), 2.38 (d, *J* = 6.7 Hz, 2H), 2.29 – 2.19 (m, 3H), 0.93 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 451 (M+H)+
51	2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.12 (s, 1H), 8.00 (s, 1H), 7.63 (d, *J* = 8.0 Hz, 2H), 7.39 (s, 1H), 7.33 (d, *J* = 8.2 Hz, 3H), 6.72 (s, 1H), 5.53 (s, 2H), 4.45 – 4.25 (m, 2H), 3.97 (d, *J* = 8.2 Hz, 2H), 3.60 – 3.33 (m,	(ESI(+)) m/e 493 (M+H)+

		2H), 3.14 (t, *J* = 7.3 Hz, 2H), 2.33 (d, *J* = 6.5 Hz, 4H), 1.65 (d, *J* = 12.9 Hz, 2H), 1.36 – 1.19 (m, 3H).	
52	2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 9.00 (s, 1H), 8.06 (s, 1H), 7.73 (s, 1H), 7.68 (d, *J* = 8.1 Hz, 2H), 7.59 (s, 1H), 7.41 (d, *J* = 8.1 Hz, 2H), 4.47 (t, *J* = 7.2 Hz, 2H), 4.34 (t, *J* = 6.9 Hz, 2H), 4.02 – 3.88 (m, 1H), 3.79 (dt, *J* = 8.1, 4.0 Hz, 1H), 3.73 (dd, *J* = 15.5, 7.6 Hz, 1H), 3.41 (t, *J* = 6.4 Hz, 2H), 3.27 – 3.23 (m, 1H), 3.19 (t, *J* = 7.2 Hz, 2H), 2.64 (d, *J* = 9.4 Hz, 2H), 2.62 – 2.57 (m, 1H), 2.24 – 2.16 (m, 2H), 2.16 – 2.08 (m, 1H), 1.47 (dd, *J* = 12.6, 6.3 Hz, 1H).	(ESI(+)) m/e 493 (M+H)+
53	2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.94 (s, 1H), 7.31 (s, 1H), 7.25 (s, 1H), 7.18 – 7.08 (m, 2H), 7.02 (t, *J* = 8.5 Hz, 2H), 6.66 (s, 1H), 5.47 (s, 2H), 4.13 (t, *J* = 6.9 Hz, 2H), 3.52 (d, *J* = 5.9 Hz, 2H), 2.68 (s, 3H), 2.44 (d, *J* = 6.8 Hz, 2H), 2.31 – 2.22 (m, 1H), 2.14 (d, *J* = 6.4 Hz, 2H), 0.93 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 458 (M+H)+
54	2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(4-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.85 (s, 1H), 7.95 (d, *J* = 7.1 Hz, 1H), 7.11 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.00 (dd, *J* = 20.2, 11.7 Hz, 4H), 5.45 (s, 2H), 4.21 (t, *J* = 6.6 Hz, 2H), 3.55 – 3.40 (m, 2H), 2.45 – 2.38 (m, 2H), 2.32 (d, *J* = 5.6 Hz, 3H), 2.29 – 2.23 (m, 1H), 2.21 – 2.15 (m, 2H), 0.92 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 458 (M+H)+

61	2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.94 (s, 1H), 7.74 – 7.70 (m, 3H), 7.58 (s, 1H), 7.36 (d, *J* = 8.1 Hz, 2H), 5.63 (d, *J* = 4.1 Hz, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 4.03 – 3.91 (m, 1H), 3.81 – 3.67 (m, 2H), 3.42 – 3.32 (m, 3H), 2.84 – 2.77 (m, 1H), 2.76 – 2.69 (m, 2H), 2.26 – 2.09 (m, 3H), 1.61 – 1.46 (m, 1H).	(ESI(+)) m/e 479 (M+H)+
62	2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.18 (s, 1H), 7.91 (s, 1H), 7.63 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 18.0 Hz, 2H), 7.28 (d, *J* = 8.3 Hz, 2H), 6.92 (s, 1H), 5.58 (s, 2H), 4.34 (t, *J* = 6.5 Hz, 2H), 3.76 (t, *J* = 6.0 Hz, 2H), 3.50 (d, *J* = 5.8 Hz, 2H), 3.33 (s, 3H), 2.77 (t, *J* = 6.0 Hz, 2H), 2.32 – 2.18 (m, 2H).	(ESI(+)) m/e 453 (M+H)+
74	2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.56 (t, *J* = 5.5 Hz, 1H), 8.15 (s, 1H), 7.72 (dd, *J* = 8.7, 5.3 Hz, 3H), 7.39 (t, *J* = 8.9 Hz, 2H), 7.23 (s, 1H), 6.92 (s, 1H), 4.04 (dd, *J* = 15.5, 8.6 Hz, 4H), 3.21 (dd, *J* = 12.8, 6.7 Hz, 2H), 1.97 (dd, *J* = 13.9, 6.9 Hz, 2H), 1.49 (dd, *J* = 15.2, 7.1 Hz, 2H), 1.38 (dt, *J* = 13.2, 6.4 Hz, 1H), 0.67 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 444 (M+H)+
75	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.80 (s, 1 H) 7.98 (s, 1 H) 7.62 (s, 1 H) 7.49 (s, 1 H) 7.11 - 7.17 (m, 3 H) 7.04 - 7.07 (m, 2 H) 5.46 (s, 2 H) 4.24 (t, *J* =7.02 Hz, 3 H) 3.65 (t, *J* =5.95 Hz, 2 H)	(ESI(+)) m/e 442 (M+H)+

		3.28 - 3.31 (m, 3 H) 2.86 (t, *J* =5.95 Hz, 2 H) 2.27 (s, 4 H) 2.06 - 2.13 (m, 2 H).	
76	N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.16 (s, 1H), 8.42 (s, 1H), 8.08 (s, 1H), 7.35 (d, *J* = 13.4 Hz, 2H), 7.24 – 7.08 (m, 1H), 7.05 (s, 1H), 4.45 (d, *J* = 6.7 Hz, 2H), 4.36 (t, *J* = 6.4 Hz, 2H), 3.55 – 3.49 (m, 2H), 2.28 – 2.23 (m, 3H), 1.75 – 1.69 (m, 2H), 1.52 (dd, *J* = 14.7, 7.1 Hz, 1H), 0.95 (d, *J* = 3.8 Hz, 6H).	(ESI(+)) m/e 417 (M+H)+
77	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (500 MHz, DMSO-d_6/D_2O) δ 8.12 (s, 1H), 7.68 (s, 1H), 7.33 (t, *J* = 8.0 Hz, 2H), 7.21 (s, 1H), 7.01 (t, *J* = 7.4 Hz, 1H), 6.97 (d, *J* = 8.3 Hz, 2H), 6.91 (s, 1H), 5.58 (q, *J* = 6.3 Hz, 1H), 4.24 (t, *J* = 9.8 Hz, 1H), 4.07 (d, *J* = 10.8 Hz, 1H), 4.02 (t, *J* = 6.9 Hz, 2H), 3.20 (t, *J* = 6.9 Hz, 2H), 1.95 (p, *J* = 6.9 Hz, 2H), 1.60 (dd, *J* = 11.9, 7.6 Hz, 1H), 1.56 (d, *J* = 6.3 Hz, 3H), 1.51 (dd, *J* = 12.9, 6.5 Hz, 1H), 0.81 (dd, *J* = 28.5, 6.3 Hz, 6H).	(ESI(+)) m/e 470 (M+H)+
85	2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.06 (s, 1H), 7.99 (s, 1H), 7.62 (d, *J* = 8.2 Hz, 2H), 7.39 – 7.33 (m, 4H), 4.42 (s, 2H), 4.32 (s, 2H), 3.75 (t, *J* = 6.1 Hz, 2H), 3.51 (d, *J* = 5.6 Hz, 2H), 3.36 (s, 3H), 3.12 – 3.16 (m, 2H), 2.74 (t, *J* = 6.1 Hz, 2H), 2.20 – 2.25 (m, 2H).	(ESI(+)) m/e 467 (M+H)+

93	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.72 (d, *J* =4.88 Hz, 2 H) 7.87 (s, 1 H) 7.59 (s, 1 H) 7.38 (t, *J* =4.88 Hz, 1 H) 7.13 (s, 1 H) 6.88 (s, 1 H) 5.65 (s, 2 H) 4.01 (t, *J* =7.02 Hz, 2 H) 3.69 (t, *J* =6.26 Hz, 2 H) 3.21 - 3.25 (m, 5 H) 2.89 (t, *J* =6.26 Hz, 2 H) 1.93 - 2.02 (m, 2 H).	(ESI(+)) m/e 430 (M+H)+
94	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.09 (d, *J* =5.19 Hz, 1 H) 7.96 (s, 1 H) 7.60 (s, 1 H) 7.13 (s, 1 H) 6.89 (s, 1 H) 6.79 (s, 1 H) 6.51 (s, 1 H) 5.47 (s, 2 H) 4.02 (t, *J* =6.87 Hz, 2 H) 3.82 - 3.86 (m, 3 H) 3.66 (t, *J* =5.95 Hz, 2 H) 3.22 - 3.25 (m, 2 H) 3.21 (s, 3 H) 2.84 (t, *J* =6.10 Hz, 2 H) 1.98 (t, *J* =7.02 Hz, 2 H).	(ESI(+)) m/e 459 (M+H)+
95	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.00 (s, 1 H), 7.60 (s, 1 H), 7.13 (s, 1 H), 6.89 (s, 1 H), 5.36 (s, 1 H), 4.02 (t, 2 H), 3.50 - 3.75 (m, 3 H), 3.22 - 3.25 (m, 4 H), 3.13 (t, *J* =6.26 Hz, 2 H), 2.29 - 2.40 (m, 1 H), 1.94 – 2.03 (m, 2 H).	(ESI(+)) m/e 419 (M+H)+
96	2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 8.46 (d, *J* = 2.4 Hz, 1H), 7.90 (s, 1H), 7.80 (dd, *J* = 8.4, 2.5 Hz, 1H), 7.70 (d, *J* = 1.6 Hz, 1H), 7.57 (s, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 5.60 (s, 2H), 4.31 (t, *J* = 6.9 Hz, 2H), 3.77 (t, *J* = 6.0 Hz, 2H), 3.38 (t, *J* = 6.3 Hz, 2H), 3.33 (s, 3H), 3.03 (t, *J* = 6.0 Hz, 2H), 2.25 – 2.08 (m, 2H).	(ESI(+)) m/e 463 (M+H)+

97	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.31 (d, *J* =4.88 Hz, 1 H), 7.93 - 7.95 (m, 1 H), 7.89 (s, 1 H), 7.60 (s, 1 H), 7.24 (d, *J* =4.88 Hz, 1 H), 7.13 (s, 1 H), 6.88 (s, 1 H), 5.48 (s, 1 H), 4.02 (t, *J* =6.87 Hz, 2 H), 3.67 (q, *J* =6.31 Hz, 2 H), 3.22 - 3.24 (m, 2 H), 3.20 (s, 3 H), 2.85 (t, *J* =5.95 Hz, 2 H), 2.39 (s, 3 H), 1.94 - 2.02 (m, 2 H).	(ESI(+)) m/e 443 (M+H)+
98	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.04 (d, *J* =2.44 Hz, 1 H), 8.00 (s, 1 H), 7.60 (s, 1 H), 7.55 (dd, *J* =8.54, 2.44 Hz, 1 H), 7.13 (s, 1 H), 6.89 (s, 1 H), 6.76 (d, *J* =8.54 Hz, 1 H), 5.43 (s, 2 H), 4.02 (t, *J* =6.87 Hz, 2 H), 3.82 - 3.86 (m, 3 H), 3.68 (t, *J* =6.10 Hz, 3 H), 3.24 (d, *J* =2.44 Hz, 2 H), 3.22 (s, 3 H), 2.90 - 2.95 (m, 2 H), 1.95 - 2.03 (m, 2 H), 1.22 (s, 1 H).	(ESI(+)) m/e 459 (M+H)+
99	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.80 (s, 1 H), 8.05 (s, 1 H), 7.60 (s, 1 H), 7.14 (s, 1 H), 6.89 (s, 1 H), 5.58 (s, 2 H), 4.02 (t, *J* =7.02 Hz, 2 H), 3.69 (t, *J* =6.10 Hz, 2 H), 3.22 - 3.25 (m, 5 H), 2.95 (t, *J* =6.10 Hz, 2 H), 2.46 (s, 3 H), 1.95 - 2.03 (m, 2 H).	(ESI(+)) m/e 449 (M+H)+
100	2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 7.63 (s, 1 H), 7.58 - 7.61 (m, 1 H), 7.33 (s, 1 H) 7.13 (s, 2 H), 6.94 - 6.99 (m, 1 H), 6.89 (s, 1 H), 3.98 - 4.02 (m, 2 H), 3.69 (t, *J* =6.26 Hz, 2 H), 3.50 (s, 2 H),	(ESI(+)) m/e 458 (M+H)+

		3.30 (s, 3 H), 3.19 (t, *J* =6.87 Hz, 2 H), 2.88 - 2.93 (m, 2 H), 2.76 - 2.80 (m, 3 H), 1.93 - 1.97 (m, *J* =6.41 Hz, 3 H).	
101	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.49 (d, *J* =4.88 Hz, 1 H), 8.03 (s, 1 H), 7.62 - 7.71 (m, 2 H), 7.21 - 7.25 (m, 2 H), 7.16 (s, 1 H), 6.91 (s, 1 H), 4.52 - 4.57 (m, 2 H), 4.04 (t, *J* =6.87 Hz, 2 H), 3.64 (t, *J* =6.26 Hz, 2 H), 3.58 - 3.62 (m, 1 H), 3.24 (s, 3 H), 3.17 - 3.21 (m, 3 H), 2.84 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.04 (m, 2 H), 1.92 (s, 1 H).	(ESI(+)) m/e 443 (M+H)+
102	2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.06 (s, 1 H), 7.61 (s, 1 H), 7.14 (s, 1 H), 6.89 (s, 1 H), 6.79 (d, *J* =7.93 Hz, 1 H), 6.76 (d, *J* =1.53 Hz, 1 H), 6.65 (dd, *J* =7.93, 1.53 Hz, 1 H), 5.93 (s, 2 H), 4.34 - 4.38 (m, 2 H), 4.03 (t, *J* =7.02 Hz, 2 H), 3.62 (t, *J* =6.26 Hz, 2 H), 3.26 - 3.27 (m, 2 H), 3.24 (s, 3 H), 2.94 (t, *J* =7.32 Hz, 2 H), 2.77 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.06 (m, 1 H), 1.88 (s, 1 H).	(ESI(+)) m/e 486 (M+H)+
103	2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.05 (s, 1 H), 7.61 (s, 1 H), 7.31 - 7.34 (m, 2 H), 7.23 (d, 2 H), 7.14 (s, 1 H), 6.89 (s, 1 H), 4.37 - 4.42 (m, 2 H), 4.03 (t, *J* =7.02 Hz, 2 H), 3.63 (t, *J* =6.26 Hz, 2 H), 3.25 (s, 2 H), 3.24 (s, 3 H), 3.02 (t, *J* =7.32 Hz, 2 H), 2.79 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.04	(ESI(+)) m/e 476 (M+H)+

		(m, 2 H), 1.88 (s, 1 H).	
104	2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.06 (s, 1 H), 7.61 (s, 1 H), 7.30 - 7.37 (m, 1 H), 7.14 (s, 1 H), 6.99 - 7.08 (m, 3 H), 6.90 (s, 1 H), 4.40 - 4.44 (m, 2 H), 4.03 (t, *J* =7.02 Hz, 2 H), 3.63 (t, *J* =6.26 Hz, 2 H), 3.25 (s, 2 H), 3.24 (s, 3 H), 3.05 (t, *J* =7.48 Hz, 2 H), 2.80 (t, *J* =6.10 Hz, 2 H), 1.96 - 2.04 (m, 2 H), 1.90 (s, 1 H).	(ESI(+)) m/e 460 (M+H)+
105	2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 7.59 - 7.63 (m, 2 H), 7.27 (d, *J* =8.24 Hz, 2 H), 7.13 (s, 1 H), 7.00 - 7.04 (m, 2 H), 6.89 (s, 1 H), 4.00 (t, *J* =7.02 Hz, 2 H), 3.69 (t, *J* =6.10 Hz, 2 H), 3.50 (t, *J* =7.17 Hz, 2 H), 3.30 (s, 2 H), 3.17 - 3.24 (m, 3 H), 2.89 (t, *J* =7.17 Hz, 2 H), 2.77 (t, *J* =6.26 Hz, 2 H), 1.96 (q, *J* =7.12 Hz, 2 H), 1.85 (s, 2 H).	(ESI(+)) m/e 458 (M+H)+
106	2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.06 (s, 1 H), 7.62 (s, 1 H), 7.23 - 7.34 (m, 3 H), 7.14 - 7.19 (m, 2 H), 6.90 (s, 1 H), 4.39 - 4.44 (m, 2 H), 4.03 (t, *J* =6.87 Hz, 2 H), 3.63 (t, *J* =6.26 Hz, 2 H), 3.22 - 3.26 (m, 5 H), 3.04 (t, *J* =7.32 Hz, 2 H), 2.81 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.04 (m, 2 H), 1.92 (s, 1 H).	(ESI(+)) m/e 476 (M+H)+

107	N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.07 (s, 1 H), 7.61 (s, 1 H), 7.21 (t, *J* =7.78 Hz, 1 H), 7.14 (s, 1 H), 6.90 (s, 1 H), 6.75 - 6.82 (m, 3 H), 4.40 (t, *J* =7.32 Hz, 2 H), 4.03 (t, *J* =7.02 Hz, 2 H), 3.73 (s, 3 H), 3.60 (t, *J* =6.10 Hz, 2 H), 3.24 (s, 2 H), 3.23 (s, 3 H), 2.99 (t, *J* =7.32 Hz, 2 H), 2.74 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.05 (m, 2 H), 1.91 (s, 1 H).	(ESI(+)) m/e 472 (M+H)+
108	2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.03 (s, 1 H), 7.61 (s, 1 H), 7.25 - 7.31 (m, 2 H), 7.08 - 7.15 (m, 3 H), 6.90 (s, 1 H), 4.43 (t, *J* =7.32 Hz, 2 H), 4.03 (t, *J* =6.87 Hz, 2 H), 3.62 (t, *J* =6.26 Hz, 2 H), 3.25 (s, 2 H), 3.23 (s, 3 H), 3.08 (t, *J* =7.17 Hz, 2 H), 2.78 (t, *J* =6.26 Hz, 2 H), 1.96 - 2.03 (m, 2 H), 1.90 (s, 1 H).	(ESI(+)) m/e 460 (M+H)+
109	2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1)	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 7.63 (s, 1 H), 7.59 (s, 1 H), 7.29 (d, *J* =8.85 Hz, 2 H), 7.13 (s, 1 H), 6.88 - 6.94 (m, 3 H), 5.89 (t, *J* =6.41 Hz, 1 H), 4.00 (t, *J* =7.02 Hz, 2 H), 3.76 (s, 3 H), 3.63 (d, *J* =6.41 Hz, 2 H), 3.56 (t, *J* =6.41 Hz, 2 H), 3.22 (s, 1 H), 3.20 (s, 3 H), 3.17 - 3.19 (m, 1 H), 2.54 - 2.57 (m, 2 H), 1.91 - 1.99 (m, 2 H), 1.86 (s, 1 H).	(ESI(+)) m/e 488 (M+H)+
110	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.95 (s, 1 H), 8.47 (s, 1 H), 7.94 (d, *J* =14.04 Hz, 1 H), 7.73 - 7.81 (m, 1 H), 7.68 (d, *J*	(ESI(+)) m/e 443 (M+H)+

	1,3-thiazole-5-carboxamide	=4.88 Hz, 1 H), 7.56 (d, *J* =1.83 Hz, 1 H), 7.40 (d, *J* =7.93 Hz, 1 H), 7.28 (d, *J* =5.19 Hz, 1 H), 6.07 - 6.14 (m, 1 H), 4.26 (q, *J* =7.02 Hz, 3 H), 3.60 - 3.69 (m, 3 H), 3.20 (s, 3 H), 2.71 (t, *J* =6.26 Hz, 2 H), 2.05 - 2.15 (m, 3 H), 1.82 (d, *J* =7.32 Hz, 3 H).	
111	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.96 (d, *J* =6.10 Hz, 1 H), 8.08 (d, *J* =27.77 Hz, 1 H), 7.69 (d, *J* =4.88 Hz, 1 H), 7.56 - 7.59 (m, 1 H), 7.49 (s, 1 H), 7.27 (s, 1 H), 5.28 (s, 1 H), 4.24 - 4.32 (m, 4 H), 4.24 - 4.31 (m, 4 H), 3.75 - 3.79 (m, 4 H), 3.70 (t, *J* =6.10 Hz, 1 H), 3.61 (t, *J* =6.41 Hz, 1 H), 3.25 (s, 2 H), 3.23 (s, 2 H), 3.00 (t, *J* =6.10 Hz, 1 H), 2.61 (t, 1 H), 2.11 (m, 1 H).	(ESI(+)) m/e 432 (M+H)+
112	2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.70 (s, 1 H), 7.93 (s, 1 H), 7.58 (s, 1 H), 7.43 (s, 1 H), 7.36 (s, 1 H), 7.01 (t, *J* =8.54 Hz, 2 H), 5.53 (s, 2 H), 4.21 (t, *J* =7.02 Hz, 2 H), 3.70 (t, *J* =6.10 Hz, 2 H), 3.24 (s, 3 H), 2.99 (t, *J* =6.26 Hz, 2 H), 2.03 - 2.10 (m, 2 H), 1.10 (td, 3 H).	(ESI(+)) m/e 461 (M+H)+
113	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.95 (s, 1 H), 8.35 (s, 1 H), 7.98 (s, 1 H), 7.68 (d, *J* =1.83 Hz, 1 H), 7.62 (dd, *J* =8.24, 2.14 Hz, 1 H), 7.56 (s, 1 H), 7.32 (d, *J* =8.24 Hz, 1 H), 5.50 (s, 2 H), 4.26 (t, *J* =7.17 Hz, 2 H), 3.65 -	(ESI(+)) m/e 443 (M+H)+

		3.70 (m, 3 H), 3.22 (s, 3 H), 2.92 (t, *J* =5.95 Hz, 2 H), 2.48 (s, 3 H), 2.10 (q, *J* =6.92 Hz, 3 H).	
114	2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.85 (s, 1 H), 7.97 (s, 1 H), 7.64 (s, 1 H), 7.51 (s, 1 H), 7.37 (d, *J* =8.24 Hz, 2 H), 7.20 (d, *J* =8.54 Hz, 2 H), 5.49 (s, 2 H), 4.24 (t, *J* =7.17 Hz, 2 H), 3.66 (t, *J* =5.95 Hz, 2 H), 3.28 - 3.30 (m, 2 H), 3.20 (s, 3 H), 2.86 (t, *J* =6.10 Hz, 2 H), 2.06 - 2.14 (m, 2 H).	(ESI(+)) m/e 462 (M+H)+
115	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.96 (s, 1 H), 8.52 (s, 1 H), 8.40 (s, 1 H), 7.92 (s, 1 H), 7.68 (s, 1 H), 7.56 (s, 1 H), 5.56 (s, 2 H), 4.25 (t, *J* =7.02 Hz, 2 H), 3.70 (t, *J* =6.26 Hz, 2 H), 3.18 - 3.25 (m, 5 H), 3.02 (t, *J* =6.10 Hz, 2 H), 2.46 (s, 3 H), 2.06 - 2.13 (m, 2 H).	(ESI(+)) m/e 444 (M+H)+
116	2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.72 (s, 1 H), 7.98 (s, 1 H), 7.59 (s, 1 H), 7.45 (s, 1 H), 7.37 (t, *J* =7.78 Hz, 2 H), 7.22 (s, 1 H), 7.12 - 7.16 (m, 1 H), 5.50 (s, 2 H), 4.22 (t, *J* =7.02 Hz, 2 H), 3.66 (t, *J* =6.10 Hz, 2 H), 3.28 - 3.30 (m, 2 H), 3.20 (s, 3 H), 2.87 (t, *J* =5.95 Hz, 2 H), 2.08 (q, *J* =6.92 Hz, 2 H).	(ESI(+)) m/e 462 (M+H)+

117	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.30 (s, 1 H), 7.92 (s, 1 H), 7.69 (s, 1 H), 7.56 - 7.61 (m, 2 H), 7.22 (d, *J* =7.93 Hz, 1 H), 5.52 (s, 1 H), 4.26 (t, *J* =6.87 Hz, 2 H), 3.68 (t, *J* =6.26 Hz, 2 H), 3.26 (s, 2 H), 3.23 (s, 3 H), 2.95 (t, *J* =6.26 Hz, 2 H), 2.27 (s, 3 H), 2.05 - 2.15 (m, 2 H).	(ESI(+)) m/e 443 (M+H)+
118	2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.73 (s, 1 H), 7.59 (s, 1 H), 7.45 (s, 1 H) 7.21 - 7.28 (m, *J* =4.88 Hz, 1 H), 7.05 - 7.17 (m, 2 H), 6.83 (s, 1 H), 5.50 (s, 2 H), 4.22 (t, *J* =6.87 Hz, 2 H), 3.69 (t, *J* =5.95 Hz, 2 H), 3.29 (t, 1 H), 3.24 (s, 1 H), 3.22 (s, 3 H), 2.91 (t, *J* =6.10 Hz, 2 H), 2.05 - 2.12 (m, 2 H).	(ESI(+)) m/e 464 (M+H)+
119	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.92 (s, 1 H), 7.67 (s, 1 H), 7.54 (s, 1 H), 7.21 - 7.25 (m, 1 H), 7.14 - 7.19 (m, 2 H), 7.05 - 7.11 (m, 1 H), 6.68 (d, *J* =7.63 Hz, 1 H), 5.45 (s, 2 H), 4.26 (t, *J* =6.87 Hz, 2 H), 3.65 (t, *J* =6.10 Hz, 2 H), 3.19 (s, 3 H), 2.80 (t, *J* =6.10 Hz, 2 H), 2.37 (s, 3 H), 2.28 (d, *J* =5.49 Hz, 2 H), 2.03 - 2.14 (m, 2 H).	(ESI(+)) m/e 442 (M+H)+
120	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.94 (s, 1 H), 7.68 (s, 1 H), 7.56 (s, 1 H), 7.21 (t, *J* =7.63 Hz, 1 H), 7.02 - 7.10 (m, 2 H), 7.00 (s, 1 H), 6.93 (d, *J* =7.63 Hz, 1 H), 5.48 (s, 2 H), 4.21 - 4.29	(ESI(+)) m/e 442 (M+H)+

		(m, 2 H), 3.65 (t, *J* =6.10 Hz, 2 H), 3.29 - 3.31 (m, 2 H), 3.20 (s, 3 H), 2.86 (t, *J* =6.10 Hz, 2 H), 2.26 (s, 3 H), 2.06 - 2.15 (m, 2 H).	
121	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.96 (s, 1 H), 8.47 (d, 1 H), 7.92 (s, 1 H), 7.72 - 7.79 (m, 1 H), 7.69 (d, *J* =1.53 Hz, 1 H), 7.57 (d, *J* =1.83 Hz, 1 H), 7.26 - 7.34 (m, 2 H), 5.57 (s, 2 H), 4.26 (t, *J* =6.87 Hz, 2 H), 3.68 (t, *J* =5.95 Hz, 2 H), 3.26 (s, 2 H), 3.22 (s, 3 H), 2.95 (t, *J* =6.26 Hz, 2 H), 2.06 - 2.14 (m, *J* =13.35, 6.60, 6.60 Hz, 2 H).	(ESI(+)) m/e 429 (M+H)+
122	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.95 (s, 1 H), 8.45 - 8.51 (m, 2 H), 7.98 (s, 1 H), 7.68 (s, 1 H), 7.64 (d, 1 H), 7.56 (s, 1 H), 7.40 (d, *J* =4.88 Hz, 1 H), 5.53 (s, 2 H), 4.26 (t, *J* =7.17 Hz, 2 H), 3.68 (t, *J* =6.10 Hz, 2 H), 3.29 - 3.31 (m, 2 H), 3.21 (s, 3 H), 2.91 (t, *J* =5.95 Hz, 2 H), 2.07 - 2.14 (m, 2 H).	(ESI(+)) m/e 429 (M+H)+
133	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.07 (s, 1H), 8.00 (s, 1H), 7.35 (d, *J* = 8.9 Hz, 2H), 7.30 (t, *J* = 8.0 Hz, 2H), 7.01 (t, *J* = 7.4 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 3H), 5.23 (d, *J* = 6.4 Hz, 1H), 4.31 (t, *J* = 6.5 Hz, 3H), 4.14 (t, *J* = 11.2 Hz, 1H), 3.48 (dd, *J* = 10.8, 5.2 Hz, 2H), 2.25 – 2.16 (m, 3H), 1.70 (d, *J* = 6.5 Hz, 3H), 1.63 (m, 2H), 0.90 (dd, *J* = 5.8, 3.4 Hz, 6H).	(ESI(+)) m/e 470 (M+H)+

134	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.06 (s, 1H), 8.00 (s, 1H), 7.35 (d, *J* = 9.8 Hz, 2H), 7.30 (t, *J* = 8.0 Hz, 2H), 7.01 (t, *J* = 7.3 Hz, 1H), 6.90 (d, *J* = 8.1 Hz, 2H), 6.77 (s, 1H), 5.23 (d, *J* = 6.3 Hz, 1H), 4.30 (t, *J* = 6.5 Hz, 3H), 4.16 (s, 1H), 3.49 (dd, *J* = 10.8, 5.2 Hz, 2H), 2.24 – 2.17 (m, 3H), 1.70 (d, *J* = 6.5 Hz, 3H), 1.63 (m, 2H), 0.90 (dd, *J* = 5.9, 3.2 Hz, 6H).	(ESI(+)) m/e 470 (M+H)+
135	N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.13 (s, 1H), 8.08 (s, 1H), 7.35 (d, *J* = 9.6 Hz, 2H), 7.12 (s, 1H), 6.44 (s, 1H), 4.61 – 4.49 (m, 2H), 4.35 (t, *J* = 6.5 Hz, 2H), 3.51 (d, *J* = 5.6 Hz, 2H), 2.54 (s, 3H), 2.29 – 2.20 (m, 2H), 1.70 – 1.61 (m, 3H), 0.90 (d, *J* = 6.0 Hz, 6H).	(ESI(+)) m/e 431 (M+H)+
136	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.06 (s, 1H), 7.99 (s, 1H), 7.36 – 7.28 (m, 4H), 7.03 (t, *J* = 7.3 Hz, 2H), 6.94 (d, *J* = 8.3 Hz, 2H), 4.99 (s, 2H), 4.30 (t, *J* = 6.5 Hz, 2H), 4.24 – 4.08 (m, 2H), 3.47 (d, *J* = 5.6 Hz, 2H), 2.23 – 2.18 (m, 2H), 1.76 – 1.63 (m, 3H), 0.99 (d, *J* = 6.2 Hz, 6H).	(ESI(+)) m/e 456 (M+H)+
137	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.07 (s, 1H), 7.98 (s, 1H), 7.36 (d, *J* = 3.5 Hz, 2H), 7.34 – 7.29 (m, 2H), 7.26 – 7.17 (m, 3H), 6.90 (s, 1H), 4.32 (t, *J* = 6.5 Hz, 2H), 4.18 – 4.05 (m, 2H), 3.50 (d, *J* = 5.8 Hz, 2H), 3.10 (t, *J* = 7.5 Hz, 2H), 2.97 – 2.92 (m, 2H), 2.27 – 2.19 (m,	(ESI(+)) m/e 454 (M+H)+

		2H), 1.66 (dt, *J* = 12.9, 6.4 Hz, 1H), 1.53 (dd, *J* = 16.0, 7.1 Hz, 2H), 0.95 (d, *J* = 6.6 Hz, 6H).	
138	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.06 (s, 1H), 7.96 (s, 1H), 7.36 (dd, *J* = 11.5, 7.2 Hz, 4H), 7.29 (d, *J* = 7.2 Hz, 1H), 7.24 (s, 2H), 6.62 (s, 1H), 4.31 (t, *J* = 6.5 Hz, 2H), 4.20 (dt, *J* = 15.7, 8.4 Hz, 1H), 4.10 (q, *J* = 6.9 Hz, 1H), 3.94 (dt, *J* = 10.3, 7.4 Hz, 1H), 3.50 (d, *J* = 5.9 Hz, 2H), 2.25 – 2.18 (m, 2H), 1.63 – 1.58 (m, 1H), 1.57 (d, *J* = 6.8 Hz, 3H), 1.45 (dd, *J* = 15.8, 7.3 Hz, 2H), 0.93 (dd, *J* = 19.8, 6.6 Hz, 6H).	(ESI(+)) m/e 454 (M+H)+
139	2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.04 (s, 1H), 7.97 (s, 1H), 7.33 (d, *J* = 9.4 Hz, 2H), 7.24 (dd, *J* = 8.4, 5.3 Hz, 2H), 7.06 (t, *J* = 8.6 Hz, 2H), 6.78 (s, 1H), 4.29 (t, *J* = 6.2 Hz, 2H), 4.24 – 4.12 (m, 2H), 3.97 (s, 2H), 3.48 (d, *J* = 5.4 Hz, 2H), 2.23 – 2.18 (m, 2H), 1.71 (dt, *J* = 13.1, 6.6 Hz, 1H), 1.65 – 1.58 (m, 2H), 0.99 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 458 (M+H)+
150	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.01 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 4.33 (t, *J* = 6.9 Hz, 2H), 4.30 – 4.23 (m, 2H), 3.79 (t, *J* = 5.9 Hz, 2H), 3.39 (t, *J* = 6.4 Hz, 2H), 3.36 (s, 3H), 2.97 (t, *J* = 5.9 Hz, 2H), 2.18 (p, *J* = 6.7 Hz, 2H), 1.72 (dt, *J* = 13.1, 6.7 Hz, 1H), 1.68 – 1.59 (m, 2H), 1.00 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 408 (M+H)+

151	N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d$_4$) δ 8.98 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 4.49 (s, 2H), 4.33 (t, *J* = 6.8 Hz, 2H), 4.19 – 4.07 (m, 2H), 3.49 (s, 3H), 3.40 (t, *J* = 6.4 Hz, 2H), 2.19 (p, *J* = 6.6 Hz, 2H), 1.71 (dt, *J* = 12.8, 6.5 Hz, 1H), 1.67 – 1.56 (m, 2H), 1.00 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 394 (M+H)+
152	2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d$_4$) δ 8.97 (s, 1H), 8.00 (s, 1H), 7.70 (t, *J* = 1.6 Hz, 1H), 7.56 (t, *J* = 1.6 Hz, 1H), 4.53 – 4.41 (m, 2H), 4.32 (t, *J* = 6.8 Hz, 2H), 3.39 (t, *J* = 6.4 Hz, 2H), 2.28 – 2.10 (m, 3H), 1.81 – 1.63 (m, 3H), 1.16 – 1.04 (m, 4H), 1.01 (d, *J* = 6.2 Hz, 6H).	(ESI(+)) m/e 390 (M+H)+
153	(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate	^{1}H NMR (400 MHz, methanol-d$_4$) δ 8.97 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 5.50 (q, *J* = 6.8 Hz, 1H), 4.53 (s, 1H), 4.33 (t, *J* = 6.8 Hz, 2H), 4.04 – 3.91 (m, 1H), 3.39 (dd, *J* = 6.9, 5.6 Hz, 2H), 2.19 (p, *J* = 6.6 Hz, 2H), 2.12 (s, 3H), 1.80 (d, *J* = 5.4 Hz, 1H), 1.72 (dt, *J* = 11.2, 6.2 Hz, 2H), 1.54 (d, *J* = 6.8 Hz, 3H), 1.00 (dd, *J* = 6.1, 2.0 Hz, 6H).	(ESI(+)) m/e 436 (M+H)+
154	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d$_4$) δ 10.13 (d, *J* = 1.5 Hz, 1H), 8.98 (s, 1H), 8.01 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 4.32 (t, *J* = 6.9 Hz, 2H), 4.28 – 4.19 (m, 2H), 3.94 (dd, *J* = 11.4, 3.5 Hz, 2H), 3.47 (t, *J* = 11.0 Hz, 2H), 3.39 (t, *J* = 6.5 Hz, 2H), 2.67 (d, *J* = 6.7 Hz, 2H), 2.19	(ESI(+)) m/e 448 (M+H)+

		(dd, *J* = 13.3, 6.7 Hz, 3H), 1.73 (dd, *J* = 13.3, 6.4 Hz, 3H), 1.61 (dd, *J* = 15.7, 7.1 Hz, 2H), 1.39 (dd, *J* = 12.9, 4.3 Hz, 2H), 1.01 (d, *J* = 6.5 Hz, 6H).	
155	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.02 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 4.31 (dt, *J* = 15.2, 7.8 Hz, 4H), 4.07 (t, *J* = 8.2 Hz, 1H), 4.02 – 3.91 (m, 2H), 3.87 (dd, *J* = 14.7, 7.5 Hz, 1H), 3.74 – 3.59 (m, 1H), 3.39 (t, *J* = 6.5 Hz, 2H), 2.31 (dt, *J* = 15.2, 7.1 Hz, 1H), 2.19 (dq, *J* = 13.2, 6.6 Hz, 3H), 1.73 (td, *J* = 13.0, 6.4 Hz, 1H), 1.64 (dd, *J* = 14.5, 7.3 Hz, 2H), 1.01 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 420 (M+H)+
156	2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 9.03 (s, 1 H), 7.74 (s, 1 H), 7.66 (s, 1 H), 7.63 (s, 1 H), 7.29 - 7.34 (m, 1 H), 6.89 - 6.96 (m, 3 H), 5.86 - 5.90 (m, 1 H), 4.23 (t, *J* =6.71 Hz, 2 H), 3.53 - 3.66 (m, 4 H), 3.22 (d, *J* =2.44 Hz, 2 H), 3.20 (s, 3 H), 2.57 - 2.62 (m, 2 H), 2.02 - 2.06 (m, 2 H), 1.01 - 1.14 (m, 3 H).	(ESI(+)) m/e 488 (M+H)+
157	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 9.04 (s, 1 H), 8.55 - 8.57 (m, 2 H), 8.50 (d, *J* =2.14 Hz, 1 H), 8.03 (s, 1 H), 7.75 (t, *J* =1.68 Hz, 1 H), 7.62 - 7.65 (m, 1 H), 4.55 - 4.59 (m, 2 H), 4.25 (t, *J* =6.87 Hz, 3 H), 3.65 (t, *J* =5.95 Hz, 2 H), 3.24 - 3.28 (m, 7 H), 2.92 (t, *J* =6.10 Hz, 2 H), 2.06 - 2.11 (m, 2	(ESI(+)) m/e 444 (M+H)+

H).

158	2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 9.02 (s, 1 H), 7.74 (t, *J* =1.83 Hz, 1 H), 7.63 (s, 2 H), 7.34 (t, *J* =7.63 Hz, 1 H), 7.14 (s, 1 H), 6.94 - 6.98 (m, 1 H), 6.59 - 6.63 (m, 1 H), 4.22 (t, *J* =6.87 Hz, 2 H), 3.66 (t, *J* =6.10 Hz, 3 H), 3.29 (s, 3 H), 3.17 - 3.24 (m, 4 H), 2.80 (t, *J* =5.95 Hz, 3 H), 2.00 - 2.08 (m, 2 H), 1.15 (d, *J* =6.41 Hz, 3 H).	(ESI(+)) m/e 472 (M+H)+
173	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.10 (s, 1H), 7.98 (s, 1H), 7.38 (d, *J* = 4.8 Hz, 2H), 6.83 (dd, *J* = 5.1, 2.6 Hz, 1H), 4.42 (dd, *J* = 12.9, 6.7 Hz, 1H), 4.34 (t, *J* = 6.5 Hz, 2H), 4.20 (t, *J* = 8.3 Hz, 2H), 3.92 (dd, *J* = 15.0, 6.9 Hz, 1H), 3.80 (dd, *J* = 15.1, 6.9 Hz, 1H), 3.51 (ddd, *J* = 5.9, 4.6, 2.9 Hz, 2H), 3.04 – 2.96 (m, 2H), 2.78 (dd, *J* = 15.9, 5.4 Hz, 2H), 2.25 (dt, *J* = 15.8, 6.1 Hz, 3H), 1.97 (dt, *J* = 13.9, 6.9 Hz, 2H), 1.79 – 1.69 (m, 1H), 1.67 – 1.52 (m, 3H), 0.99 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 434 (M+H)+
174	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.15 (s, 1H), 8.00 (s, 1H), 7.37 (d, *J* = 9.6 Hz, 2H), 6.81 (dd, *J* = 7.5, 3.3 Hz, 1H), 4.34 (t, *J* = 6.5 Hz, 2H), 4.15 (dd, *J* = 9.7, 6.7 Hz, 2H), 4.04 (dd, *J* = 8.7, 6.9 Hz, 1H), 3.94 (td,	(ESI(+)) m/e 434 (M+H)+

		J = 8.3, 5.1 Hz, 1H), 3.81 (dd, J = 15.9, 7.6 Hz, 1H), 3.51 (dt, J = 10.0, 5.1 Hz, 3H), 2.84 (dt, J = 10.4, 4.2 Hz, 1H), 2.79 – 2.66 (m, 2H), 2.36 – 2.18 (m, 3H), 1.72 (dt, J = 13.2, 6.6 Hz, 1H), 1.66 – 1.55 (m, 3H), 1.05 – 0.89 (m, 6H).	
175	N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.21 – 9.10 (m, 1H), 7.99 (s, 1H), 7.42 – 7.33 (m, 2H), 7.04 – 6.85 (m, 1H), 4.40 (t, J = 4.9 Hz, 2H), 4.34 (dd, J = 9.2, 3.5 Hz, 2H), 3.79 (t, J = 6.2 Hz, 2H), 3.68 (t, J = 4.9 Hz, 2H), 3.53 – 3.46 (m, 2H), 3.39 (s, 3H), 3.30 (s, 3H), 3.09 (t, J = 6.2 Hz, 2H), 2.26 – 2.21 (m, 2H).	(ESI(+)) m/e 396 (M+H)+
176	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.26 – 9.13 (m, 1H), 8.05 – 7.97 (m, 1H), 7.36 (d, J = 8.6 Hz, 2H), 7.04 – 6.87 (m, 1H), 4.40 – 4.32 (m, 2H), 4.32 – 4.23 (m, 2H), 3.81 (t, J = 6.1 Hz, 2H), 3.50 (d, J = 5.5 Hz, 2H), 3.44 (t, J = 5.6 Hz, 2H), 3.39 (s, 3H), 3.34 (s, 3H), 2.98 (t, J = 6.1 Hz, 2H), 2.26 – 2.20 (m, 2H), 2.08 – 1.99 (m, 2H).	(ESI(+)) m/e 410 (M+H)+
177	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.17 (s, 1H), 8.00 (s, 1H), 7.37 (dd, J = 8.1, 3.9 Hz, 2H), 6.88 – 6.77 (m, 1H), 4.46 – 4.36 (m, 1H), 4.37 – 4.30 (m, 2H), 4.03 – 3.84 (m, 2H), 3.84 – 3.73 (m, 2H), 3.74 – 3.61 (m, 2H), 3.55 – 3.46 (m, 2H), 3.39 (s, 3H), 3.33 – 3.19 (m, 3H), 2.99 (dt, J = 16.8, 6.8 Hz, 1H), 2.28 – 2.21 (m, 2H), 1.89 – 1.85 (m, 1H),	(ESI(+)) m/e 436 (M+H)+

		1.73 (ddd, *J* = 3.0, 1.3, 0.6 Hz, 1H), 1.52 – 1.48 (m, 2H), 1.23 – 1.13 (m, 2H).	
178	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.16 (d, *J* = 4.8 Hz, 1H), 8.00 (d, *J* = 4.2 Hz, 1H), 7.36 (d, *J* = 7.9 Hz, 2H), 6.89 – 6.78 (m, 1H), 4.54 (dd, *J* = 14.5, 1.6 Hz, 1H), 4.37 – 4.30 (m, 2H), 4.30 – 4.23 (m, 1H), 4.10 – 3.95 (m, 1H), 3.87 (dd, *J* = 14.7, 6.5 Hz, 1H), 3.82 – 3.76 (m, 2H), 3.71 (dd, *J* = 8.2, 6.6 Hz, 1H), 3.55 – 3.45 (m, 2H), 3.39 (s, 3H), 3.26 – 3.12 (m, 1H), 3.03 (dt, *J* = 16.7, 6.8 Hz, 1H), 2.24 – 2.20 (m, 2H), 1.93 (d, *J* = 7.2 Hz, 2H), 1.66 – 1.50 (m, 2H).	(ESI(+)) m/e 422 (M+H)+
179	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.25 – 9.09 (m, 1H), 8.07 – 7.96 (m, 1H), 7.35 (d, *J* = 11.4 Hz, 2H), 6.98 – 6.78 (m, 1H), 4.38 (t, *J* = 4.9 Hz, 2H), 4.36 – 4.30 (m, 2H), 3.79 (dd, *J* = 8.1, 4.5 Hz, 2H), 3.75 – 3.68 (m, 3H), 3.49 (dd, *J* = 10.9, 4.8 Hz, 2H), 3.38 (s, 3H), 3.27 (dd, *J* = 7.0, 3.4 Hz, 1H), 3.13 (dd, *J* = 8.1, 4.4 Hz, 2H), 2.24 – 2.20 (m, 2H), 1.06 (d, *J* = 6.1 Hz, 6H).	(ESI(+)) m/e 424 (M+H)+
180	2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.59 – 8.49 (m, 1H), 8.02 (s, 1H), 7.71 (d, *J* = 1.5 Hz, 1H), 7.57 (s, 1H), 4.95 (t, *J* = 4.3 Hz, 1H), 4.37 (dd, *J* = 12.7, 5.0 Hz, 2H), 4.34 – 4.29 (m, 2H), 3.99 – 3.91 (m, 2H), 3.85 (dd, *J* = 8.8, 5.1	(ESI(+)) m/e 438 (M+H)+

		Hz, 2H), 3.79 (t, *J* = 6.0 Hz, 2H), 3.43 – 3.37 (m, 2H), 3.36 (s, 3H), 3.03 (t, *J* = 6.0 Hz, 2H), 2.26 – 2.17 (m, 2H), 2.17 – 2.11 (m, 2H).	
181	2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide		(ESI(+)) m/e 438 (M+H)+
182	2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.99 (s, 1H), 7.70 (t, *J* = 1.7 Hz, 1H), 7.57 (t, *J* = 1.6 Hz, 1H), 7.27 (dd, *J* = 8.6, 5.5 Hz, 2H), 6.99 (t, *J* = 8.8 Hz, 2H), 4.41 (t, *J* = 5.1 Hz, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.66 (t, *J* = 5.0 Hz, 2H), 3.40 (t, *J* = 6.4 Hz, 2H), 3.26 (s, 3H), 3.17 (t, *J* = 7.3 Hz, 2H), 3.01 (t, *J* = 7.2 Hz, 2H), 2.24 – 2.09 (m, 2H).	(ESI(+)) m/e 55460 (M+H)+
183	N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.84 (s, 1H), 8.70 (d, *J* = 5.5 Hz, 1H), 8.59 (d, *J* = 8.2 Hz, 1H), 8.01 (dd, *J* = 8.1, 5.7 Hz, 1H), 7.99 (s, 1H), 7.70 (t, *J* = 1.7 Hz, 1H), 7.57 (t, , *J* = 1.7 Hz, 1H), 4.45 (t, *J* = 5.0 Hz, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.69 (t, *J* = 4.9 Hz, 2H), 3.40 (dt, *J* = 9.9, 6.9 Hz, 4H), 3.27 (s, 3H), 2.18 (m, 2H).	(ESI(+)) m/e 443 (M+H)+
184	N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 8.81 (d, *J* = 9.1 Hz, 2H), 8.52 (d, *J* = 8.1 Hz, 1H), 8.06 (dd, *J* = 7.9, 5.9 Hz, 1H), 8.04 (s, 1H), 7.70 (t, *J* = 1.7 Hz, 1H), 7.56	(ESI(+)) m/e 429 (M+H)+

		(t, *J* = 1.7 Hz, 1H), 4.61 (t, *J* = 5.0 Hz, 2H), 4.58 (s, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.80 (t, *J* = 4.9 Hz, 2H), 3.39 (t, *J* =6.4 Hz, 2H), 3.38 (s, 3H), 2.18 (m, 2H).	
185	N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.04 (s, 1H), 7.92 – 7.79 (m, 0033H), 7.74 (d, *J* = 15.9 Hz, 2H), 7.59 (s, 1H), 7.51 (dd, *J* = 6.8, 2.8 Hz, 2H), 7.42 (dd, *J* = 8.5, 1.7 Hz, 1H), 4.57 (t, *J* = 5.1 Hz, 2H), 4.44 (s, 2H), 4.35 (t, *J* = 6.8 Hz, 2H), 3.78 (t, *J* = 5.0 Hz, 2H), 3.42 (t, *J* = 6.2 Hz, 2H), 3.40 (s, 3H), 2.29 – 2.11 (m, 2H).	(ESI(+)) m/e 478 (M+H)+
186	N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.95 (s, 1H), 8.03 (t, *J* = 1.3 Hz, 1H), 7.70 (s, 1H), 7.58 (s, 1H), 7.40 – 7.33 (m, 2H), 7.27 (d, *J* = 8.5 Hz, 2H), 7.12 (dd, *J* = 11.3, 3.9 Hz, 2H), 7.03 – 6.95 (m, 4H), 4.52 (t, *J* = 5.1 Hz, 2H), 4.35 (t, *J* = 6.9 Hz, 2H), 4.24 (s, 2 H), 3.76 (t, *J* = 5.1 Hz, 2H), 3.43 (t, *J* =6.5 Hz, 2H), 3.38 (s, 3H), 2.34 – 2.12 (m, 2H).	(ESI(+)) m/e 520 (M+H)+
187	2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ ppm 8.94 (s, 1 H), 8.01 (s, 1H), 7.70 (m, 3 H), 7.55 (s, 1 H), 7.44 (d, *J* =8.1 Hz, 2H), 4.53 (t, *J* =4.9 Hz, 2H), 4.35 (s, 2H), 4.32 (t, *J* =6.9 Hz, 2H), 3.75 (t, *J* =4.9 Hz, 2H), 3.39 (t, *J* =6.5 Hz, 2H), 3.36 (s, 3H), 2.19 (m, 2H).	(ESI(+)) m/e 453 (M+H)+

188	2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 9.02 (s, 1H), 8.07 (s, 1H), 7.74 (s, 1H), 7.59 (s, 1H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 4.57 (t, *J* = 4.9 Hz, 2H), 4.40 – 4.28 (m, 4H), 3.79 (t, *J* = 5.0 Hz, 2H), 3.42 (t, *J* = 6.5 Hz, 2H), 3.39 (s, 3H), 2.21 (m, 2H).	(ESI(+)) m/e 443 (M+H)+
189	2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.98 (s, 1 H), 8.05 (s, 1 H), 7.70 (s, 1 H), 7.59 (s, 1 H), 5.89 - 6.01 (m, 2 H), 5.49 - 5.59 (m, 4 H), 4.51 (t, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 3.77 (d, *J* =7.02 Hz, 4 H), 3.72 (t, *J* =6.26 Hz, 2 H), 3.31 - 3.37 (m, 3 H), 3.29 (s, 4 H), 2.98 (t, *J* =6.26 Hz, 2 H).	(ESI(+)) m/e 461 (M+H)+
190	2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.96 (s, 1 H), 8.04 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.21 - 4.30 (m, 4 H), 3.74 (t, *J* =6.10 Hz, 2 H), 3.31 (s, 2 H), 3.29 (s, 3 H), 3.12 - 3.20 (m, 6 H), 2.98 (t, *J* =6.10 Hz, 2 H), 2.07 - 2.15 (m, 4 H), 1.23 (t, *J* =7.17 Hz, 6 H).	(ESI(+)) m/e 451 (M+H)+
191	2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.07 (s, 1 H), 7.69 (s, 1 H), 7.58 (s, 1 H), 4.52 (t, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 3.74 (t, *J* =6.10 Hz, 2 H), 3.44 (t, 2 H), 3.30 (s, 4 H), 3.29 - 3.29 (m, 3 H), 3.27 (s, 2 H), 3.01 (t, *J* =6.10 Hz, 2 H), 2.07 - 2.16 (m, 2 H), 1.29 (t, *J* =7.32 Hz, 6 H).	(ESI(+)) m/e 437 (M+H)+

192	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.04 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.21 - 4.31 (m, 4 H), 3.74 (t, *J* =5.95 Hz, 2 H), 3.29 - 3.31 (m, 6 H), 3.22 - 3.27 (m, 5 H), 2.98 (t, *J* =6.10 Hz, 2 H), 2.07 - 2.16 (m, 4 H), 1.94 - 2.03 (m, 4 H).	(ESI(+)) m/e 449 (M+H)+
193	2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.02 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.24 - 4.33 (m, 4 H), 3.72 (t, *J* =6.10 Hz, 2 H), 3.41 (dd, *J* =9.77, 7.63 Hz, 1 H), 3.29 - 3.31 (m, 2 H), 3.27 (s, 4 H), 3.14 - 3.21 (m, 3 H), 2.96 (t, *J* =5.95 Hz, 2 H), 2.35 (dd, *J* =16.63, 8.70 Hz, 1 H), 2.08 - 2.15 (m, 3 H), 1.00 - 1.04 (m, 3 H).	(ESI(+)) m/e 463 (M+H)+
194	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.94 (s, 1 H), 8.01 (s, 1 H), 7.68 (s, 1 H), 7.56 (s, 1 H), 4.21 - 4.31 (m, 4 H), 3.72 (t, *J* =6.26 Hz, 2 H), 3.29 - 3.31 (m, 2 H), 3.28 (s, 3 H), 2.89 - 3.04 (m, 3 H), 2.24 - 2.31 (m, 1 H), 2.07 - 2.19 (m, 4 H), 1.77 - 1.84 (m, 1 H).	(ESI(+)) m/e 435 (M+H)+
195	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.02 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.39 - 4.43 (m, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 3.71 (t, *J* =6.10 Hz, 2 H), 3.29 - 3.43 (m, 8 H), 3.03 (t, *J* =6.26 Hz, 2 H), 2.71 - 2.76 (m, 2 H), 2.08 - 2.15 (m, 2 H), 1.73 - 1.89 (m, 4 H).	(ESI(+)) m/e 463 (M+H)+

196	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 7.95 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 5.13 (s, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 3.68 (t, *J* =6.26 Hz, 2 H), 3.42 - 3.54 (m, 4 H), 3.29 - 3.31 (m, 2 H), 3.27 - 3.27 (m, 3 H), 2.80 (t, *J* =6.26 Hz, 2 H), 2.07 - 2.15 (m, 2 H), 1.47 - 1.68 (m, 6 H).	(ESI(+)) m/e 463 (M+H)+
197	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.98 (s, 1 H), 8.03 (s, 1 H), 7.67 - 7.72 (m, 1 H), 7.57 (s, 1 H), 4.27 (t, *J* =7.02 Hz, 2 H), 4.15 - 4.19 (m, 2 H), 3.72 (t, *J* =6.10 Hz, 2 H), 3.38 (t, *J* =7.02 Hz, 2 H), 3.31 (s, 1 H), 3.28 (s, 5 H), 3.26 (s, 1 H), 2.95 (t, *J* =6.10 Hz, 2 H), 2.24 (t, *J* =8.09 Hz, 2 H), 2.07 - 2.15 (m, 2 H), 1.88 - 2.00 (m, 4 H).	(ESI(+)) m/e 463 (M+H)+
198	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.03 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.39 (t, *J* =6.26 Hz, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 4.16 - 4.20 (m, 2 H), 3.73 (t, *J* =6.10 Hz, 2 H), 3.57 - 3.62 (m, 2 H), 3.53 (t, *J* =6.26 Hz, 2 H), 3.28 - 3.32 (m, 5 H), 2.98 (t, *J* =6.26 Hz, 2 H), 2.08 - 2.15 (m, 2 H).	(ESI(+)) m/e 451 (M+H)+
199	N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.02 (s, 1 H), 7.66 - 7.71 (m, 1 H), 7.57 - 7.58 (m, 1 H), 4.26 (q, *J* =6.92 Hz, 4 H), 3.71 (t, *J* =6.10 Hz, 2 H), 3.43 (t, *J* =6.41 Hz, 2 H), 3.29 -	(ESI(+)) m/e 451 (M+H)+

		3.32 (m, 2 H), 3.28 (s, 3 H), 3.00 (t, *J* =6.26 Hz, 2 H), 2.27 - 2.35 (m, 1 H), 2.08 - 2.15 (m, 2 H), 0.98 (d, *J* =7.02 Hz, 6 H).	
200	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.97 (s, 1 H), 8.02 (s, 1 H), 7.69 (s, 1 H), 7.57 (s, 1 H), 4.37 - 4.41 (m, 2 H), 4.27 (t, *J* =7.02 Hz, 2 H), 3.71 (t, *J* =6.10 Hz, 2 H), 3.31 (s, 2 H), 3.28 (s, 3 H), 3.01 (t, *J* =6.26 Hz, 2 H), 2.58 (s, 3 H), 2.07 - 2.15 (m, 2 H).	(ESI(+)) m/e 423 (M+H)+
201	2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.98 (s, 1 H), 8.02 (s, 1 H), 7.68 - 7.70 (m, 1 H), 7.57 (s, 1 H), 4.27 (t, *J* =7.02 Hz, 2 H), 4.17 - 4.22 (m, 2 H), 3.72 (t, *J* =6.10 Hz, 2 H), 3.31 (s, 2 H), 3.28 (s, 3 H), 3.13 (t, *J* =6.87 Hz, 2 H), 2.94 (t, *J* =6.10 Hz, 2 H), 2.08 - 2.15 (m, 2 H), 1.85 - 1.90 (m, 2 H), 1.84 (s, 3 H).	(ESI(+)) m/e 437 (M+H)+
202	N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ ppm 8.96 - 8.98 (m, 1 H), 8.02 (s, 1 H), 7.68 - 7.70 (m, 1 H), 7.58 (s, 1 H), 4.25 - 4.32 (m, 4 H), 3.72 (t, *J* =5.95 Hz, 2 H), 3.40 (dd, *J* =10.07, 7.63 Hz, 1 H), 3.29 - 3.31 (m, 2 H), 3.28 - 3.29 (m, 3 H), 3.15 (dd, *J* =10.07, 5.49 Hz, 1 H), 2.95 (t, *J* =6.10 Hz, 2 H), 2.85 - 2.92 (m, 1 H), 2.71 (s, 3 H), 2.34 (dd, *J* =16.63, 8.70 Hz, 1 H), 2.08 - 2.15 (m, 3 H).	(ESI(+)) m/e 449 (M+H)+

205	2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (500 MHz, methanol-d_4) δ 8.97 (s, 1H), 8.45 (d, *J* = 2.3 Hz, 1H), 7.91 (s, 1H), 7.81 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.70 (s, 1H), 7.56 (s, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 5.66 (s, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.96 (dd, *J* = 11.6, 2.0 Hz, 2H), 3.44 (t, *J* = 11.2 Hz, 2H), 3.38 (t, *J* = 6.4 Hz, 2H), 3.26 (dt, *J* = 7.0, 5.2 Hz, 1H), 2.18 (p, *J* = 6.7 Hz, 2H), 1.90 (qd, *J* = 12.3, 4.4 Hz, 2H), 1.73 (d, *J* = 13.1 Hz, 2H).	(ESI(+)) m/e 489 (M+H)+
206	2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (500 MHz, methanol-d_4) δ 8.97 (s, 1H), 8.45 (d, *J* = 2.4 Hz, 1H), 7.95 – 7.76 (m, 2H), 7.70 (t, *J* = 1.6 Hz, 1H), 7.56 (t, *J* = 1.6 Hz, 1H), 7.42 (d, *J* = 8.5 Hz, 1H), 5.66 (s, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.97 (dq, *J* = 14.5, 6.0 Hz, 3H), 3.80 (dt, *J* = 14.3, 7.3 Hz, 2H), 3.38 (t, *J* = 6.4 Hz, 2H), 2.19 (tt, *J* = 13.2, 6.8 Hz, 4H).	(ESI(+)) m/e 475 (M+H)+
207	2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 9.00 (s, 1H), 8.52 (d, *J* = 2.5 Hz, 1H), 8.01 (s, 1H), 7.81 (dd, *J* = 8.4, 2.5 Hz, 1H), 7.72 (t, *J* = 1.6 Hz, 1H), 7.58 (t, *J* = 1.6 Hz, 1H), 7.32 (d, *J* = 8.4 Hz, 1H), 4.69 – 4.54 (m, 2H), 4.34 (t, *J* = 6.8 Hz, 2H), 3.73 (t, *J* = 5.9 Hz, 2H), 3.40 (t, *J* = 6.4 Hz, 2H), 3.34 (s, 3H), 3.27 (d, *J* = 7.3 Hz, 2H), 2.90 (t, *J* = 5.9 Hz, 2H), 2.27 – 2.08 (m, 2H).	(ESI(+)) m/e 477 (M+H)+

208	2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 9.00 (s, 1H), 8.51 (d, *J* = 2.5 Hz, 1H), 8.03 (s, 1H), 7.79 (dd, *J* = 8.3, 2.5 Hz, 1H), 7.72 (t, *J* = 1.6 Hz, 1H), 7.58 (t, *J* = 1.5 Hz, 1H), 7.32 (d, *J* = 8.4 Hz, 1H), 4.64 (dd, *J* = 8.2, 6.1 Hz, 2H), 4.34 (t, *J* = 6.8 Hz, 2H), 4.01 – 3.94 (m, 1H), 3.91 (dd, *J* = 8.5, 5.9 Hz, 2H), 3.86 – 3.79 (m, 1H), 3.71 – 3.56 (m, 1H), 3.40 (t, *J* = 6.5 Hz, 2H), 3.28 (d, *J* = 7.1 Hz, 2H), 2.27 – 2.18 (m, 2H), 2.17 – 1.98 (m, 2H).	(ESI(+)) m/e 489 (M+H)+
209	2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.54 (d, *J* = 2.4 Hz, 1H), 8.01 – 7.77 (m, 2H), 7.71 (t, *J* = 1.6 Hz, 1H), 7.58 (t, *J* = 1.5 Hz, 1H), 7.35 (d, *J* = 8.4 Hz, 1H), 4.46 (t, *J* = 7.1 Hz, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.51 (dd, *J* = 8.2, 3.0 Hz, 2H), 3.45 (t, *J* = 5.1 Hz, 2H), 3.40 (t, *J* = 6.7 Hz, 2H), 3.38 (s, 3H), 3.24 (t, *J* = 7.1 Hz, 2H), 2.18 (p, *J* = 6.7 Hz, 2H).	(ESI(+)) m/e 493 (M+H)+
210	2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.54 (d, *J* = 2.5 Hz, 1H), 7.89 (s, 1H), 7.80 (dd, *J* = 8.4, 2.5 Hz, 1H), 7.71 (s, 1H), 7.58 (d, *J* = 1.5 Hz, 1H), 7.34 (d, *J* = 8.4 Hz, 1H), 4.46 (t, *J* = 7.1 Hz, 2H), 4.33 (t, *J* = 6.8 Hz, 2H), 3.65 (dt, *J* = 12.2, 6.1 Hz, 1H), 3.56 (t, *J* = 5.7 Hz, 2H), 3.43 (t, *J* = 5.6 Hz, 2H), 3.38 (t, *J* = 6.4 Hz, 2H), 3.22 (dt, *J* = 7.8, 4.0 Hz, 2H), 2.18 (p, *J* = 6.7 Hz, 2H), 1.16 (d, *J* = 6.1 Hz, 6H).	(ESI(+)) m/e 521 (M+H)+

211	2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.01 (s, 1H), 7.71 (s, 1H), 7.19 (s, 1H), 6.98 (s, 1H), 6.87 – 6.69 (m, 3H), 5.95 (s, 2H), 4.49 (t, *J* = 5.0 Hz, 2H), 4.15 (s, 3H), 4.12 (t, *J* = 7.0 Hz, 2H), 3.73 (t, *J* = 5.1 Hz, 2H), 3.40 – 3.35 (m, 5H), 2.17 – 1.88 (m, 2H).	(ESI(+)) m/e 472 (M+H)+
213	N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.55 – 8.31 (m, 1H), 8.09 (s, 1H), 7.79 (td, *J* = 7.7, 1.8 Hz, 1H), 7.64 (s, 1H), 7.64 (s, 1H), 7.37 (d, *J* = 7.8 Hz, 1H), 7.31 (dd, *J* = 7.5, 4.9 Hz, 1H), 7.19 (s, 1H), 6.88 (s, 1H), 4.45 (t, *J* = 5.2 Hz, 2H), 4.00 (t, *J* = 6.9 Hz, 2H), 3.66 (t, *J* = 5.3 Hz, 2H), 3.26 (s, 3H), 3.23 – 3.11 (m, 2H), 2.16 – 1.83 (m, 2H).	(ESI(+)) m/e 429 (M+H)+

Example 46

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6B (0.072 g, 0.2 mmol) was dissolved in acetonitrile (1 ml) and pyridine (0.1 ml) and treated with bis(2,5-dioxopyrrolidin-1-yl)carbonate (0.064 g, 0.25 mmol). The reaction mixture was stirred at 50 °C for 3 hours, cooled, and treated with Hunig's base (0.105 ml, 0.6 mmol) and propan-2-amine (0.02 ml, 0.23 mmol). The reaction mixture was stirred further at 25 °C for 3 hours, concentrated purified by reverse-phase HPLC (as described in Example 6C) to provide the title compound. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.12 (s, 1H), 8.45 (t, *J* = 5.6 Hz, 1H), 7.90 (s, 1H), 7.82 (d, *J* = 1.5 Hz, 1H), 7.70 (d, *J* = 1.5 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.22 (dd, *J* = 8.7, 5.7 Hz, 2H), 7.16 (t, *J* = 8.9 Hz, 2H), 5.37 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.93 – 3.87 (m, 1H), 3.21 (q, *J* = 6.3 Hz, 2H), 2.04 (t, *J* = 6.8 Hz, 2H), 1.10 (d, *J* = 6.6 Hz, 6H); MS (ESI(+)) m/e 444.5 (M+H)+.

The following examples were prepared as described in Example 6B followed by Example 46, substituting the appropriate amines in Example 6B and Example 46. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as described in Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA
63	2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.15 (s, 1H), 8.70 (s, 1H), 7.83 (s, 1H), 7.32 (d, *J* = 20.0 Hz, 2H), 7.27 (dd, *J* = 9.4, 4.5 Hz, 2H), 7.11 (s, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 5.15 (s, 2H), 4.30 (t, *J* = 6.5 Hz, 2H), 3.44 – 3.38 (m, 4H), 2.26 – 2.16 (m, 2H), 1.62 (dt, *J* = 13.4, 6.8 Hz, 1H), 1.48 (dd, *J* = 14.6, 7.1 Hz, 2H), 0.92 (t, *J* = 6.8 Hz, 6H).	(ESI(+)) m/e 473 (M+H)+
64	2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.15 (s, 1H), 8.80 (s, 1H), 7.84 (s, 1H), 7.35 (s, 1H), 7.30 (s, 1H), 7.27 (d, *J* = 4.4 Hz, 2H), 7.04 (s, 1H), 7.02 (t, *J* = 8.5 Hz, 2H), 5.16 (s, 2H), 4.30 (t, *J* = 6.5 Hz, 2H), 3.44 (dd, *J* = 11.6, 6.0 Hz, 2H), 3.22 (t, *J* = 6.0 Hz, 2H), 2.28 – 2.17 (m, 2H), 1.85 (dd, *J* = 13.5, 6.7 Hz, 1H), 0.93 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 459 (M+H)+
65	N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.16 (dd, *J* = 1.6, 1.0 Hz, 1H), 7.79 (s, 1H), 7.34 (d, *J* = 0.5 Hz, 1H), 7.33 – 7.31 (m, 1H), 7.30 (d, *J* = 5.4 Hz, 1H), 7.28 (s, 1H), 7.03 – 6.97 (m, 3H), 6.82 – 6.75 (m, 1H), 6.48 – 6.39 (m, 1H), 5.04 (d, *J* = 9.7 Hz, 2H), 4.36 – 4.30 (m, 2H), 3.69 – 3.62 (m, 1H), 3.56 (s, 1H), 3.50 – 3.42 (m, 3H), 3.04	(ESI(+)) m/e 514 (M+H)+

		(ddd, *J* = 11.6, 6.9, 2.5 Hz, 1H), 2.49 (d, *J* = 3.9 Hz, 1H), 2.26 – 2.21 (m, 2H), 1.42 – 1.33 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 2H).	
66	2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 7.85 (s, 1H), 7.70 (d, *J* = 1.6 Hz, 1H), 7.57 (s, 1H), 7.21 (dd, *J* = 8.6, 5.3 Hz, 2H), 7.05 (t, *J* = 8.7 Hz, 2H), 5.28 (s, 2H), 4.49 (ddd, *J* = 11.2, 5.6, 3.4 Hz, 1H), 4.31 (dd, *J* = 14.6, 7.2 Hz, 4H), 3.88 (dd, *J* = 9.6, 4.4 Hz, 2H), 3.37 (dd, *J* = 12.9, 6.5 Hz, 2H), 2.17 (p, *J* = 6.7 Hz, 2H).	(ESI(+)) m/e 459 (M+H)+
67	N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.07 (s, 1H), 7.84 (s, 1H), 7.34 (d, *J* = 13.9 Hz, 2H), 7.30 – 7.24 (m, 2H), 6.99 (t, *J* = 8.5 Hz, 2H), 6.86 (s, 1H), 5.09 (s, 2H), 4.29 (t, *J* = 6.3 Hz, 2H), 3.96 (dd, *J* = 11.8, 3.4 Hz, 4H), 3.91 (dd, *J* = 12.4, 5.1 Hz, 2H), 3.61 (t, *J* = 7.2 Hz, 2H), 3.48 – 3.52 (m, 2H), 2.24 – 2.19 (m, 2H), 2.04 (t, *J* = 7.3 Hz, 2H).	(ESI(+)) m/e 515 (M+H)+
68	2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.06 (s, 1H), 7.85 (s, 1H), 7.34 (s, 1H), 7.31 (s, 1H), 7.29 – 7.24 (m, 2H), 7.16 (s, 1H), 6.98 (t, *J* = 8.6 Hz, 2H), 5.19 – 5.01 (m, 2H), 4.29 (t, *J* = 6.5 Hz, 2H), 3.94 (s, 1H), 3.56 (dt, *J* = 12.6, 7.3 Hz, 2H), 3.46 (dd, *J* = 13.5, 7.7 Hz, 4H), 3.27 (s, 3H), 2.23 – 2.16 (m, 2H), 2.09 – 2.03 (m, 1H), 1.98 – 1.81 (m, 1H).	(ESI(+)) m/e 487 (M+H)+

69	2-{(4-fluorobenzyl)[(2-methoxyethyl)(methyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.10 (s, 1H), 7.82 (s, 1H), 7.34 (d, *J* = 8.9 Hz, 3H), 7.28 (s, 1H), 7.11 (s, 1H), 6.98 (t, *J* = 8.6 Hz, 2H), 5.03 (s, 2H), 4.29 (t, *J* = 6.3 Hz, 2H), 3.49 (s, 4H), 3.43 (d, *J* = 5.4 Hz, 2H), 3.30 (s, 3H), 2.98 (s, 3H), 2.21 – 2.16 (m, 2H).	(ESI(+)) m/e 475 (M+H)+
70	N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.16 – 9.05 (m, 1H), 7.81 (s, 1H), 7.38 – 7.28 (m, 4H), 7.03 – 6.95 (m, 2H), 6.96 – 6.88 (m, 1H), 5.06 (s, 2H), 4.30 (dd, *J* = 8.4, 4.0 Hz, 2H), 3.65 (d, *J* = 12.8 Hz, 2H), 3.45 (dd, *J* = 6.9, 3.2 Hz, 4H), 2.66 (dd, *J* = 12.9, 10.8 Hz, 2H), 2.21 – 2.17 (m, 2H), 1.12 (d, *J* = 6.2 Hz, 6H).	(ESI(+)) m/e 501 (M+H)+
71	2-{[ethyl(2-methoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.07 (s, 1H), 7.80 (s, 1H), 7.41 – 7.28 (m, 4H), 6.98 (t, *J* = 8.6 Hz, 3H), 5.04 (s, 2H), 4.29 (d, *J* = 6.1 Hz, 2H), 3.50 – 3.39 (m, 6H), 3.37 (d, *J* = 7.0 Hz, 2H), 3.29 (s, 3H), 2.20 – 2.16 (m, 2H), 1.07 (t, *J* = 7.0 Hz, 3H).	(ESI(+)) m/e 489 (M+H)+
72	N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.12 – 9.04 (m, 1H), 7.80 (s, 1H), 7.34 (dt, *J* = 4.2, 3.7 Hz, 3H), 7.29 (d, *J* = 0.4 Hz, 1H), 7.03 – 6.95 (m, 2H), 6.86 – 6.79 (m, 1H), 5.06 (s, 2H), 4.29 (td, *J* = 6.4, 3.2 Hz, 2H), 3.64 (dd, *J* = 5.9, 3.7 Hz, 2H), 3.48 – 3.41 (m, 2H), 3.39 – 3.34 (m, 2H), 3.21 (d, *J* = 3.6 Hz, 2H), 2.23 – 2.17 (m, 2H), 1.10 (d,	(ESI(+)) m/e 501 (M+H)+

J = 4.9 Hz, 6H).

73	N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.14 – 9.06 (m, 1H), 7.80 (s, 1H), 7.38 – 7.33 (m, 3H), 7.28 (s, 1H), 7.00 (t, J = 8.6 Hz, 2H), 6.94 (s, 1H), 5.02 (s, 2H), 4.30 (dd, J = 7.9, 4.8 Hz, 2H), 3.66 – 3.62 (m, 2H), 3.62 – 3.58 (m, 2H), 3.53 (dd, J = 11.0, 5.9 Hz, 4H), 3.48 – 3.39 (m, 2H), 2.21 – 2.17 (m, 2H), 1.85 (dd, J = 10.1, 4.6 Hz, 2H).	(ESI(+)) m/e 487 (M+H)+
78	2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.11 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.90 (s, 1H), 7.85 (t, J = 5.3 Hz, 1H), 7.81 (t, J = 1.4 Hz, 1H), 7.69 (t, J = 1.4 Hz, 1H), 7.23 (dd, J = 8.6, 5.6 Hz, 2H), 7.13 (dd, J = 12.3, 5.4 Hz, 2H), 5.33 (s, 2H), 4.22 (t, J = 6.9 Hz, 2H), 3.40 (t, J = 5.6 Hz, 2H), 3.32 (dd, J = 10.9, 5.4 Hz, 2H), 3.26 (d, J = 6.6 Hz, 2H), 3.21 (dd, J = 12.3, 6.3 Hz, 2H), 2.03 (t, J = 6.8 Hz, 2H), 1.43 (dd, J = 14.1, 7.0 Hz, 2H), 1.33 – 1.09 (m, 1H), 0.80 (t, J = 7.4 Hz, 3H).	(ESI(+)) m/e 489 $(M+H)^+$
79	2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.12 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.91 (s, 1H), 7.85 (t, J = 5.5 Hz, 1H), 7.81 (t, J = 1.5 Hz, 1H), 7.70 (t, J = 1.5 Hz, 1H), 7.28 – 7.20 (m, 2H), 7.20 – 7.10 (m, 2H), 5.37 (q, J = 17.1 Hz, 2H), 4.23 (t,	(ESI(+)) m/e 487 $(M+H)^+$

		J = 7.0 Hz, 2H), 3.87 (dd, J = 12.2, 5.9 Hz, 1H), 3.28 – 3.17 (m, 4H), 2.08 – 2.00 (m, 2H), 1.82 – 1.65 (m, 3H), 1.42 (ddd, J = 9.1, 8.3, 6.0 Hz, 1H).	
80	2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.10 (s, 1H), 8.44 (t, J = 5.7 Hz, 1H), 7.90 (s, 1H), 7.81 (t, J = 1.5 Hz, 1H), 7.69 (t, J = 1.4 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.31 – 7.21 (m, 2H), 7.21 – 7.09 (m, 2H), 5.36 (d, J = 2.5 Hz, 2H), 4.22 (t, J = 7.0 Hz, 2H), 4.00 (dt, J = 18.2, 5.6 Hz, 1H), 3.32 (dd, J = 9.6, 6.6 Hz, 2H), 3.26 – 3.21 (m, 5H), 2.03 (t, J = 6.8 Hz, 2H), 1.08 (d, J = 6.8 Hz, 3H).	(ESI(+)) m/e 475 $(M+H)^+$
81	2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.11 (s, 1H), 8.45 (t, J = 5.7 Hz, 1H), 7.91 (s, 1H), 7.87 – 7.75 (m, 2H), 7.69 (t, J = 1.4 Hz, 1H), 7.24 (dd, J = 8.6, 5.6 Hz, 2H), 7.20 – 7.09 (m, 2H), 5.36 (s, 2H), 4.22 (dd, J = 9.0, 5.0 Hz, 2H), 3.82 (dd, J = 11.0, 2.7 Hz, 1H), 3.32 – 3.24 (m, 2H), 3.23 – 3.15 (m, 4H), 2.09 – 1.98 (m, 2H), 1.76 – 1.66 (m, 1H), 1.46 – 1.33 (m, 4H), 1.09 – 0.98 (m, 1H).	(ESI(+)) m/e 501 $(M+H)^+$
82	2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.12 (s, 1H), 8.46 (t, J = 5.7 Hz, 1H), 7.91 (s, 1H), 7.87 (t, J = 5.1 Hz, 1H), 7.82 (t, J = 1.5 Hz, 1H), 7.70 (t, J = 1.5 Hz, 1H), 7.30 – 7.20 (m, 2H), 7.20 – 7.12 (m, 2H), 5.35 (s, 2H), 4.23 (t, J = 7.0 Hz,	(ESI(+)) m/e 461 $(M+H)^+$

		2H), 3.39 (dd, *J* = 8.4, 3.2 Hz, 2H), 3.34 (dd, *J* = 9.9, 4.6 Hz, 2H), 3.24 – 3.18 (m, 5H), 2.04 (t, *J* = 6.8 Hz, 2H).	
83	2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.11 (s, 1H), 8.46 (t, *J* = 5.6 Hz, 1H), 7.90 (s, 1H), 7.85 (t, *J* = 5.3 Hz, 1H), 7.80 (d, *J* = 1.4 Hz, 1H), 7.69 (d, *J* = 1.4 Hz, 1H), 7.29 – 7.18 (m, 2H), 7.18 – 7.09 (m, 2H), 5.34 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.41 – 3.38 (m, 2H), 3.37 (d, *J* = 7.0 Hz, 2H), 3.33 (dd, *J* = 9.9, 4.7 Hz, 2H), 3.24 – 3.17 (m, 2H), 2.11 – 1.94 (m, 2H), 1.05 (t, *J* = 7.0 Hz, 3H).	(ESI(+)) m/e 475 $(M+H)^+$
84	2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.11 (s, 1H), 8.44 (t, *J* = 5.8 Hz, 1H), 7.90 (s, 1H), 7.81 (d, *J* = 1.4 Hz, 1H), 7.69 (d, *J* = 1.3 Hz, 1H), 7.41 (d, *J* = 8.2 Hz, 1H), 7.24 (dd, *J* = 8.6, 5.6 Hz, 2H), 7.16 (t, *J* = 8.9 Hz, 2H), 5.39 (dd, *J* = 39.3, 17.0 Hz, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.85 – 3.78 (m, 1H), 3.30 (dt, *J* = 9.7, 3.7 Hz, 2H), 3.24 – 3.19 (m, 5H), 2.09 – 1.98 (m, 2H), 1.52 (ddd, *J* = 12.5, 7.2, 5.0 Hz, 1H), 1.42 – 1.32 (m, 1H), 0.73 (t, *J* = 7.4 Hz, 3H).	(ESI(+)) m/e 489 $(M+H)^+$
86	2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.35 – 9.24 (m, 1H), 8.88 – 8.68 (m, 1H), 7.94 – 7.85 (m, 1H), 7.39 – 7.34 (m, 1H), 7.32 – 7.27 (m, 3H), 7.21 – 7.08 (m, 1H), 7.01 (t, *J* = 8.6 Hz, 2H), 5.21 – 5.09 (m,	(ESI(+)) m/e 489 (M+H)+

		2H), 5.06 (t, *J* = 3.4 Hz, 1H), 4.35 – 4.25 (m, 2H), 3.99 – 3.82 (m, 4H), 3.64 (dd, *J* = 5.1, 3.5 Hz, 2H), 3.44 (dt, *J* = 10.2, 2.9 Hz, 2H), 2.24 – 2.19 (m, 2H).	
87	2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.30 (ddd, *J* = 3.5, 2.1, 0.8 Hz, 1H), 8.55 – 8.35 (m, 1H), 7.94 – 7.86 (m, 1H), 7.35 (s, 1H), 7.32 – 7.27 (m, 3H), 7.10 – 7.04 (m, 1H), 7.03 – 6.95 (m, 2H), 5.18 (s, 2H), 4.32 (dd, *J* = 9.5, 3.5 Hz, 2H), 3.62 – 3.49 (m, 6H), 3.48 – 3.41 (m, 2H), 2.23 – 2.20 (m, 2H), 1.13 (t, *J* = 4.9 Hz, 6H).	(ESI(+)) m/e 489 (M+H)+
88	2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.43 – 9.29 (m, 1H), 8.77 – 8.63 (m, 1H), 7.98 – 7.88 (m, 1H), 7.35 (s, 1H), 7.31 – 7.27 (m, 3H), 7.22 – 7.11 (m, 1H), 7.06 – 6.95 (m, 2H), 5.27 – 5.06 (m, 2H), 4.33 (ddd, *J* = 5.9, 4.1, 3.0 Hz, 2H), 3.82 – 3.73 (m, 3H), 3.73 – 3.67 (m, 2H), 3.63 – 3.49 (m, 2H), 3.49 – 3.39 (m, 2H), 3.39 – 3.25 (m, 2H), 2.23 – 2.20 (m, 2H).	(ESI(+)) m/e 503 (M+H)+
89	2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.26 – 9.18 (m, 1H), 8.30 (s, 1H), 7.89 (s, 1H), 7.35 (s, 1H), 7.30 (d, *J* = 1.8 Hz, 1H), 7.28 (d, *J* = 3.0 Hz, 2H), 7.13 – 7.04 (m, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 5.19 (s, 2H), 4.31 (t, *J* = 6.4 Hz, 2H), 4.24 – 4.13 (m, 1H), 3.55 (dd, *J* = 9.5, 4.5 Hz, 2H), 3.44 (dd, *J* = 9.6, 5.6 Hz, 4H), 3.34 (s, 6H), 2.27 – 2.15	(ESI(+)) m/e 505 (M+H)+

(m, 2H).

90	2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.22 (s, 1H), 8.47 – 8.29 (m, 1H), 7.88 (s, 1H), 7.35 (s, 1H), 7.30 (s, 1H), 7.29 – 7.26 (m, 2H), 7.14 – 7.05 (m, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 5.19 (q, *J* = 16.6 Hz, 2H), 4.31 (t, *J* = 6.5 Hz, 2H), 3.68 – 3.59 (m, 1H), 3.48 – 3.40 (m, 2H), 3.32 (s, 3H), 3.30 – 3.23 (m, 2H), 2.27 – 2.15 (m, 2H), 1.66 – 1.53 (m, 1H), 1.47 (dt, *J* = 13.6, 6.9 Hz, 1H), 0.93 (dd, *J* = 9.4, 5.6 Hz, 3H).	(ESI(+)) m/e 489 (M+H)+
91	2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.47 – 9.31 (m, 2H), 7.94 – 7.85 (m, 1H), 7.35 (s, 1H), 7.29 (d, *J* = 8.7 Hz, 3H), 7.25 – 7.18 (m, 1H), 7.08 – 6.95 (m, 2H), 5.12 (s, 2H), 4.59 – 4.50 (m, 1H), 4.33 (td, *J* = 5.4, 1.1 Hz, 2H), 4.00 – 3.90 (m, 2H), 3.86 (td, *J* = 8.6, 5.5 Hz, 1H), 3.78 (dd, *J* = 9.4, 2.8 Hz, 1H), 3.44 (dt, *J* = 8.9, 3.6 Hz, 2H), 2.35 – 2.28 (m, 1H), 2.26 – 2.20 (m, 2H), 1.96 – 1.87 (m, 1H).	(ESI(+)) m/e 473 (M+H)+
92	2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.22 (s, 1H), 9.01 – 8.81 (m, 1H), 7.88 (s, 1H), 7.35 (s, 1H), 7.29 (t, *J* = 6.9 Hz, 3H), 7.07 (dd, *J* = 8.5, 3.5 Hz, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 5.26 (d, *J* = 16.7 Hz, 1H), 5.08 (d, *J* = 16.6 Hz, 1H), 4.31 (t,	(ESI(+)) m/e 487 (M+H)+

		J = 6.4 Hz, 2H), 3.99 (ddd, *J* = 8.8, 3.5, 1.6 Hz, 1H), 3.83 – 3.78 (m, 1H), 3.64 (dddd, *J* = 22.5, 16.6, 7.9, 3.3 Hz, 3H), 3.44 (dd, *J* = 11.4, 5.9 Hz, 2H), 2.29 – 2.14 (m, 2H), 1.91 (ddd, *J* = 8.1, 6.4, 2.7 Hz, 1H), 1.79 – 1.68 (m, 1H), 1.68 – 1.53 (m, 2H).	
123	2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.22 – 9.13 (m, 1H), 8.93 – 8.79 (m, 1H), 7.82 (s, 1H), 7.63 (d, *J* = 8.1 Hz, 2H), 7.45 – 7.32 (m, 3H), 7.29 (s, 1H), 7.07 – 6.96 (m, 1H), 5.25 (s, 2H), 4.30 (t, *J* = 6.4 Hz, 2H), 3.65 – 3.54 (m, 5H), 3.46 – 3.40 (m, 2H), 2.23 (dd, *J* = 7.3, 3.9 Hz, 2H), 1.15 (d, *J* = 6.1 Hz, 6H).	(ESI(+)) m/e 496 (M+H)+
124	2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.33 – 9.20 (m, 1H), 8.83 – 8.73 (m, 1H), 7.90 – 7.81 (m, 1H), 7.63 (d, *J* = 8.2 Hz, 2H), 7.39 (dd, *J* = 15.0, 7.1 Hz, 3H), 7.28 (s, 1H), 7.12 – 6.99 (m, 1H), 5.33 – 5.14 (m, 2H), 4.37 – 4.25 (m, 2H), 4.21 – 4.11 (m, 1H), 3.48 – 3.39 (m, 4H), 3.36 (s, 3H), 2.26 – 2.20 (m, 2H), 1.29 – 1.23 (m, 3H).	(ESI(+)) m/e 482 (M+H)+
125	2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.39 – 9.27 (m, 1H), 9.26 – 9.16 (m, 1H), 7.81 (s, 1H), 7.62 (d, *J* = 8.2 Hz, 2H), 7.41 – 7.34 (m, 3H), 7.28 (s, 1H), 7.15 – 7.05 (m, 1H), 5.22 (s, 2H), 4.55 – 4.5 (m, 2H), 4.36 – 4.29 (m, 2H), 3.85 – 3.75 (m, 2H), 3.67 (d, *J* = 4.7 Hz, 3H),	(ESI(+)) m/e 498 (M+H)+

		3.65 – 3.60 (m, 2H), 3.46 – 3.40 (m, 2H), 2.25 – 2.19 (m, 2H).	
126	2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.26 – 9.14 (m, 1H), 8.61 (s, 1H), 7.81 (s, 1H), 7.62 (d, *J* = 8.2 Hz, 2H), 7.38 (d, *J* = 8.2 Hz, 3H), 7.29 (s, 1H), 6.96 (s, 1H), 5.24 (s, 2H), 4.35 – 4.30 (m, 2H), 3.53 (dt, *J* = 16.3, 5.8 Hz, 5H), 3.45 – 3.40 (m, 2H), 2.26 – 2.20 (m, 2H), 1.88 – 1.82 (m, 2H), 1.12 (d, *J* = 6.1 Hz, 6H).	(ESI(+)) m/e 510 (M+H)+
127	2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.67 (s, 1H), 9.34 (s, 1H), 7.87 (s, 1H), 7.63 (d, *J* = 8.2 Hz, 2H), 7.45 – 7.34 (m, 3H), 7.25 – 7.18 (m, 1H), 5.20 (s, 2H), 4.32 (t, *J* = 6.1 Hz, 2H), 4.18 – 4.12 (m, 2H), 3.42 (d, *J* = 4.4 Hz, 2H), 3.38 (d, *J* = 6.1 Hz, 2H), 2.25 – 2.20 (m, 2H), 1.06 (s, 6H).	(ESI(+)) m/e 496 (M+H)+
128	2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.85 (s, 1H), 9.32 (s, 1H), 7.85 – 7.74 (m, 1H), 7.63 (d, *J* = 8.2 Hz, 2H), 7.42 – 7.35 (m, 3H), 7.24 (s, 1H), 5.39 – 5.29 (m, 1H), 5.28 – 5.10 (m, 2H), 4.40 – 4.25 (m, 2H), 3.93 – 3.81 (m, 1H), 3.53 – 3.46 (m, 1H), 3.46 – 3.36 (m, 2H), 2.27 – 2.21 (m, 2H), 1.43 (d, *J* = 6.4 Hz, 3H).	(ESI(+)) m/e 468 (M+H)+

129	2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.74 – 9.65 (m, 1H), 9.38 – 9.18 (m, 1H), 7.80 (d, *J* = 4.4 Hz, 1H), 7.63 (d, *J* = 8.3 Hz, 2H), 7.42 – 7.35 (m, 3H), 7.23 – 7.08 (m, 1H), 5.20 (dt, *J* = 21.5, 9.8 Hz, 2H), 4.63 – 4.52 (m, 1H), 4.47 – 4.40 (m, 1H), 4.40 – 4.34 (m, 1H), 4.34 – 4.27 (m, 2H), 3.48 – 3.38 (m, 2H), 2.26 – 2.21 (m, 4H), 1.37 (d, *J* = 6.7 Hz, 3H).	(ESI(+)) m/e 468 (M+H)+
130	2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.58 (d, *J* = 4.9 Hz, 1H), 9.41 (d, *J* = 6.0 Hz, 1H), 7.90 (s, 1H), 7.63 (d, *J* = 8.2 Hz, 2H), 7.39 (d, *J* = 8.3 Hz, 2H), 7.35 (s, 1H), 7.24 (s, 1H), 5.19 (s, 2H), 4.47 (t, *J* = 6.1 Hz, 2H), 4.33 (dd, *J* = 7.1, 5.8 Hz, 2H), 3.54 (d, *J* = 5.9 Hz, 2H), 3.42 (d, *J* = 2.0 Hz, 2H), 2.27 – 2.21 (m, 2H), 2.13 – 2.08 (m, 2H).	(ESI(+)) m/e 468 (M+H)+
131	2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 10.02 (s, 1H), 9.31 (s, 1H), 7.84 (s, 1H), 7.63 (d, *J* = 8.2 Hz, 2H), 7.45 – 7.34 (m, 3H), 7.23 (s, 1H), 6.01 – 5.84 (m, 1H), 5.38 (t, *J* = 14.8 Hz, 2H), 5.20 (dd, *J* = 39.0, 17.5 Hz, 2H), 4.98 – 4.90 (m, 1H), 4.61 (dd, *J* = 11.2, 4.3 Hz, 1H), 4.50 (dd, *J* = 11.1, 5.0 Hz, 1H), 4.31 (t, *J* = 6.4 Hz, 2H), 3.42 (d, *J* = 5.8 Hz, 2H), 2.26 – 2.21 (m, 2H).	(ESI(+)) m/e 480 (M+H)+

132	2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.53 (s, 1H), 9.30 (s, 1H), 7.85 (s, 1H), 7.62 (d, *J* = 8.2 Hz, 2H), 7.39 (d, *J* = 8.2 Hz, 2H), 7.35 (s, 1H), 5.20 (s, 2H), 4.41 (t, *J* = 6.4 Hz, 2H), 4.32 (t, *J* = 6.3 Hz, 2H), 3.54 – 3.45 (m, 2H), 3.45 – 3.36 (m, 2H), 2.26 – 2.21 (m, 3H), 1.85 (dd, *J* = 15.1, 6.7 Hz, 2H), 1.75 (dd, *J* = 14.9, 6.5 Hz, 2H).	(ESI(+)) m/e 482 (M+H)+
140	2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.79 (s, 1H), 7.73 (d, *J* = 8.2 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.47 (t, *J* = 6.4 Hz, 2H), 3.35 (t, *J* = 6.4 Hz, 2H), 2.41 (dd, *J* = 16.2, 9.2 Hz, 2H), 2.15 (p, *J* = 6.6 Hz, 2H).	(ESI(+)) m/e 481 (M+H)+
141	2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.76 (d, *J* = 9.6 Hz, 2H), 7.73 (s, 1H), 7.69 (s, 1H), 7.57 (s, 1H), 7.52 (d, *J* = 8.1 Hz, 2H), 5.36 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.35 (t, *J* = 6.4 Hz, 2H), 3.10 (d, *J* = 6.4 Hz, 4H), 2.14 (p, *J* = 6.5 Hz, 2H), 1.95 (s, 3H), 1.85 (dd, *J* = 12.9, 6.4 Hz, 1H), 0.92 (d, *J* = 6.8 Hz, 3H).	(ESI(+)) m/e 523 (M+H)+
142	2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.78 (s, 1H), 7.73 (d, *J* = 8.3 Hz, 2H), 7.70 (s, 1H), 7.57 (s, 1H), 7.49 (d, *J* = 8.0 Hz, 2H), 5.34 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.47 (t, *J* = 6.8 Hz, 2H), 3.35 (t, *J* = 6.4 Hz, 2H), 3.03 (s,	(ESI(+)) m/e 509 (M+H)+

		3H), 2.92 (s, 3H), 2.64 (d, *J* = 14.3 Hz, 2H), 2.22 – 2.07 (m, 2H)	
143	2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.78 (s, 1H), 7.73 (t, *J* = 7.2 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.1 Hz, 2H), 5.36 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.82 (t, *J* = 4.8 Hz, 1H), 3.52 (q, *J* = 7.1 Hz, 2H), 3.48 – 3.38 (m, 2H), 3.35 (d, *J* = 6.6 Hz, 2H), 3.22 (dd, *J* = 13.7, 7.0 Hz, 2H), 2.15 (t, *J* = 6.6 Hz, 2H), 1.18 (t, *J* = 7.1 Hz, 3H).	(ESI(+)) m/e 512 (M+H)+
144	2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.85 (s, 1H), 7.73 (d, *J* = 8.2 Hz, 2H), 7.70 (s, 1H), 7.57 (s, 1H), 7.50 (d, *J* = 8.2 Hz, 2H), 5.36 (s, 2H), 4.31 (t, *J* = 6.9 Hz, 2H), 3.35 (dd, *J* = 11.6, 5.0 Hz, 4H), 3.23 (q, *J* = 7.3 Hz, 4H), 3.18 – 3.11 (m, 2H), 2.15 (p, *J* = 6.8 Hz, 2H), 2.03 – 1.85 (m, 2H), 1.31 (t, *J* = 7.3 Hz, 6H).	(ESI(+)) m/e 523 (M+H)+
145	2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.79 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.1 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.35 (t, *J* = 6.5 Hz, 2H), 2.22 – 2.07 (m, 2H), 1.93 (s, 3H).	(ESI(+)) m/e 495 (M+H)+

146	2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.87 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.70 (s, 1H), 7.58 (s, 1H), 7.49 (d, *J* = 8.2 Hz, 2H), 5.37 (s, 2H), 4.31 (t, *J* = 6.9 Hz, 2H), 3.56 (t, *J* = 5.9 Hz, 2H), 3.35 (t, *J* = 6.5 Hz, 2H), 3.27 (dd, *J* = 7.3, 2.8 Hz, 4H), 2.15 (t, *J* = 6.7 Hz, 2H), 1.33 (t, *J* = 7.3 Hz, 6H).	(ESI(+)) m/e 509 (M+H)+
147	2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.78 (s, 1H), 7.73 (d, *J* = 8.2 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.50 (d, *J* = 8.2 Hz, 2H), 5.34 (s, 2H), 4.29 (t, *J* = 6.8 Hz, 2H), 3.34 (t, *J* = 6.5 Hz, 2H), 2.39 (dt, *J* = 13.9, 7.0 Hz, 1H), 2.14 (p, *J* = 6.6 Hz, 2H), 1.07 (d, *J* = 6.9 Hz, 6H).	(ESI(+)) m/e 523 (M+H)+
148	2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.78 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.52 (d, *J* = 8.1 Hz, 2H), 5.97 – 5.81 (m, 1H), 5.47 – 5.31 (m, 2H), 5.24 (d, *J* = 17.0 Hz, 1H), 5.16 (d, *J* = 10.6 Hz, 1H), 4.39 – 4.33 (m, 1H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.64 – 3.50 (m, 2H), 3.35 (t, *J* = 6.4 Hz, 2H), 2.14 (p, *J* = 6.8 Hz, 2H).	(ESI(+)) m/e 480 (M+H)+
149	2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.84 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.69 (d, *J* = 1.5 Hz, 1H), 7.58 (t, *J* = 1.6 Hz, 1H), 7.50 (d, *J* = 8.0 Hz, 2H), 5.36 (s, 2H), 4.68 – 4.58 (m, 1H),	(ESI(+)) m/e 523 (M+H)+

		4.47 (dd, *J* = 10.2, 8.2 Hz, 1H), 4.30 (t, *J* = 6.9 Hz, 2H), 4.26 – 4.14 (m, 1H), 4.06 (d, *J* = 8.9 Hz, 1H), 3.87 – 3.79 (m, 1H), 3.35 (t, *J* = 6.5 Hz, 2H), 3.27 (t, *J* = 6.7 Hz, 3H), 3.23 – 3.16 (m, 1H), 2.15 (p, *J* = 6.7 Hz, 2H), 1.80 (dt, *J* = 13.9, 7.1 Hz, 2H).	
159	ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.15 (s, 1H), 8.04 – 7.96 (m, 1H), 7.96 – 7.84 (m, 1H), 7.64 (d, *J* = 8.2 Hz, 2H), 7.37 (d, *J* = 8.1 Hz, 2H), 7.31 (s, 1H), 5.50 – 5.36 (m, 2H), 4.33 (t, *J* = 6.2 Hz, 2H), 4.14 (q, *J* = 7.2 Hz, 2H), 3.57 (t, *J* = 6.2 Hz, 2H), 3.41 (td, *J* = 5.6, 1.0 Hz, 2H), 2.61 – 2.51 (m, 2H), 2.21 (qd, *J* = 6.8, 3.4 Hz, 2H), 1.25 (t, *J* = 7.2 Hz, 3H).	(ESI(+)) m/e 510 (M+H)+
160	ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.39 (s, 1H), 8.00 (d, *J* = 46.6 Hz, 1H), 7.71 – 7.60 (m, 2H), 7.44 – 7.34 (m, 3H), 7.28 (d, *J* = 1.5 Hz, 1H), 5.50 – 5.42 (m, 1H), 4.41 – 4.31 (m, 2H), 4.18 – 4.05 (m, 2H), 3.46 – 3.37 (m, 2H), 3.38 – 3.26 (m, 2H), 2.39 – 2.34 (m, 3H), 2.24 – 2.20 (m, 3H), 1.96 – 1.82 (m, 2H), 1.33 – 1.18 (m, 3H).	(ESI(+)) m/e 524 (M+H)+
161	ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.15 (s, 1H), 8.09 – 8.00 (m, 1H), 7.65 (d, *J* = 8.2 Hz, 2H), 7.39 (dd, *J* = 11.3, 4.8 Hz, 3H), 7.33 (s, 1H), 5.54 – 5.47 (m, 2H), 4.40 – 4.23 (m, 3H), 4.12 (q, *J* = 7.1 Hz, 2H), 3.42 (dd, *J* = 10.1, 5.1 Hz,	(ESI(+)) m/e 524 (M+H)+

		2H), 2.65 – 2.43 (m, 2H), 2.28 – 2.18 (m, 2H), 1.29 – 1.18 (m, 6H).	
162	ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.13 (s, 1H), 8.10 (dd, *J* = 6.0, 1.4 Hz, 1H), 8.05 (s, 1H), 7.65 (d, *J* = 8.2 Hz, 2H), 7.39 (d, *J* = 8.6 Hz, 3H), 7.33 (d, *J* = 7.9 Hz, 1H), 7.04 – 6.94 (m, 1H), 5.48 (d, *J* = 24.0 Hz, 2H), 5.35 – 5.26 (m, 1H), 4.33 (t, *J* = 6.3 Hz, 2H), 4.16 – 3.94 (m, 3H), 3.46 – 3.34 (m, 2H), 2.64 – 2.41 (m, 2H), 2.26 – 2.15 (m, 2H), 1.20 (t, *J* = 7.1 Hz, 3H), 0.93 (d, *J* = 6.5 Hz, 6H).	(ESI(+)) m/e 552 (M+H)+
163	ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.21 – 9.08 (m, 1H), 8.06 – 7.96 (m, 1H), 7.91 (dd, *J* = 5.9, 1.8 Hz, 1H), 7.65 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 8.2 Hz, 3H), 7.31 (s, 1H), 6.90 – 6.64 (m, 1H), 5.44 (d, *J* = 20.7 Hz, 2H), 4.33 (t, *J* = 6.1 Hz, 2H), 4.18 – 4.08 (m, 2H), 3.49 – 3.37 (m, 4H), 2.24 – 2.13 (m, 2H), 1.31 – 1.17 (m, 9H).	(ESI(+)) m/e 538 (M+H)+
164	3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.80 (s, 1H), 7.74 (d, *J* = 8.0 Hz, 2H), 7.69 (s, 1H), 7.57 (s, 1H), 7.52 (d, *J* = 7.9 Hz, 2H), 5.37 (d, *J* = 9.8 Hz, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 4.26 – 4.11 (m, 1H), 3.34 (d, *J* = 3.4 Hz, 2H), 2.80 (d, *J* = 8.4 Hz, 1H), 2.55 (d, *J* = 8.1 Hz, 2H), 2.25 – 2.04 (m, 4H).	(ESI(+)) m/e 508 (M+H)+

165	ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate	^{1}H NMR (400 MHz, $CDCl_3$) δ 9.26 (s, 1H), 7.94 (s, 1H), 7.78 (ddd, *J* = 3.7, 2.7, 2.0 Hz, 1H), 7.64 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 7.2 Hz, 3H), 7.29 (s, 1H), 6.52 (d, *J* = 1.6 Hz, 1H), 5.37 (s, 2H), 4.34 (t, *J* = 6.2 Hz, 2H), 4.21 – 4.07 (m, 2H), 3.46 – 3.33 (m, 4H), 2.75 – 2.68 (m, 1H), 2.24 – 2.15 (m, 2H), 1.33 – 1.12 (m, 6H).	(ESI(+)) m/e 524 (M+H)+
166	2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 8.96 (s, 1H), 7.75 (d, *J* = 5.6 Hz, 2H), 7.73 (s, 1H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 5.35 (s, 2H), 4.33 – 4.24 (m, 2H), 3.44 (t, *J* = 6.3 Hz, 2H), 3.39 – 3.34 (m, 3H), 3.28 – 3.23 (m, 2H), 2.20 – 2.08 (m, 2H), 1.84 – 1.72 (m, 2H).	(ESI(+)) m/e 482 (M+H)+
167	3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.75 (d, *J* = 6.1 Hz, 2H), 7.72 (s, 1H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 3H), 4.25 – 4.12 (m, 1H), 3.39 – 3.33 (m, 2H), 2.59 (dd, *J* = 15.3, 6.2 Hz, 1H), 2.42 (dd, *J* = 15.3, 7.0 Hz, 1H), 2.20 – 2.09 (m, 2H), 1.23 (d, *J* = 6.7 Hz, 3H).	(ESI(+)) m/e 496 (M+H)+
168	3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.73 (d, *J* = 8.3 Hz, 3H), 7.69 (s, 1H), 7.57 (s, 1H), 7.52 (d, *J* = 8.2 Hz, 2H), 5.37 (dt, *J* = 26.9, 11.8 Hz, 2H), 4.36 – 4.24 (m, 2H), 4.08 – 3.93 (m, 1H), 3.35 (d, *J* = 6.6 Hz, 2H), 2.54 (dd,	(ESI(+)) m/e 524 (M+H)+

		J = 15.4, 5.1 Hz, 1H), 2.49 – 2.38 (m, 1H), 2.22 – 2.07 (m, 2H), 1.91 – 1.79 (m, 1H), 0.94 (dd, *J* = 6.7, 2.6 Hz, 6H).	
169	3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.80 – 7.71 (m, 3H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 5.37 (s, 2H), 4.29 (t, *J* = 6.8 Hz, 2H), 3.43 – 3.32 (m, 4H), 2.22 – 2.07 (m, 2H), 1.18 (s, 6H).	(ESI(+)) m/e 510 (M+H)+
170	3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.96 (s, 1H), 7.81 – 7.71 (m, 3H), 7.69 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.1 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.50 – 3.33 (m, 4H), 2.75 – 2.61 (m, 1H), 2.15 (dd, *J* = 12.9, 6.4 Hz, 2H), 1.17 (d, *J* = 7.2 Hz, 3H)	(ESI(+)) m/e 496 (M+H)+
171	N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.77 (s, 1H), 7.73 (d, *J* = 8.2 Hz, 2H), 7.70 (s, 1H), 7.57 (s, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.46 (t, *J* = 6.8 Hz, 2H), 3.39 – 3.33 (m, 2H), 2.54 (t, *J* = 6.8 Hz, 2H), 2.22 – 2.08 (m, 2H).	(ESI(+)) m/e 482 (M+H)+
172	4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid	^{1}H NMR (400 MHz, methanol-d_4) δ 8.97 (s, 1H), 7.77 (s, 1H), 7.74 (d, *J* = 8.2 Hz, 2H), 7.70 (s, 1H), 7.57 (s, 1H), 7.52 (d, *J* = 8.1 Hz, 2H), 5.35 (s, 2H), 4.30 (t, *J* = 6.8 Hz, 2H), 3.39 – 3.33 (m, 2H), 3.24 (t, *J* = 6.9 Hz, 2H), 2.34 (t, *J* = 7.5 Hz, 2H), 2.14 (dd, *J* = 8.4, 4.9 Hz, 2H), 1.81 (dd, *J* = 8.4, 5.9 Hz,	(ESI(+)) m/e 496 (M+H)+

2H).

Example 9

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6B (0.018 g, 0.05 mmol) was dissolved in acetonitrile (0.5 ml), and treated with potassium carbonate (0.021 g, 0.15 mmol) and 1-(2-chloroethyl)pyrrolidine (0.017 g, 0.1 mmol). The reaction mixture was heated via microwave at 180 °C for 30 minutes, concentrated in vacuo, and submitted to reverse-phase HPLC (as described in Example 6C) to provide the title compound. ^{1}H NMR (400 MHz, $CDCl_3$) δ 10.78 (s, 1H), 9.07 (s, 1H), 7.94 (s, 1H), 7.33 (dd, J = 8.7, 5.1 Hz, 3H), 7.11 (s, 1H), 7.04 (t, J = 8.6 Hz, 2H), 4.48 – 4.38 (m, 4H), 4.30 (t, J = 5.8 Hz, 2H), 3.41 (dd, J = 11.1, 5.5 Hz, 2H), 2.88 (d, J = 5.4 Hz, 2H), 2.65 – 2.55 (m, 4H), 2.20 – 2.19 (m, 3H), 1.78 (t, J = 3.2 Hz, 5H); MS (ESI(+)) m/e 456.6 (M+H)+.

The following examples were prepared as described in Example 6B followed by Example 9, substituting the appropriate amine in Example 6B and the appropriate alkyl halide in Example 9. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as in Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA
7	2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 10.52 (s, 1H), 8.75 (d, J = 5.5 Hz, 1H), 7.85 (s, 1H), 7.33 (dd, J = 8.5, 5.3 Hz, 2H), 7.20 (s, 1H), 7.10 (s, 1H), 7.04 (t, J = 8.6 Hz, 2H), 4.47 – 4.37 (m, 4H), 4.25 (t, J = 7.0 Hz, 2H), 3.74 – 3.66 (m, 5H), 3.42 (dd, J = 11.2, 5.6 Hz, 2H), 2.44 – 2.36 (m, 4H), 2.34 (t, J = 6.6 Hz, 2H), 2.22 (dd, J =	(ESI(+)) m/e 487 $(M+H)^+$

		11.3, 5.7 Hz, 2H), 2.02 – 1.91 (m, 2H).	
8	2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 10.69 (s, 1H), 8.90 (s, 1H), 7.90 (s, 1H), 7.33 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.21 (s, 1H), 7.15 (s, 1H), 7.04 (t, *J* = 8.6 Hz, 2H), 4.42 (d, *J* = 10.4 Hz, 4H), 4.26 (t, *J* = 7.0 Hz, 2H), 3.42 (dd, *J* = 11.1, 5.6 Hz, 2H), 2.44 (d, *J* = 27.4 Hz, 4H), 2.26 – 2.18 (m, 2H), 2.02 – 1.93 (m, 4H), 1.64 – 1.61 (m, 4H), 1.46 – 1.5 (m, 2H).	(ESI(+)) m/e 485 $(M+H)^+$
10	2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.56 (s, 1H), 7.48 (s, 1H), 7.32 (dd, *J* = 8.5, 5.5 Hz, 2H), 7.07 (s, 1H), 7.01 (t, *J* = 8.7 Hz, 2H), 6.97 (s, 1H), 4.24 (s, 2H), 4.04 (t, *J* = 6.9 Hz, 2H), 3.93 (t, *J* = 6.1 Hz, 2H), 3.39 (d, *J* = 6.3 Hz, 2H), 2.85 – 2.78 (m, 2H), 2.75 – 2.65 (m, 5H), 2.10 – 2.05 (m, 4H), 1.11 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 514 (M+H)+
14	2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 11.17 (s, 1H), 9.15 (t, *J* = 5.6 Hz, 1H), 7.99 (s, 1H), 7.38 – 7.29 (m, 2H), 7.14 (s, 1H), 7.09 (dt, *J* = 11.7, 1.7 Hz, 2H), 7.06 – 6.98 (m, 2H), 6.86 (s, 1H), 6.02 (s, 2H), 5.38 (s, 2H), 4.45 (s, 2H), 4.43 – 4.38 (m, 2H), 3.41 (dd, *J* = 11.0, 5.6 Hz, 2H), 2.28 – 2.14 (m, 2H), 2.06 (s, 6H).	(ESI(+)) m/e 529 (M+H)+

15	2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 11.45 (s, 1H), 9.23 (dd, *J* = 7.2, 3.6 Hz, 1H), 8.02 (s, 1H), 7.43 – 7.36 (m, 2H), 7.36 – 7.31 (m, 2H), 7.29 (t, *J* = 5.4 Hz, 2H), 7.13 (t, *J* = 1.7 Hz, 1H), 7.09 – 6.95 (m, 2H), 6.89 (t, *J* = 1.7 Hz, 1H), 5.34 (s, 2H), 4.45 (s, 2H), 4.45 – 4.37 (m, 2H), 3.48 – 3.35 (m, 2H), 2.29 – 2.17 (m, 2H).	(ESI(+)) m/e 484 (M+H)+
16	2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 11.25 (s, 1H), 9.21 – 9.12 (m, 1H), 8.03 (s, 1H), 7.62 (dd, *J* = 6.8, 2.4 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.40 – 7.30 (m, 4H), 7.10 (dt, *J* = 12.9, 1.6 Hz, 2H), 7.06 – 6.98 (m, 2H), 5.50 (s, 2H), 4.45 (s, 2H), 4.42 (d, *J* = 6.1 Hz, 2H), 3.41 (dd, *J* = 11.1, 5.6 Hz, 2H), 2.22 (ddd, *J* = 7.4, 5.9, 2.1 Hz, 2H).	(ESI(+)) m/e 484 (M+H)+
17	2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.23 (s, 1H), 8.61 (t, *J* = 6.0 Hz, 1H), 8.25 (t, *J* = 5.8 Hz, 1H), 7.81 (t, *J* = 1.7 Hz, 1H), 7.75 (t, *J* = 1.7 Hz, 1H), 7.63 (s, 1H), 7.59 – 7.55 (m, 2H), 7.53 (dd, *J* = 8.6, 2.4 Hz, 1H), 7.34 (dd, *J* = 8.6, 5.6 Hz, 2H), 7.15 (dd, *J* = 12.3, 5.5 Hz, 2H), 5.47 (s, 2H), 4.41 (d, *J* = 5.1 Hz, 2H), 4.18 (t, *J* = 7.0 Hz, 2H), 3.15 (s, 2H), 1.98 (t, *J* = 6.8 Hz, 2H).	(ESI(+)) m/e 519 (M+H)+

23	2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.10 (d, *J* = 1.2 Hz, 1H), 8.28 (t, *J* = 5.7 Hz, 1H), 7.79 (dd, *J* = 5.8, 4.1 Hz, 2H), 7.68 (t, *J* = 1.6 Hz, 1H), 7.38 – 7.27 (m, 2H), 7.21 – 7.11 (m, 6H), 4.72 (s, 2H), 4.68 (s, 2H), 4.20 (d, *J* = 7.0 Hz, 2H), 3.18 (q, *J* = 6.6 Hz, 3H), 2.01 (p, *J* = 6.8 Hz, 2H).	(ESI(+)) m/e 464 (M+H)+
47	2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.11 (s, 1H), 8.27 (t, *J* = 5.7 Hz, 1H), 7.81 (d, *J* = 1.4 Hz, 1H), 7.75 (s, 1H), 7.69 (t, *J* = 1.5 Hz, 1H), 7.33 (dd, *J* = 8.6, 5.6 Hz, 2H), 7.23 – 7.08 (m, 2H), 4.69 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.46 – 3.42 (m, 2H), 3.19 (dd, *J* = 11.6, 5.5 Hz, 2H), 2.02 (p, *J* = 6.8 Hz, 2H), 1.54 (dt, *J* = 12.9, 6.5 Hz, 1H), 1.46 (dd, *J* = 15.0, 7.1 Hz, 2H), 0.88 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 430 (M+H)+
55	2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 9.22 (s, 1H), 7.78 (t, *J* = 1.7 Hz, 1H), 7.73 (t, *J* = 1.7 Hz, 1H), 7.67 (s, 1H), 7.53 – 7.46 (m, 2H), 7.33 – 7.26 (m, 2H), 5.48 (s, 2H), 4.21 (t, *J* = 7.0 Hz, 2H), 3.31 – 3.22 (m, 2H), 3.20 (t, *J* = 6.6 Hz, 2H), 2.10 – 1.95 (m, 2H), 1.63 (dt, *J* = 13.3, 6.7 Hz, 1H), 1.45 (dd, *J* = 14.4, 7.0 Hz, 2H), 0.89 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 430 (M+H)+

56	2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 9.03 (s, 1H), 7.74 (d, *J* = 2.1 Hz, 2H), 7.64 (s, 1H), 7.41 (dd, *J* = 14.1, 7.9 Hz, 1H), 7.10 (dd, *J* = 17.6, 9.2 Hz, 3H), 4.73 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.54 – 3.42 (m, 2H), 3.20 (t, *J* = 6.5 Hz, 2H), 2.03 (t, *J* = 6.8 Hz, 2H), 1.59 – 1.51 (m, 1H), 1.50 – 1.43 (m, 2H), 0.88 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 430 (M+H)+
57	2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 9.22 (s, 1H), 7.80 (t, *J* = 1.7 Hz, 1H), 7.71 (t, *J* = 1.7 Hz, 1H), 7.67 (s, 1H), 7.57 (d, *J* = 7.5 Hz, 1H), 7.51 – 7.42 (m, 3H), 5.51 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.28 – 3.23 (m, 2H), 3.20 (t, *J* = 6.7 Hz, 2H), 2.03 (p, *J* = 6.7 Hz, 2H), 1.63 (dt, *J* = 13.3, 6.7 Hz, 1H), 1.45 (dd, *J* = 14.4, 7.0 Hz, 2H), 0.89 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 447 (M+H)+
58	2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 9.02 (s, 1H), 7.74 (s, 2H), 7.63 (s, 1H), 7.39 (dd, *J* = 13.9, 6.6 Hz, 3H), 7.32 (s, 1H), 7.25 (d, *J* = 7.4 Hz, 1H), 4.72 (s, 2H), 4.22 (t, *J* = 7.0 Hz, 2H), 3.47 (d, *J* = 7.1 Hz, 2H), 3.20 (t, *J* = 6.5 Hz, 2H), 2.09 – 1.97 (m, 2H), 1.54 (d, *J* = 6.2 Hz, 1H), 1.50 – 1.44 (m, 2H), 0.88 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 447 (M+H)+

59	2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 7.73 (s, 2H), 7.62 (s, 1H), 7.41 (d, *J* = 8.5 Hz, 3H), 7.38 (s, 1H), 7.30 (d, *J* = 8.5 Hz, 2H), 4.69 (s, 2H), 4.21 (t, *J* = 7.1 Hz, 2H), 3.47 (dd, *J* = 11.5, 4.4 Hz, 2H), 3.19 (t, *J* = 6.6 Hz, 2H), 2.03 (t, *J* = 6.8 Hz, 2H), 1.53 (d, *J* = 6.7 Hz, 1H), 1.51 – 1.44 (m, 2H), 0.88 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 447 (M+H)+
60	2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, DMSO-d_6/D_2O) δ 7.85 – 7.78 (m, 3H), 7.74 (s, 1H), 7.72 (s, 1H), 7.64 (s, 1H), 7.46 (d, *J* = 8.2 Hz, 2H), 4.80 (s, 2H), 4.22 (t, *J* = 6.9 Hz, 2H), 3.49 (m, 2H), 3.19 (t, *J* = 6.7 Hz, 2H), 2.09 – 1.97 (m, 2H), 1.55 (s, 1H), 1.48 (d, *J* = 8.4 Hz, 2H), 0.89 (d, *J* = 6.4 Hz, 6H).	(ESI(+)) m/e 437 (M+H)+

Example 18

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6B (0.018 g, 0.05 mmol) was dissolved in DMSO:CH_3OH 1:1 (0.5 ml), Hunig's base (0.02 mL, 0.15 mmol) and 2-chloro-N-methylacetamide (0.006 g, 0.6 mmol). The reaction mixture was heated at 80 °C overnight and submitted to reverse-phase HPLC (as described in Example 6C) to afford the title compound. ^{1}H NMR (400 MHz, methanol-d_4) δ 7.70 (d, J = 1.9 Hz, 1H), 7.64 (s, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.36 (dd, J = 8.4, 5.5 Hz, 2H), 7.06 (t, J = 8.7 Hz, 2H), 4.97 (s, 2H), 4.48 (s, 2H), 4.29 (t, J = 6.9 Hz, 2H), 3.35 (t, J = 6.4 Hz, 2H), 2.79 (s, 3H), 2.14 (p, J = 6.7 Hz, 2H); MS (ESI(+)) m/e 431 (M+H)+.

The following examples were prepared as described in Example 18, substituting the appropriate chloro-acetamide. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as described in Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA
19	2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 10.95 – 10.86 (m, 1H), 8.81 – 8.68 (m, 1H), 8.67 – 8.53 (m, 1H), 8.02 – 7.93 (m, 1H), 7.51 (ddd, *J* = 5.5, 4.8, 1.7 Hz, 1H), 7.34 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.14 (s, 1H), 7.07 – 6.99 (m, 2H), 5.04 (s, 2H), 4.46 (s, 2H), 4.38 – 4.27 (m, 2H), 3.96 (dd, *J* = 13.5, 6.8 Hz, 1H), 3.40 – 3.27 (m, 2H), 2.19 – 2.17 (m, 2H), 1.18 (d, *J* = 6.6 Hz, 6H).	(ESI(+)) m/e 459 $(M+H)^+$
20	2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 10.99 – 10.90 (m, 1H), 8.97 – 8.89 (m, 1H), 8.01 (s, 1H), 7.36 – 7.29 (m, 2H), 7.22 (t, *J* = 1.6 Hz, 1H), 7.13 (t, *J* = 1.7 Hz, 1H), 7.07 – 6.99 (m, 2H), 5.36 (s, 2H), 4.45 (s, 2H), 4.41 – 4.32 (m, 2H), 3.38 (dd, *J* = 11.1, 5.7 Hz, 2H), 3.12 (s, 3H), 3.00 (s, 3H), 2.23 – 2.19 (m, 2H).	(ESI(+)) m/e 445 $(M+H)^+$
21	2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 11.08 – 11.00 (m, 1H), 9.04 – 8.96 (m, 1H), 8.11 – 8.02 (m, 1H), 7.33 (dd, *J* = 8.5, 5.4 Hz, 2H), 7.25 (t, *J* = 1.6 Hz, 1H), 7.13 (s, 1H), 7.04 (dd, *J* = 9.8, 7.5 Hz, 2H), 5.34 (s, 2H), 4.45 (s, 2H), 4.36 (dd, *J* = 7.8, 4.0 Hz, 2H), 3.44 – 3.37 (m, 6H), 2.24 – 2.19 (m, 2H), 1.29 (t, *J* = 5.4 Hz, 3H), 1.15 (t, *J* = 7.1 Hz, 3H).	(ESI(+)) m/e 473 $(M+H)^+$

22	2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$) δ 11.09 – 11.00 (m, 1H), 8.92 – 8.79 (m, 1H), 8.11 – 8.02 (m, 1H), 7.36 – 7.29 (m, 2H), 7.24 (d, *J* = 1.5 Hz, 1H), 7.19 – 7.11 (m, 1H), 7.06 – 6.99 (m, 2H), 5.46 (dd, *J* = 4.8, 2.0 Hz, 2H), 4.45 (d, *J* = 3.3 Hz, 2H), 4.41 – 4.30 (m, 2H), 3.78 (ddd, *J* = 6.4, 5.3, 2.4 Hz, 2H), 3.75 – 3.70 (m, 2H), 3.63 – 3.57 (m, 4H), 3.37 (tdd, *J* = 7.3, 2.3, 1.4 Hz, 2H), 2.27 – 2.18 (m, 2H).	(ESI(+)) m/e 487 $(M+H)^+$

Example 26

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6B (0.036 g, 0.1 mmol) was dissolved in dichloromethane:pyridine 10:1 (1 ml), cooled to -10 °C, and treated with chloroacetyl bromide (0.011 mL, 0.125 mmol). The resultant solution was stirred at room temperature for 30 minutes. The reaction mixture was then treated with an excess of dimethylamine in tetrahydrofuran (0.5 mL, 1M solution). The reaction mixture was heated at 80 °C overnight and purified by reverse-phase HPLC (as described in Example 6C) to afford the title compound. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.35 – 7.23 (m, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.48 (s, 2H), 4.60 – 4.45 (m, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.40 (t, *J* = 6.5 Hz, 2H), 2.98 (s, 6H), 2.18 (t, *J* = 6.7 Hz, 2H); MS (ESI(+)) m/e 445 (M+H)+.

The following examples were prepared as described in Example 26, substituting the appropriate alkyl halide in Example 26. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as in described Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA

27	2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.95 (s, 1H), 8.03 (s, 1H), 7.69 (s, 1H), 7.56 (s, 1H), 7.28 (s, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.98 (s, 1H), 5.73 (s, 1H), 5.51 (s, 2H), 4.53 – 2.44 (m, 2H), 4.32 (t, *J* = 6.9 Hz, 2H), 3.88 – 3.78 (m, 1H), 3.57 – 3.42 (m, 1H), 3.40 (t, *J* = 6.6 Hz, 1H), 2.52 – 2.46 (m, 2H), 2.17 (dd, *J* = 13.5, 6.8 Hz, 2H).	(ESI(+)) m/e 483 $(M+H)^+$
28	2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.27 (s, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.49 (s, 2H), 4.45 (s, 2H), 4.32 (dd, *J* = 8.9, 4.9 Hz, 2H), 3.63 (d, *J* = 10.7 Hz, 2H), 3.40 (t, *J* = 6.5 Hz, 2H), 3.04 (t, *J* = 12.6 Hz, 2H), 2.21 – 2.14 (m, 2H), 1.92 (d, *J* = 15.0 Hz, 2H), 1.71 (s, 1H), 1.56 (d, *J* = 12.4 Hz, 2H), 1.03 (d, *J* = 6.4 Hz, 3H).	(ESI(+)) m/e 499 $(M+H)^+$
29	2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.28 (s, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.49 (s, 2H), 4.49 (s, 2H), 4.32 (t, *J* = 7.0 Hz, 2H), 3.46 (d, *J* = 5.3 Hz, 1H), 3.40 (t, *J* = 6.6 Hz, 2H), 2.19 (dd, *J* = 13.7, 6.8 Hz, 2H), 2.12 (d, *J* = 22.1 Hz, 2H), 1.91 – 1.85 (m, 2H).	(ESI(+)) m/e 501 $(M+H)^+$
30	2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.99 (s, 1H), 7.71 (d, *J* = 1.4 Hz, 1H), 7.59 (s, 1H), 7.27 – 7.15 (m, 2H), 7.08 (t, *J* = 8.7 Hz, 2H), 5.54 (s, 2H), 4.33 (t,	(ESI(+)) m/e 500 $(M+H)^+$

		J = 7.0 Hz, 2H), 3.71 (s, 2H), 3.40 (t, J = 6.5 Hz, 2H), 3.13 – 2.91 (m, 4H), 2.88 (s, 3H), 2.82 – 2.66 (m, 2H), 2.19 (p, J = 7.0 Hz, 2H).	
31	2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.99 (s, 1H), 7.72 (t, J = 1.6 Hz, 1H), 7.59 (t, J = 1.6 Hz, 1H), 7.21 (dd, J = 8.6, 5.3 Hz, 2H), 7.08 (dd, J = 12.2, 5.3 Hz, 2H), 5.55 (s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.71 (s, 2H), 3.51 – 3.37 (m, 4H), 3.15 – 2.91 (m, 4H), 2.75 – 2.67 (m, 1H), 2.19 (t, J = 6.7 Hz, 2H), 1.33 (d, J = 6.7 Hz, 6H).	(ESI(+)) m/e 528 $(M+H)^+$
32	2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.05 (s, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.72 (s, 1H), 7.59 (s, 1H), 7.31 – 7.19 (m, 2H), 7.15 – 7.03 (m, 2H), 5.66 – 5.41 (m, 2H), 4.33 (t, J = 7.0 Hz, 2H), 4.21 – 4.03 (m, 2H), 3.68 (tdd, J = 5.0, 4.5, 1.3 Hz, 2H), 3.66 – 3.60 (m, 2H), 3.46 – 3.38 (m, 2H), 3.16 – 2.93 (m, 4H), 2.25 – 2.13 (m, 2H).	(ESI(+)) m/e 514 $(M+H)^+$
33	2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.99 (s, 1H), 7.72 (t, J = 1.6 Hz, 1H), 7.59 (t, J = 1.5 Hz, 1H), 7.21 (dd, J = 8.5, 5.3 Hz, 2H), 7.08 (t, J = 8.7 Hz, 2H), 5.54 (s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.81 – 3.68 (m, 2H), 3.39 (d, J = 6.5 Hz, 2H), 3.26 – 2.68 (m, 6H), 2.28 – 2.01 (m, 5H).	(ESI(+)) m/e 526 $(M+H)^+$

34	2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.00 (s, 1H), 7.72 (t, *J* = 1.7 Hz, 1H), 7.59 (s, 1H), 7.27 – 7.15 (m, 2H), 7.15 – 7.02 (m, 2H), 5.55 (s, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.72 (s, 2H), 3.65 – 3.50 (m, 2H), 3.40 (dd, *J* = 8.0, 5.1 Hz, 2H), 3.17 – 2.97 (m, 6H), 2.88 – 2.68 (m, 2H), 2.26 – 2.11 (m, 2H), 1.06 (d, *J* = 7.2 Hz, 1H), 0.83 – 0.70 (m, 2H), 0.43 (dd, *J* = 5.6, 4.9 Hz, 2H).	(ESI(+)) m/e 540 $(M+H)^+$
35	2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.99 (s, 1H), 7.72 (s, 1H), 7.59 (s, 1H), 7.21 (dd, *J* = 8.6, 5.2 Hz, 2H), 7.09 – 7.06 (m, 2H), 5.55 (s, 2H), 4.39 – 4.24 (m, 2H), 3.74 (dd, *J* = 6.4, 3.6 Hz, 2H), 3.71 (s, 2H), 3.57 (q, *J* = 7.1 Hz, 2H), 3.40 (t, *J* = 6.5 Hz, 2H), 2.95 (d, *J* = 58.3 Hz, 6H), 2.26 – 2.09 (m, 2H), 1.22 (t, *J* = 7.0 Hz, 3H).	(ESI(+)) m/e 558 $(M+H)^+$
37	2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.00 (s, 1H), 7.71 (d, *J* = 7.5 Hz, 1H), 7.58 (s, 1H), 7.21 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.08 (t, *J* = 8.7 Hz, 2H), 6.01 – 5.82 (m, 1H), 5.62 (s, 1H), 5.59 (d, *J* = 6.2 Hz, 1H), 5.54 (s, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.74 (d, *J* = 7.3 Hz, 2H), 3.75 – 3.70 (m, 2H), 3.40 (t, *J* = 6.5 Hz, 2H), 2.95 – 2.9 (m, 4H), 2.19 (p, *J* = 6.9 Hz, 2H).	(ESI(+)) m/e 526 (M+H)+

38	2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.00 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.21 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.08 (t, *J* = 8.7 Hz, 2H), 5.55 (s, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.71 (s, 2H), 3.48 (t, *J* = 5.6 Hz, 2H), 3.40 (t, *J* = 6.5 Hz, 2H), 3.34 (s, 3H), 3.23 (t, *J* = 8.0 Hz, 2H), 2.26 – 2.09 (m, 2H), 1.97 (dd, *J* = 9.7, 5.8 Hz, 2H).	(ESI(+)) m/e 558 (M+H)+
39	2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.01 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.24 (dd, *J* = 8.5, 5.3 Hz, 2H), 7.08 (t, *J* = 8.7 Hz, 2H), 5.51 (s, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 4.06 (d, *J* = 32.5 Hz, 2H), 3.97 – 3.90 (m, 1H), 3.52 – 3.43 (m, 1H), 3.40 (t, *J* = 6.5 Hz, 2H), 3.13 (s, 1H), 2.91 (s, 6H), 2.40 (dd, *J* = 13.1, 4.6 Hz, 1H), 2.26 – 2.06 (m, 3H).	(ESI(+)) m/e 514 (M+H)+
40	2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.04 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.35 – 7.23 (m, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.50 (s, 2H), 4.54 (s, 2H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.99 – 3.90 (m, 4H), 3.53 – 3.33 (m, 6H), 2.19 (p, *J* = 6.8 Hz, 2H).	(ESI(+)) m/e 487 (M+H)+
41	2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.04 (s, 1H), 7.71 (s, 1H), 7.59 (s, 1H), 7.34 – 7.23 (m, 2H), 7.10 (t, *J* = 8.7 Hz, 2H), 5.50 (s, 2H), 4.50 (m, 1H), 4.33 (t, *J* = 7.0 Hz, 2H), 4.15 – 4.1 (m, 1H), 3.76 – 3.49 (m, 1H), 3.40 (t,	(ESI(+)) m/e 501 (M+H)+

		J = 6.6 Hz, 2H), 3.27 – 2.95 (m, 2H), 2.19 (p, J = 6.8 Hz, 2H), 1.79 (d, J = 15.5 Hz, 2H).	
42	2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.00 (s, 1H), 7.72 (s, 1H), 7.58 (s, 1H), 7.22 (dd, J = 8.6, 5.3 Hz, 2H), 7.08 (t, J = 8.7 Hz, 2H), 5.55 (s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.91 – 3.80 (m, 2H), 3.75 – 3.65 (m, 2H), 3.40 (t, J = 6.5 Hz, 2H), 3.26 – 3.21 (m, 2H), 2.98 – 2.88 (m, 4H), 2.19 (p, J = 6.7 Hz, 2H).	(ESI(+)) m/e 530 (M+H)+
43	2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 8.03 (s, 1H), 7.71 (s, 1H), 7.58 (s, 1H), 7.35 – 7.23 (m, 2H), 7.10 (t, J = 8.7 Hz, 2H), 5.48 (s, 2H), 4.64 (s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.99 (d, J = 3.7 Hz, 4H), 3.72 – 3.63 (m, 2H), 3.6 – 3.5 (m, 2H), 3.40 (t, J = 6.5 Hz, 2H), 2.29 (t, J = 7.7 Hz, 2H), 2.19 (p, J = 6.7 Hz, 2H).	(ESI(+)) m/e 529 (M+H)+

Example 212

2-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide

Example 6A (0.095 g, 0.3 mmol), (R)-2-((2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione (0.049 g, 0.2 mmol), and potassium phosphate (0.127 g, 0.6 mmol) were suspended in dry dioxane, and nitrogen was bubbled through for 5 minutes. Tris(dibenzylideneacetone)dipalladium(0) (0.018 g. 0.02 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos, 0.035 g, 0.06 mmol) were added to the reaction, and the vial capped. The reaction was stirred at 90 °C for 5 hours, concentrated and submitted to reverse phase HPLC (as described in Example 6C) to afford the title compound. ^{1}H NMR (400 MHz, methanol-d_4) δ 8.98 (s, 1H), 7.95 (s, 1H), 7.90 (dt, J = 7.3, 3.7 Hz, 2H), 7.87 – 7.80 (m, 2H), 7.71 (d, J = 1.6 Hz, 1H), 7.58 (t, J = 1.6 Hz, 1H), 5.16 (dt,

J = 12.7, 5.8 Hz, 1H), 4.40 (dd, J = 10.2, 8.8 Hz, 1H), 4.33 (t, J = 6.8 Hz, 2H), 4.20 (dd, J = 10.4, 5.8 Hz, 1H), 4.10 (ddd, J = 19.6, 14.6, 5.9 Hz, 2H), 3.39 (dd, J = 11.2, 6.1 Hz, 2H), 2.18 (p, J = 6.7 Hz, 2H); MS (ESI(+)) m/e 480.5 (M+H)+.

The following examples were prepared as described in Example 212, substituting the appropriate imidazolidinone for the oxazolidinone. Title compounds were purified by either flash chromatography (silica gel column eluting with a gradient of 0-10% methanol in dichloromethane) or reverse-phase HPLC (as described in Example 6C). Accordingly, some examples were isolated as trifluoroacetic acid salts.

EX	NAME	^{1}H NMR DATA	MS DATA
203	2-[3-(2-hydroxyethyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 7.89 (s, 1H), 7.70 (s, 1H), 7.18 (s, 1H), 6.97 (s, 1H), 4.10 (dd, J = 11.6, 4.7 Hz, 4H), 3.74 (dd, J = 12.9, 7.2 Hz, 4H), 3.43 (t, J = 5.4 Hz, 2H), 3.34 (t, J = 6.8 Hz, 2H), 2.07 (p, J = 6.8 Hz, 2H).	(ESI(+)) m/e 365 $(M+H)^+$
204	2-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide	^{1}H NMR (400 MHz, methanol-d_4) δ 8.99 (s, 1H), 7.95 (s, 1H), 7.76 – 7.54 (m, 4H), 7.15 (t, J = 8.8 Hz, 2H), 4.34 (t, J = 6.8 Hz, 2H), 4.24 (dd, J = 10.0, 6.5 Hz, 2H), 4.13 (dd, J = 9.9, 6.7 Hz, 2H), 3.40 (dd, J = 11.5, 6.0 Hz, 2H), 2.19 (p, J = 6.6 Hz, 2H).	(ESI(+)) m/e 415 $(M+H)^+$

WHAT IS CLAIMED IS:

1. A compound of formula (I), or a therapeutically acceptable salt thereof,



Formula (I),

wherein

R^1 and R^2 are each independently selected from the group consisting of R^6, $C(O)R^6$, $C(O)NHR^6$, and $C(O)N(R^6)_2$; wherein at least one of R^1 and R^2 is R^6; or

R^1 and R^2, together with the nitrogen to which they are attached form a heterocycloalkyl or heterocycloalkenyl ring; wherein the ring formed with R^1 and R^2 together with the nitrogen to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of R^7, OR^7, SR^7, $S(O)R^7$, SO_2R^7, $C(O)R^7$, $CO(O)R^7$, $OC(O)R^7$, $OC(O)OR^7$, NH_2, NHR^7, $N(R^7)_2$, $NHC(O)R^7$, $NR^7C(O)R^7$, $NHS(O)_2R^7$, $NR^7S(O)_2R^7$, $NHC(O)OR^7$, $NR^7C(O)OR^7$, $NHC(O)NH_2$, $NHC(O)NHR^7$, $NHC(O)N(R^7)_2$, $NR^7C(O)NHR^7$, $NR^7C(O)N(R^7)_2$, $C(O)NH_2$, $C(O)NHR^7$, $C(O)N(R^7)_2$, $C(O)NHOH$, $C(O)NHOR^7$, $C(O)NHSO_2R^7$, $C(O)NR^7SO_2R^7$, SO_2NH_2, SO_2NHR^7, $SO_2N(R^7)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^7$, $C(N)N(R^7)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^3, R^4, and R^5 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, F, Cl, Br and I;

R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, SR^8, $S(O)R^8$, SO_2R^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $OC(O)OR^8$, NH_2, NHR^8, $N(R^8)_2$, $NHC(O)R^8$, $NR^8C(O)R^8$, $NHS(O)_2R^8$, $NR^8S(O)_2R^8$, $NHC(O)OR^8$, $NR^8C(O)OR^8$, $NHC(O)NH_2$, $NHC(O)NHR^8$, $NHC(O)N(R^8)_2$, $NR^8C(O)NHR^8$, $NR^8C(O)N(R^8)_2$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, $C(O)NHOH$, $C(O)NHOR^8$, $C(O)NHSO_2R^8$, $C(O)NR^8SO_2R^8$, SO_2NH_2, SO_2NHR^8, $SO_2N(R^8)_2$, $C(O)H$, $C(O)OH$, $C(N)NH_2$, $C(N)NHR^8$, $C(N)N(R^8)_2$, $CNOH$, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^6 are each independently optionally substituted with one or

more substituents independently selected from the group consisting of R^9, OR^9, SR^9, $S(O)R^9$, SO_2R^9, $C(O)R^9$, $CO(O)R^9$, $OC(O)R^9$, $OC(O)OR^9$, NH_2, NHR^9, $N(R^9)_2$, $NHC(O)R^9$, $NR^9C(O)R^9$, $NHS(O)_2R^9$, $NR^9S(O)_2R^9$, $NHC(O)OR^9$, $NR^9C(O)OR^9$, $NHC(O)NH_2$, $NHC(O)NHR^9$, $NHC(O)N(R^9)_2$, $NR^9C(O)NHR^9$, $NR^9C(O)N(R^9)_2$, $C(O)NH_2$, $C(O)NHR^9$, $C(O)N(R^9)_2$, C(O)NHOH, $C(O)NHOR^9$, $C(O)NHSO_2R^9$, $C(O)NR^9SO_2R^9$, SO_2NH_2, SO_2NHR^9, $SO_2N(R^9)_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^9$, $C(N)N(R^9)_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^7, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^7 are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^8, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{10}, OR^{10}, SR^{10}, $S(O)R^{10}$, SO_2R^{10}, $C(O)R^{10}$, $CO(O)R^{10}$, $OC(O)R^{10}$, $OC(O)OR^{10}$, NH_2, NHR^{10}, $N(R^{10})_2$, $NHC(O)R^{10}$, $NR^{10}C(O)R^{10}$, $NHS(O)_2R^{10}$, $NR^{10}S(O)_2R^{10}$, $NHC(O)OR^{10}$, $NR^{10}C(O)OR^{10}$, $NHC(O)NH_2$, $NHC(O)NHR^{10}$, $NHC(O)N(R^{10})_2$, $NR^{10}C(O)NHR^{10}$, $NR^{10}C(O)N(R^{10})_2$, $C(O)NH_2$, $C(O)NHR^{10}$, $C(O)N(R^{10})_2$, C(O)NHOH, $C(O)NHOR^{10}$, $C(O)NHSO_2R^{10}$, $C(O)NR^{10}SO_2R^{10}$, SO_2NH_2, SO_2NHR^{10}, $SO_2N(R^{10})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{10}$, $C(N)N(R^{10})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^8 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{11}, OR^{11}, SR^{11}, $S(O)R^{11}$, SO_2R^{11}, $C(O)R^{11}$, $CO(O)R^{11}$, $OC(O)R^{11}$, $OC(O)OR^{11}$, NH_2, NHR^{11}, $N(R^{11})_2$, $NHC(O)R^{11}$, $NR^{11}C(O)R^{11}$, $NHS(O)_2R^{11}$, $NR^{11}S(O)_2R^{11}$, $NHC(O)OR^{11}$, $NR^{11}C(O)OR^{11}$, $NHC(O)NH_2$, $NHC(O)NHR^{11}$, $NHC(O)N(R^{11})_2$, $NR^{11}C(O)NHR^{11}$, $NR^{11}C(O)N(R^{11})_2$, $C(O)NH_2$, $C(O)NHR^{11}$, $C(O)N(R^{11})_2$, C(O)NHOH, $C(O)NHOR^{11}$, $C(O)NHSO_2R^{11}$, $C(O)NR^{11}SO_2R^{11}$, SO_2NH_2, SO_2NHR^{11}, $SO_2N(R^{11})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{11}$, $C(N)N(R^{11})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^9, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{12}, OR^{12}, SR^{12}, $S(O)R^{12}$, SO_2R^{12}, $C(O)R^{12}$, $CO(O)R^{12}$, $OC(O)R^{12}$, $OC(O)OR^{12}$, NH_2, NHR^{12}, $N(R^{12})_2$, $NHC(O)R^{12}$, $NR^{12}C(O)R^{12}$, $NHS(O)_2R^{12}$, $NR^{12}S(O)_2R^{12}$, $NHC(O)OR^{12}$, $NR^{12}C(O)OR^{12}$, $NHC(O)NH_2$, $NHC(O)NHR^{12}$, $NHC(O)N(R^{12})_2$, $NR^{12}C(O)NHR^{12}$, $NR^{12}C(O)N(R^{12})_2$, $C(O)NH_2$, $C(O)NHR^{12}$, $C(O)N(R^{12})_2$, C(O)NHOH, $C(O)NHOR^{12}$, $C(O)NHSO_2R^{12}$, $C(O)NR^{12}SO_2R^{12}$, SO_2NH_2, SO_2NHR^{12}, $SO_2N(R^{12})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{12}$, $C(N)N(R^{12})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^9 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^{13}, OR^{13}, SR^{13}, $S(O)R^{13}$, SO_2R^{13}, $C(O)R^{13}$, $CO(O)R^{13}$, $OC(O)R^{13}$, $OC(O)OR^{13}$, NH_2, NHR^{13}, $N(R^{13})_2$, $NHC(O)R^{13}$, $NR^{13}C(O)R^{13}$, $NHS(O)_2R^{13}$, $NR^{13}S(O)_2R^{13}$, $NHC(O)OR^{13}$, $NR^{13}C(O)OR^{13}$, $NHC(O)NH_2$, $NHC(O)NHR^{13}$, $NHC(O)N(R^{13})_2$, $NR^{13}C(O)NHR^{13}$, $NR^{13}C(O)N(R^{13})_2$, $C(O)NH_2$, $C(O)NHR^{13}$, $C(O)N(R^{13})_2$, C(O)NHOH, $C(O)NHOR^{13}$, $C(O)NHSO_2R^{13}$, $C(O)NR^{13}SO_2R^{13}$, SO_2NH_2, SO_2NHR^{13}, $SO_2N(R^{13})_2$, C(O)H, C(O)OH, $C(N)NH_2$, $C(N)NHR^{13}$, $C(N)N(R^{13})_2$, CNOH, $CNOCH_3$, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{10}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl;

R^{11}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{11} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I;

R^{12}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of C_{1-6} alkoxy, aryl, heterocycloalkyl,

heterocycloalkenyl, heteroaryl, cycloalkyl, cycloalkenyl, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; wherein the aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, cycloalkyl, and cycloalkenyl represented by R^{12} are each independently optionally substituted with one or more substituents independently selected from the group consisting of NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I; and

R^{13}, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl; wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl represented by R^{13} are each independently optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, NH_2, C(O)H, C(O)OH, OH, CN, N_3, NO_2, F, Cl, Br and I.

2. The compound of claim 1, wherein R^1 is $C(O)R^6$; and R^2 is R^6.

3. The compound of claim 1, wherein R^1 and R^2 are each R^6.

4. The compound of claim 1, wherein R^1 is $C(O)NHR^6$; and R^2 is R^6.

5. The compound of claim 1, wherein R^1 is $C(O)N(R^6)_2$; and R^2 is R^6.

6. The compound of any one of claims 1-5, wherein R^3, R^4, and R^5 are hydrogen.

7. The compound of any one of claims 1-5, wherein R^6, at each occurrence, is independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, aryl, heterocycloalkyl, heteroaryl, and cycloalkyl; wherein the C_{1-6} alkyl, and C_{2-6} alkenyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^8, OR^8, $C(O)R^8$, $CO(O)R^8$, $OC(O)R^8$, $N(R^8)_2$, $NHC(O)R^8$, $C(O)NH_2$, $C(O)NHR^8$, $C(O)N(R^8)_2$, C(O)OH, and OH; wherein the aryl, heterocycloalkyl, heteroaryl, and cycloalkyl represented by R^6 are each independently optionally substituted with one or more substituents independently selected from the group consisting of R^9, OR^9, $C(O)NH_2$, C(O)OH, OH, CN, F, Cl, Br and I.

8. The compound of claim 1, selected from the group consisting of:

2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{methyl[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclohexylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(morpholin-4-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[3-(piperidin-1-yl)propyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(pyrrolidin-1-yl)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){2-[4-(propan-2-yl)piperazin-1-yl]ethyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzoyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloro-1,3-benzodioxol-4-yl)methyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2,5-dichlorobenzyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(methylamino)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-oxo-2-(propan-2-ylamino)ethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(dimethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)-2-oxoethyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(4-methylbenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(methoxyacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(N,N-dimethylglycyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3,6-dihydropyridin-1(2H)-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-methylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(propan-2-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(4-formylpiperazin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(cyclopropylmethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[4-(2-ethoxyethyl)piperazin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(prop-2-en-1-yl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(3-methoxypropyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(dimethylamino)pyrrolidin-1-yl]acetyl}(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(morpholin-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-hydroxypiperidin-1-yl)acetyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[4-(2-hydroxyethyl)piperazin-1-yl]acetyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxa-7-azaspiro[4.4]non-7-ylacetyl)(4-fluorobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

1-{2-[(4-fluorobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)amino]-2-oxoethyl}pyridinium;

2-{[2-(4-fluorophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(propan-2-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methylbutanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydro-2H-pyran-4-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](tetrahydrofuran-3-ylacetyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(3-methylbutanoyl)amino]-N-[3-(4-methyl-1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-fluorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(2-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(tetrahydrofuran-3-ylacetyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(3-methylbutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N^1-(4-fluorobenzyl)-N^1-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)piperidine-1,3-dicarboxamide;

2-{(4-fluorobenzyl)[(3-hydroxyazetidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonane-7-carboxamide;

2-{(4-fluorobenzyl)[(3-methoxypyrrolidin-1-yl)carbonyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)(methyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,6-dimethylmorpholine-4-carboxamide;

2-{[ethyl(2-methoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-2,2-dimethylmorpholine-4-carboxamide;

N-(4-fluorobenzyl)-N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-1,4-oxazepane-4-carboxamide;

2-[(4-fluorobenzoyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(4-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-N-(3-methylbutyl)-1,2-oxazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-propoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydrofuran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(2-ethoxyethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(1-methoxybutan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(4-cyanophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dioxolan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,4-dioxan-2-ylmethyl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(1,3-dimethoxypropan-2-yl)carbamoyl](4-fluorobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-fluorobenzyl)[(2-methoxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydrofuran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-fluorobenzyl)(tetrahydro-2H-pyran-3-ylcarbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyrimidin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(2-methoxypyridin-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(1,3-oxazol-4-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methoxypyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(4-methyl-1,3-thiazol-5-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(3-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(1,3-benzodioxol-5-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(4-hydroxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(3-chlorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{[2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-(2-fluorophenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

2-{[2-hydroxy-2-(4-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide acetate (1:1);

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[1-(pyridin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(1-methyl-1H-pyrazol-4-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,6-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(6-methylpyridin-3-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(4-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyrazin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(3-chlorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-methylpyridin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

2-[(2,5-difluorobenzyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(2-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbenzyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(pyridin-3-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(propan-2-yloxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(2-hydroxyethoxy)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(propan-2-yloxy)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxy-2,2-dimethylpropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(1-hydroxypropan-2-yl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2S)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(4-hydroxybutyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2R)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methylbutyl)[(2S)-2-phenoxypropanoyl]amino}-1,3-thiazole-5-carboxamide;

N-(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)-5-methyl-N-(3-methylbutyl)-1,2-oxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(phenoxyacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(3-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(2-phenylpropanoyl)amino]-1,3-thiazole-5-carboxamide;

2-{[(4-fluorophenyl)acetyl](3-methylbutyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(3-amino-3-oxopropyl)carbamoyl](4-cyanobenzyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[3-(acetylamino)-2-methylpropyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(dimethylamino)-3-oxopropyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(4-cyanobenzyl)[(3-ethoxy-2-hydroxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(diethylamino)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{[2-(acetylamino)ethyl]carbamoyl}(4-cyanobenzyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[2-(diethylamino)ethyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl)({2-[(2-methylpropanoyl)amino]ethyl}carbamoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[(2R)-1-hydroxybut-3-en-2-yl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(4-cyanobenzyl){[3-(3-hydroxyazetidin-1-yl)propyl]carbamoyl}amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(methoxyacetyl)(3-methylbutyl)amino]-1,3-thiazole-5-carboxamide;

2-[(cyclopropylcarbonyl)(3-methylbutyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

(2S)-1-[(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)(3-methylbutyl)amino]-1-oxopropan-2-yl acetate;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydro-2H-pyran-4-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylcarbonyl)amino]-1,3-thiazole-5-carboxamide;

2-{[2-hydroxy-2-(3-methoxyphenyl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(pyrazin-2-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[1-(3-hydroxyphenyl)propan-2-yl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

ethyl N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alaninate;

ethyl 4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoate;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoate;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}cyclobutanecarboxylic acid;

ethyl 3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoate;

2-{(4-cyanobenzyl)[(3-methoxypropyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-4-methylpentanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2,2-dimethylpropanoic acid;

3-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}-2-methylpropanoic acid;

N-[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]-beta-alanine;

4-{[(4-cyanobenzyl)(5-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}-1,3-thiazol-2-yl)carbamoyl]amino}butanoic acid;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methylbutyl)(tetrahydrofuran-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(3-methoxypropanoyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(3-methoxypropyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydro-2H-pyran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl)(tetrahydrofuran-2-ylmethyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(propan-2-yloxy)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-{[2-(1,3-dioxolan-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,4-dioxan-2-ylmethyl)(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(4-fluorophenyl)propanoyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[3-(pyridin-3-yl)propanoyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-3-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(naphthalen-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(2-methoxyethyl)[(4-phenoxyphenyl)acetyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(4-cyanophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(4-aminophenyl)acetyl](2-methoxyethyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[{2-[di(prop-2-en-1-yl)amino]ethyl}(3-methoxypropanoyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[3-(diethylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(diethylamino)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

2-{[(1-ethyl-5-oxopyrrolidin-3-yl)methyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[(5-oxopyrrolidin-2-yl)methyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-oxo-3-(pyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(piperidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(3-methoxypropanoyl){2-[(2-methylpropanoyl)amino]ethyl}amino]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[3-(methylamino)-3-oxopropyl]amino}-1,3-thiazole-5-carboxamide;

2-{[3-(acetylamino)propyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-{(3-methoxypropanoyl)[2-oxo-2-(pyrrolidin-1-yl)ethyl]amino}-1,3-thiazole-5-carboxamide;

2-[3-(2-hydroxyethyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[3-(4-fluorophenyl)-2-oxoimidazolidin-1-yl]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydro-2H-pyran-4-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[(5-chloropyridin-2-yl)methyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](3-methoxypropanoyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl](tetrahydrofuran-3-ylcarbonyl)amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{[2-(5-chloropyridin-2-yl)ethyl][(2-methoxyethyl)carbamoyl]amino}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-([2-(5-chloropyridin-2-yl)ethyl]{[2-(propan-2-yloxy)ethyl]carbamoyl}amino)-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-[(1,3-benzodioxol-5-ylacetyl)(2-methoxyethyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

2-{(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-N-[3-(1H-imidazol-1-yl)propyl]-1,3-thiazole-5-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-2-[(2-methoxyethyl)(pyridin-2-ylacetyl)amino]-1,3-thiazole-5-carboxamide; and pharmaceutically acceptable salts thereof.

9. A composition for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory

distress syndrome, and ataxia telengiectasia, said composition comprising an excipient and a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salts thereof.

10. A method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salts thereof.

11. A method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of claim 1, or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/040485

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D417/12 C07D417/14 A61K31/427 A61P37/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2004/054186 A1 (DAS JAGABANDHU [US] ET AL) 18 March 2004 (2004-03-18) paragraph [0002]; claim 1; compound 43	1-11
A	JEFFREY W. LOCKMAN ET AL: "Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3 H -quinazolin-6-yl)methylprop-2-ynylamino]-N -(3-pyridylmethyl)benzamide (CB-30865) as Potent Inhibitors of Nicotinamide Phosphoribosyltransferase (Nampt)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 24, 23 December 2010 (2010-12-23), pages 8734-8746, XP55014723, ISSN: 0022-2623, DOI: 10.1021/jm101145b figure 1	1-11

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
11 June 2013	17/06/2013

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Johnson, Claire

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2013/040485

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004054186 A1	18-03-2004	AR 044506 A1	14-09-2005
		AT 464898 T	15-05-2010
		AU 2004223828 A1	07-10-2004
		BR PI0408782 A	28-03-2006
		CA 2519898 A1	07-10-2004
		CL 6102004 A1	06-05-2005
		CN 1764454 A	26-04-2006
		CN 1989969 A	04-07-2007
		DK 1610780 T3	09-08-2010
		EP 1610780 A2	04-01-2006
		ES 2342937 T3	19-07-2010
		GE P20074234 B	12-11-2007
		HK 1078491 A1	15-10-2010
		HR P20050826 A2	31-12-2005
		IL 170873 A	28-04-2011
		IS 8038 A	21-09-2005
		JP 2006523216 A	12-10-2006
		KR 20050115305 A	07-12-2005
		MX PA05010145 A	16-11-2005
		MY 139730 A	30-10-2009
		NZ 542171 A	31-10-2008
		PE 10682004 A1	21-01-2005
		PT 1610780 E	22-06-2010
		RS 52291 B	31-10-2012
		RS 20050698 A	04-04-2008
		RU 2365372 C2	27-08-2009
		SI 1610780 T1	30-11-2010
		TW I351404 B	01-11-2011
		US 2004054186 A1	18-03-2004
		WO 2004085388 A2	07-10-2004
		ZA 200507718 A	28-02-2007